



US 20150191702A1

(19) **United States**(12) **Patent Application Publication**
Wang et al.(10) **Pub. No.: US 2015/0191702 A1**(43) **Pub. Date: Jul. 9, 2015**(54) **PARAMYXOVIRUS AND METHODS OF USE**(22) PCT Filed: **Jul. 2, 2013**(71) Applicants: **The Henry M Jackson Foundation for
the Advancement of Military
Medicine, Inc., Bethesda, MD (US);
COMMON WEALTH SCIENTIFIC
AND INDUSTRIAL RESEARCH
ORGANIZATION, Clayton South
(AU); THE STATE OF
QUEENSLAND, DEPARTMENT OF
AGRICULTURE FISHERIES AND
FORESTRY, Brisbane (AU)**(86) PCT No.: **PCT/US13/49069**


§ 371 (c)(1),

(2) Date: **Jan. 2, 2015****Related U.S. Application Data**

(60) Provisional application No. 61/667,194, filed on Jul. 2, 2012.

Publication Classification(72) Inventors: **Linfa Wang, Wandana Heights (AU);
Glenn A. Marsh, Leopold (AU); Hume
Field, Ormiston (AU); Christopher
Broder, Silver Spring, MD (US)**(51) **Int. Cl.**
C12N 7/00 (2006.01)
C07K 16/10 (2006.01)
C07K 14/005 (2006.01)(73) Assignees: **Commonwealth Scientific and
Industrial Research Organization,
Clayton south (AU); The State of
Queensland, Department of
Agriculture Fisheries and Forestry,
Brisbane (AU)**(52) **U.S. Cl.**
CPC **C12N 7/00** (2013.01); **C07K 14/005**
(2013.01); **C07K 16/1027** (2013.01); **C07K**
2317/76 (2013.01); **C12N 2760/18221**
(2013.01); **C12N 2760/18231** (2013.01); **A61K**
39/00 (2013.01)(21) Appl. No.: **14/412,533**(57) **ABSTRACT**

The present invention is directed towards a novel virus, called Cedar Virus, and its methods of use.

**FIG. 1**

A. LEADER AND TRAILER REGIONS OF THE ANTIGENOME SEQUENCE

CedPV 5'-ACCAGAAAAAGG.....CCTTTTTTAGGA-3'
HeV 5'-ACCGAACAAGGG.....CCCTTGTTTCGGA-3'
NiV 5'-ACCAAACAAGGG.....CCCTTGTTTCGGA-3'

B. SEQUENCE OF INTERGENIC REGIONS (IGR) AND TRANSCRIPTIONAL START AND STOP SIGNALS

GENES	GENE START	IGR	GENE STOP
/N		CTT	AGGATCCCCGG
N/P	TTACAAAAAA	CTT	AGGATCCAAG
P/M	TTAGAAAAAA	CTT	AGGATCCCAG
M/F	TTAAGAAAAA	CTT	AGGATCCCAG
F/G	TTAAATAAAA	CTT	AGGATCCCAG
G/L	TTAAAGAAAA	CTT	AGGATCCCAG
L/	TTAAAGAAAA	CTT	

CONSENSUS

CedPV	TTAvrdAAAA	CTT	AGGATCCmrG
HeV	TTAmrDAAAA	CTT	AGGAnmCArG
NiV	TwAwrDAAAA	CTT	AGGAnmCArG

FIG. 2




FIG. 3A





FIG. 3B

FIG. 3C






FIG. 4




FIG. 5




FIG. 6




FIG. 7




FIG.8A




FIG.8B




FIG.8C







FIG.8D

**FIG. 9**

**FIG. 10**

**FIG. 11**

PARAMYXOVIRUS AND METHODS OF USE**STATEMENT REGARDING FEDERALLY
SPONSORED RESEARCH OR DEVELOPMENT**

[0001] Part of the work performed during development of this invention utilized U.S. Government funds under National Institutes of Health Grant Nos. AI054715. The U.S. Government has certain rights in this invention.

**SEQUENCE LISTING SUBMISSION VIA
EFS-WEB**

[0002] A computer readable text file, entitled "044508-5045-WO-SequenceListing.txt" created on or about Jul. 2, 2013 with a file size of about 70 kb contains the sequence listing for this application and is hereby incorporated by reference in its entirety.

BACKGROUND OF THE INVENTION

[0003] 1. Field of the Invention

[0004] The present invention relates to a novel virus, called Cedar Virus, and its methods of use.

[0005] 2. BACKGROUND OF THE INVENTION

[0006] Henipaviruses were first discovered in the 1990s in disease outbreaks in farm animals and humans in Australia and Malaysia (1, 2). These viruses comprise the only known Biosafety Level 4 (BSL4) agents in the family Paramyxoviridae (3), and mortality is between 40% to 100% in both humans and animals (4, 5), depending upon the virus, animal species and geographic locations of outbreaks. The genus Henipavirus in the subfamily Paramyxovirinae currently contains two members, Hendra virus (HeV) and Nipah virus (NiV), with fruit bats, commonly known as flying foxes, as having been identified as the main natural reservoir of both viruses. Serological evidence, however, also suggests that henipaviruses may circulate in other types of bats (7-10).

[0007] The discovery of henipaviruses has had a significant impact on our overall understanding of paramyxoviruses. Indeed, Paramyxoviruses, such as measles virus and canine distemper virus, have a narrow host range and are known to be genetically stable with a close to uniform genome size shared by all members of Paramyxovirinae (3). Henipaviruses, however, shifted these paradigms as these viruses have a much wider host range and a significantly larger genome (6).

[0008] Recently, research on henipavirus has successfully identified functional cellular receptors and has driven the development of novel diagnostics, vaccine and therapeutics (15-25). There is, however, little understanding of the pathogenesis of these highly lethal viruses, due in part to the requirement of a high security BSL4 facility needed to conduct live infection studies and in part to the limited number of research tools available used in the current animal models. Research into the mechanisms of henipavirus pathogenesis is also hampered by the lack of related, non-pathogenic or less pathogenic viruses that could be used in comparative pathogenetic studies.

[0009] Recent serological investigations in China and other regions indicated the presence of cross-reactive, but not necessarily cross-neutralizing, antibodies to henipaviruses in bats of different species (8). Detection of henipavirus-like genomic sequences in African bats further support the results obtained from the serological investigations (26).

[0010] The invention disclosed herein is directed to the isolation and characterization of a newly discovered henipavirus.

SUMMARY OF THE INVENTION

[0011] The present invention is directed towards a novel virus, named Cedar Virus ("CedPV"), and its methods of use.

[0012] The present invention is also directed towards the individual proteins, and fragments thereof, as well as the coding sequences of the individual proteins that make up the CedPV.

[0013] The present invention is also directed to antibodies or fragments thereof that specifically bind to CedPV.

[0014] The present invention is also directed to vaccines and/or other therapeutic compositions comprising at least a portion of the CedPV.

BRIEF DESCRIPTION OF THE DRAWINGS

[0015] FIG. 1 depicts the genome sizes and organization of CedPV compared to those of the prototype viruses of the five existing genera in the subfamily Paramyxovirinae. Each of the coding and non-coding regions is drawn to scale. The six major genes present in all paramyxovirus genomes are indicated as follows: shaded=RNA polymerase and nucleocapsid genes (N, P and L); slanted=envelope membrane protein genes (F and attachment protein); dotted=matrix protein (M). The small in the genome of the mumps virus represents the gene (SH) not commonly shared among members of the subfamily.

[0016] FIG. 2 depicts a comparison of genomic features among different henipaviruses. (A) Alignment of leader and trailer sequences (antigenome sequences shown). (B) Sequences of intergenic regions (IGR) and transcriptional start and stop sites of CedPV in comparison with those of HeV and NiV.

[0017] FIG. 3 depicts a phylogenetic tree of selected paramyxoviruses. 2A: The tree is based on the N protein sequences. Virus name (abbreviation) and GenBank accession numbers are as follows: Avian paramyxovirus 6 (APMV6) AY029299; Atlantic salmon paramyxovirus (AsaPV) EU156171; Beilong virus (BeiPV) DQ100461; Bovine parainfluenza virus 3 (bPIV3) AF178654; Canine distemper virus (CDV) AF014953; Cedar virus (CedPV) J0001776; Fer-de-lance virus (FdIPV) AY141760; Hendra virus (HeV) AF017149; Human parainfluenza virus 2 (hPIV2) AF533010; Human parainfluenza virus 3 (hPIV3) Z11575; Human parainfluenza virus 4a (hPIV4a) AB543336; Human parainfluenza virus 4b (hPIV4b) EU627591; J virus (JPV) AY900001; Menangle virus (MenPV) AF326114; Measles virus (MeV) AB016162; Mossman virus (MosPV) AY286409; Mopeia virus (MprPV) EF095490; Mumps virus (MuV) AB000388; Newcastle disease virus (NDV) AF077761; Nipah virus, Bangladesh strain (NiV-B) AY988601; Nipah virus, Malaysian strain (NiV-M) AJ627196; Parainfluenza virus 5 (PIV5) AF052755; Pestivirus (PPRV) X74443; Porcine rubulavirus (PorPV) BK005918; Rinderpest virus (RPV) Z30697; Salem virus (SalPV) AF237881; Sendai virus (SeV) M19661; Simian virus 41 (SV41) X64275; Tioman virus (TioPV) AF298895; Tupaia paramyxovirus (TupPV) AF079780. (B) The tree is based on whole genome sequence. (C) The tree is based on a 550-nt region of the L-gene.

[0018] FIG. 4 depicts the sequencing trace files for the editing site of P genes for HeV and NiV in comparison to the editing site of the CedPV P gene. Trace files showing editing of the HeV and NiV P gene (indicated by the * sign) and lack of editing in CedPV P gene mRNA in infected cells. Sequencing of PCR products covering all potential editing sites in the P gene of CedPV did not reveal any RNA editing activity. A representative potential editing site of the CedPV P gene is shown.

[0019] FIG. 5 depicts the antigenic cross reactivity between CedPV and HeV. Vero cells infected with CedPV and HeV, respectively, were stained with rabbit sera raised against recombinant N proteins of each virus.

[0020] FIG. 6 depicts antigenic cross reactivity of CedPV with other paramyxoviruses. An Indirect Fluorescent Antibody (IFAT) assay conducted with anti-CedPV serum on Vero cells infected with J paramyxovirus (JPV), Rinderpest virus (RPV), Sendai virus (SeV), Menangle virus (MenPV) and CedPV, respectively. Mock infected cell monolayer was included as a negative control. The only panel showing reactivity is the CedPV panel.

[0021] FIG. 7 depicts the functional testing of ephrin-B2 and -B3 as an entry receptor for CedPV. Infection of CedPV into HeLa-USU cells in the presence and absence of ephrin gene products is shown. The susceptibility of infection, as an indirect measurement of receptor function, is demonstrated by the formation of syncytial cytopathic effect (CPE).

[0022] FIG. 8 depicts the immunohistochemical analysis of bronchial lymph node of CedPV-infected ferrets. Bronchial lymph node of ferret #2, euthanized on day 6 pi, was stained with rabbit antiserum against recombinant N protein of CedPV (B) and NiV (D), respectively. Bronchial lymph node of an unrelated ferret (infected with influenza H5N1 from another experiment) was used as negative control and stained with the same anti-CedPV (A) and anti-NiV (C) antisera under identical conditions.

[0023] FIG. 9 depicts the results of CedPV glycoprotein mediated cell-cell fusion and heterotypic mixing with HeV and NiV glycoproteins. Various target cell populations are shown in the legend.

[0024] FIG. 10 depicts purified soluble ephrin-FC proteins alone or pre-mixed with CedPV-sG, precipitated and analyzed by SDS-PAGE and coomassie. The separated sG is marked and the different ephrin protein patterns are noted. CedPV-sG and ephrin-B2 run close together in lane 3.

[0025] FIG. 11 depicts the results of HeLa-USU target cell populations prepared by transfecting in the indicated ephrin receptor constructs and then used in cell-cell fusion assay with effector cells expressing either CedPV, HeV or NiV F and G glycoproteins, and a standard fusion-reporter gene assay was carried out.

DETAILED DESCRIPTION OF THE INVENTION

[0026] The present invention is directed towards a novel virus, named Cedar Virus ("CedPV"), and its methods of use. The present invention is also directed towards the individual proteins, and fragments thereof, as well as the coding sequences of the individual proteins that make up the CedPV.

[0027] The inventors have isolated a novel paramyxovirus, in particular a Henipavirus. As is well established, the Henipavirus genus belongs to the paramyxovirus family of viruses and includes both the Hendravirus (HeV) and Nipahvirus (NiV). In all likelihood, the newly isolated CedPV will belong to the henipavirus genus based on phylogenetic studies, see FIG. 3. Regardless of its classification, the inventors establish herein that CedPV is a novel virus that shares antigenic properties, among other properties, with Hendra virus. The newly discovered CedPV is an RNA virus containing a single strand of RNA.

[0028] The genome of the virus is presented herein as SEQ ID NO:1.

(SEQ ID NO: 1)

```

1 accagacaaa ggaagtctag tctccggatt aaatcatatt cgtatgatta atcttaggat
61 cccgggtatct agaactctgga tctggattcg gtttaattga attgcgatcg ttataaaatt
121 agaaaggaga ttactactc aaaatgtctg acattttcaa tgagactcaa tcatttagaa
181 actatcagtc caacttaggc agagatggca gggccagtgc agcaacgact actttgacaa
241 ctaaagttag gatctttgtt ccagcgaata ataatccaaa cctcagatgg cgtttaacac
301 tattcttgat ggatgtcgtg aggtcacctg cctccgcaga gtctatgaaa gtgggtgctg
361 ggatatacct ggtatctatg tatgctgaaa aacccggggc tcttgtaga gcatatttga
421 atgaccacga tgttgaagcg ataatcatag atgtttatgg ctttgatgaa ggtattccta
481 taatggaacg aagaggtgat aaagctacag atgacatgga ttccctaaga aagattgtta
541 aagctgcaca tgatttcagc agaggaagga gtttatttgt tgatcaaaagg gtccaggata
601 ttgttatgtc agatattggg tcatttgtag atgctattac ttccatagag acgcagatat
661 ggattttgat cgcaaaggct gtaactgccc cagatacagc agaagagagc gaaggaagaa
721 gatgggcaaa atatgttcag caaaagaggg ttaatccttt gttcttgatt tctccacaat
781 ggatcaatga catgagatcc ctgattgcgg caagtcttcc gtttcgtaaa ttcattggtg
841 aactactgat ggaagctaag aaaggacggg ggacaaaagg aagaataatg gagattgtat
901 ccgatatcgg aaattacggt gaagagacag gaatggcagg gttcttcgct acaataaagg

```


-continued

961 tcggtcttga gaccaaattc cctgctttgg cacttaatga gctccagagt gacttgaaca
1021 caatgaaaag tctcatgata ctgtacagaa gcataggacc aaaggccccc tttatggtgt
1081 tgttggaaga ttcaattcag accaaatttg ctccaggaag ctatccactt ctttgaggtt
1141 ttgcatggg ttaggcacac actattgaca gagctatggg tgccttgaac attaacagaa
1201 gttatcttga acctgtctat tttaggctag ggcaacaatc agctaaacat caagcaggaa
1261 atgttgacaa agaaatggca gaaaagttag gattgacaga agaccagatc gtgcacctat
1321 cagctaattg gaaggatgca agtcaaggta gagatgacaa tcaaatcaac atccgagaag
1381 ggaagttcac aaatgttgtt gatgacatcc aggatcatgc ccagagttcc tctgaggatt
1441 acaatcctag taaaagagt ttctcaatat tgacgagcat cacatccacc gtagatagtg
1501 ctgacagtag gtctgcaatg aatgagtcaa tgacaacaac atccttgctg aaattgagac
1561 agaggctggc agagaagaaa ggagactcca agaacagtca agacacacct ccaaaaccac
1621 ccagagcaaa agatcaaccc actgatgagg tctccttcac ggattccaat atatgatcag
1681 aatgatgggt aaaaacaccc aactaagggc gcgtagagta ccttcagata gaacactaca
1741 ttaatcgggt gaaacaatag atttatgggt ttggtgctta atttttattt aatcttactt
1801 gcaaacagg cagctgtcac actcgtaac actcctcaca gtaagggcaa cacgggtcat
1861 agaacttatg cctatagatt acctctatct gtatatctag ctatgattaa aatgtatact
1921 tctgctgacc ggttttctag caacagtcca cattattact ttatgggtat tttttaatca
1981 accttttata atcaaatata ttacaaaaaa cttaggatcc aagtgggtcca aacttttttt
2041 gatcaagagt catattggct actttaggag gacactttaa acacaaattg ttacaagagg
2101 atattcatca gatggacaaa ctacaattga ttgaagatgg cctctctact atcaatttta
2161 tacaggaaaa taaggaaaa ttacagcatt cttacggaag atcctccatc agagagccac
2221 ccacaagtgt cagggttgaa gagggtgaga aatttattcg aaagatcgct tctggacctg
2281 aacaagttca agggggaggga tctgagactg agatcacagg cgataatgga gatagaggca
2341 attttaccaa tctgtatcag ggaggcggag tcacaggaca attcgaagaa aggtatcaaa
2401 aatgggggtc acaagattca gaattacaac tggacccaat ggtgtacac gatttcttct
2461 atgacgagag aaggggagaat cccgacaatg gaaaatatga ccgagctctt aaaaaacggg
2521 ataatatcag agaaggaaca cgacaggata agtacaataa tcagtctact gatgaattac
2581 tgtcctgcct acaacctatc tctaagaacg atgtcatcaa gaatgaaagt acatcagttg
2641 caaatttgca tgttacagga aataaactga atcctgacgc aaaacccttt gaaccacct
2701 ccagtcgaa agagcaccca accaccacac agcacaacaa aaatgacat cagaccgatg
2761 atgattataa gaatagaaga tccagtgaac acaatgtgat ctctgatcat gccaccacaa
2821 tggaagacaa caacaatttt atcccggcga ccaaaagaaa gaatgcattg agcgaaccca
2881 tatacgtcca ggtattgccc tcaaacacag aggggtttctc gggaaaagat tatccactcc
2941 tcaaggacaa ctctgtcaag aagcgtgcag agccagtcac cctagaaact gccaacacc
3001 ctgcaggctc tgccgaccaa gacacaaatc agattgaaga aaacatgcag ttcaaccttc
3061 caaaactgct cacagaagat acagacgatg aaccagagga taacaatgat tccatgcctc
3121 ttgaggaaga cattagagag atcggttcca tgctaaaaga tggaacacaa gatatacaga
3181 caaggatgaa tgagatagat gacgcaatca agaagataaa taagaaatca aaaaatagaa
3241 gtctggatct agaatacagc ggtaagatc aggggagaag agatccatca gtagacctcg

-continued

3301 ggattaaaaa aagaaaggaa gggctaaagg ccgcaatgca aaagacaaaa gagcaattgt
3361 ctataaaagt ggagagagag attggattga acgacaggat atgtcaaaat tcgaagatga
3421 gtacagaaaa gaaattgata tatgctggga tggaaatgga gtatggacaa acgagtactg
3481 ggtcaggagg tccacaagga tcaaaggatg ggacttctga tgatgtccag gtagacgaag
3541 actacgatga aggggaagac tatgaggcta tgccgtcaga taggttttat acaacattat
3601 caggtgaaca aaaggataga ttgatctag atgctaacca aatgtctcag tatgacctcg
3661 agggccagggt ggatgaatta accagaatga atctcact ctattctaga ttagaaacta
3721 ctaataagtt gcttattgac atattagatc tagctaaaga aatgccaaag ttagttagaa
3781 aagtggataa tcttgagaga cagatgggta acttgaatat gttaacctct acccttgagg
3841 gtcacctatc ttctgtaatg attatgatac cgggtaagga taagagcgaa aaggaaatcc
3901 ctaaaaatcc ggacctgaga ccaatactgg ggagaagcaa cacgtcgta actgatgtta
3961 tcgacctaga ccattaccct gataaaggct ccaaaggat caaaccaagt ggatctggag
4021 acagacagta catcggtctct ctagagagca aattttctat aatgatgag tacaattttg
4081 ctccataccc tatcagggac gaactcctat tgccaggttt aagagatgac aaaaccaatg
4141 cttcatcggt catccagat gacacggaca ggtctccaat ggtgctcaaa ataataatc
4201 gacagaacat ccatgatgaa gaagtgaagg atgagctact gtccatacta gaacaacata
4261 aactgtgga ggaattgaat gaaatatgga atactgtgaa tgattacctc gatggcaaca
4321 tctgattaac agatattgag attgatccta ttctaacaa gtaatctctg ataatgatag
4381 tatggaataa gaataactat cacactattg tactcttgta gaatcttaac gagtgtctaa
4441 tgtcagatct tagcaacaca tactaataac ttgtaatcca tttctcctta ttccatttaa
4501 tctcacatta gaaaaaactt aggatcccag atttgcaaag tcaaacggg atctactatc
4561 aggtgttgga gctaacaata gcgaggtctg cataacaaat agcgttcaaa gaagtgtgaa
4621 aaccatcata gaatatggat ccgtcagatt tgaggaggat tataatggag gatgataaga
4681 gtctggtcaa caatgatgat agtacagaaa ctgattttct cgagaaaact tggagagaag
4741 ggagtaagat tgacaagatc acaccagggt ttgatgaaaa cgggaatatg gtccccaagt
4801 acgttgtctt caaccggggg aaaaatgaga ggaaaacatc cggatatcaa tatatgatct
4861 gttatggttt cattgaggat ggacctatca atggctcacc aagagtcaaa ggtaatatca
4921 gaaccaccgc ttcttttctt ttgggtgttg gaaaaactta ctctctcca gaagagatct
4981 tacaagagct gacaacactc aagatcactg tcagaaggac agccggatca aatgagaagt
5041 tgggtgatgg aataacaggg cctttaaatc acctttaccg gtggtataaa gttttgacag
5101 gtggctccat ttttagtgcg gtgaaggctt gtaggaatgt ggatcaata ctattagaca
5161 gaccccaaat acttagagta ttctttctaa gtataactaa attaacagat aaagggtgtg
5221 atatgatacc caaaagtgtt ctcgacttca gatcggataa ttcgatggcc ttcaatctgc
5281 ttgtgtatct caagatagac actgacatca ccaaagcagg catcagaggg attgtcaaca
5341 aagaagggga gaggataacg tcattcatgt tacacatcgg taactttaca agaagaggag
5401 gaaaacatta ctcagtggag tattgcaaaa ggaaaattga caaatgaag ctcacattcg
5461 ccttaggcac tataggcgtt ctaagcttac atatcaggat cgatggaagg ataagtaaaa
5521 ggctccaagc acaagttggc tttcagagaa acatttgcta ctactaatg gacacaaacc
5581 catgggtgaa taaattaacg tggaacaata gttgtgaaat acacaaagtc accgctgtca

-continued

5641 ttcagccatc tgtgccaaag gacttcatgt tgtatgagga catcttaata gataatacag
5701 gcaagatctt aaaataaagt aggagagtca gtcattaccc agtatattga atactaatga
5761 caactttatt aatccaattc tatctccagt tactagaatt tctaaaacaa ttctactgct
5821 cagcaacgca tctcaaactc tgtgatcttc aattatgacg gacgcattgt aatctatata
5881 gcttttagtt catgaaatac taaaagggc ttaatcttgt aagttctcag caaatactcc
5941 aatgcaaaag agcgcctcaa catctcaagc agcaccacaaa taaaccacaa tcaatgtgca
6001 acaagagcaa tcgtctaaag tgtgaaaacc aaaatcacag atcagaaagg gcacatattt
6061 cagtccctga aaaataccaa gtgggattaa taaaagagga tcaatcctta tcattttaag
6121 aaaaacttag gatcccagag atcctaaaga gccaatcctt ttatatattg atcttgaagg
6181 gctagaagtc aggctgaaac acagagggtg aggaacacag gaactaaat tgatgaaatc
6241 aaccttagct caacatctaa tcaatcaagc ttaagtcac ctaatactgt atacaaccag
6301 cagcgtagag agtggtattg atttcggcac ccttgcgaa gaaaggctat tactgcctgt
6361 cctttcaatc agaaaattac atttaccat aaagtaactc caacatgtct aacaagagga
6421 caacagtatt gatcataata agctatacgt tattttattt gaataatgca gcaattgtag
6481 gggttgattt tgataaattg aataaaatag gtgtgggtgca agggagagtc ctaaattata
6541 aaattaaagg agatccaatg acaaaagacc ttgtcttgaa atttatccct aacatagtga
6601 atatcactga atgtgtgaga gagcccttga gtagggtacaa tgagaccgtg aggagattgc
6661 ttttacctat acacaacatg cttgggttat acttgaataa cacaatgct aaaatgactg
6721 gggtgatgat cgcggtgtg atcatgggtg ggatagcaat aggtatagcc acagcagctc
6781 agatcacagc aggttttctt ctttatgagg caaaaaagaa cacagaaaat attcagaaat
6841 taacagacag catcatgaaa acacaggact cgattgataa acttactgac agtgtgggga
6901 caagcatact tatattgaat aagctacaga catacatcaa caatcaactg gtaccaaact
6961 tagagcttct atcctgccga caaaacaaaa ttgagtttga tctaattgta accaagtatt
7021 tgggtgatct tatgactgtt attggctcta atatcaataa tctgtttaat aaagatatga
7081 ctattcaatc tttgtcactt ctttttgatg gcaattatga tataatgatg tcagaacttg
7141 gttatacacc tcaggatttc ttagatttga tagagagtaa gagtataaca gggcaaataa
7201 tttatgttga tatggaaaac ttgtacgttg tgatcaggac atatctacct accctaattg
7261 aagtacctga tgcccaata tatgagttca acaaaataac tatgagtagc aatggaggag
7321 aatacttgct aaccatacct aatttcatat taataagagg taattatatg tctaatatag
7381 atgttgcaac atgttatatg accaaagcaa gcgtaatttg taatcaagat tattcactcc
7441 cgatgagcca aaacttaaga agctgttacc aaggtagagc agaatactgt cctgttgagg
7501 cagtcacgc gtcacactct ccaagatttg ctcttacaaa tggagttatt ttcgccaaat
7561 gtataaatac aatttgtagg tgtaagaca atggtaagac tatcactcaa aacataaacc
7621 aattcgtaag catgatcgac aacagtactt gtaatgatgt catggtagat aagtttacta
7681 tcaaggtagg aaaatatatg gggagaaaag atatcaataa tattaatatc cagataggac
7741 cgcagatcat aattgataag gttgacttgt ctaatgaaat aaacaagatg aatcaatctt
7801 taaaagatag tattttctac ctgagagaag ccaagagaat tttagactca gtaaatatca
7861 gtcttatatc tccaagcgtt caattgttct taataataat atcagtcctc tcatttatta
7921 tattattgat tatcatagta tacttgtagt gtaaatcaaa acattcatat aaatataaca

-continued

7981 aatttataga tgatcctgat tattacaatg attacaaaag agaacgtatt aatggcaaag
8041 ccagtaagag taacaatata tattatgtag gtgattaaca atcgataatc taaaggatta
8101 cctcactatc actaccaagg taacttccat gtaagatcgg accttccccg aagacattaa
8161 ataaaaactta ggatcccaga gtatccctct aagtgatcct tctagattgg ttactgatat
8221 atatacatat ttatcctctt tccgtcgttg tttattgatc attaataatg ctttctcagc
8281 tccaaaaaaa ttacttagac aactcaaacc aacaagggtga taaaaatgaac aaccagata
8341 agaaattaag tgtaacttc aacccttttag aattagataa aggtcaaaaa gatctcaata
8401 agtcttatta tgttaaaaac aagaattata acgtttcaaa tctattaaat gaaagtctgc
8461 acgatatcaa gttttgtatt tattgtatat tctcactgct aattatcatt acaataatca
8521 atataatcac aatatcaatt gtataactc gtctgaaagt acatgaagag aataatggca
8581 tggaatctcc taatttacia tctattcaag atagtctctc atctcttact aacatgatca
8641 atacagagat aactcctaga atagggattt tagttacagc cacttctgtt actctctctt
8701 catctatcaa ttatgtcggg actaagacaa atcaactggg caatgaatta aaagattata
8761 taacccaaaag ttgtggcttt aagggtccctg aattaaagtt acatgaatgc aacataagtt
8821 gtgctgatcc aaaaattagc aaatctgcaa tgtacagcac caatgcctat gccgagcttg
8881 ctgggtccacc taagatattht tgtaaaagtgt tatccaaaga ccccgacttt agactgaagc
8941 agatagatta tgtaatacca gtgcagcaag atcgggtctat ttgtatgaac aaccctttat
9001 tggatatttc tgatgggttt ttacctaca tacattatga aggaataaat agctgtaaaa
9061 aatcagattc atttaaagtgt ctgctgtcac atgggtgaaat agttgacagg ggtgattatc
9121 gaccatcatt atacttatta tcaagtcatt accatcctta ttcaatgcag gtaataaaat
9181 gtgtacctgt gacttgtaac cagtcacctt ttgtattctg tcatatctcc aacaacacta
9241 aaacattgga caattcagat tactcgtcag acgagtacta cataacatat ttcaatggca
9301 tagatcgtcc caaaaccaag aagattccca ttaacaatat gacagcagac aatcgttata
9361 tccattttac attctcaggt gggggagggtg tatgtttagg tgaagaattt attattcctg
9421 ttaccacagt catcaatact gatgtattca cgcagatta ttgtgagagt ttcaactgtt
9481 cagtccaaac cggtaaaagt ctaaaggaga tatgctctga gtcattaaaga tctccaacga
9541 actcatcgcg atacaattta acgggaatca tgattataag tcaaaacaac atgacagatt
9601 ttaagattca gttgaatggt ataacttata acaaactgtc attcggaagt cctggaagac
9661 tgagcaagac actggggccag gtcctttatt accaatcttc aatgagttgg gatacttata
9721 taaaggcagg atttgtcgag aaatggaaac cctttacccc gaattggatg aacaatactg
9781 tgatatccag acctaaccaa ggtaattgtc caaggatatc taaatgcccc gagatatgtt
9841 atggaggggac atacaatgat attgctcctt tagatctagg aaaagacatg tatgttagcg
9901 ttattctaga ttcatagcag cttgcagaga atccagagat tacagtattt aactctacta
9961 ctatacttta taaggagaga gtatccaaag atgaactaaa cacaagaagt actacaacga
10021 gctgttttct tttcctagat gaaccttggt gtatatcagt attagaaaca aacagattta
10081 acggcaaact tattaggccc gagatttatt cataaaaaat tcctaagtat tgttaatttg
10141 atgagcttat tctcatact tcaatcaaat ttaatataac taatatcaaa ttgttgact
10201 cagctattat taaaactgga tcatcagaca ataaagatgt atacaaagat atatcgaaga
10261 gggattataa gaaaacttag gatccagat ccttcaataa ggcagagcct tgattgtatc

-continued

10321 agcgtcattt acaattgaat ctcaattaac aacactgatt aataacttaa gcagaatact
10381 cctattacag tgtttaattg acttaatttt aattgaggat tttataatcc tataattgga
10441 gcagatctaa actctcaccg attcagttct aatcctttat taactaaaga acaaattcta
10501 aataattgga tgacgtcaca ggagacaagc tggaaacaat ttagttagaa ggaagaaacc
10561 ttttaccaga tatggaaagt gactttgata tatctgtag cgacgtactg taccagaat
10621 gtcatttga cagtcctata gtcggcgga agctcattac ttctcttgag tatgcgaatt
10681 tgactcataa ccaacctcat gaagatcaga cattgctgac taatataaat gtcaataaaa
10741 agaagaagat aaaaagtcct ctaatatccc aacaatcttt atttggaat gaggttaata
10801 aggagatttt cgatcttaaa aattattacc atgtccccta tccagaatgt aacagagatt
10861 tattcttaat ctctgatgac aaaaatagcat tcaaactcag taaaatcatg gataattcta
10921 ataaactggt tgatggttta gagaggaaac tgagtcgctt aatttcgaat gtagataatc
10981 aactattaaa tgcaacctct cttcataata attctgagat ggatcggaag ggaaaagaac
11041 atccttgctt cccagaaaag agcacaattg atgatgtaag acagcagaga cagacacgag
11101 attttccaaa gaattcaact agagaggga gatctccaaa acaccctgat gccggtccta
11161 cacctgaaaa cagtgcctaa aacgatttgc atagagacaa cacagacaat atgccaacag
11221 gccatagttc gacatctatg aaaaaacctt aaatatctgg agaagaatat cttagtatgt
11281 ggctagactc agaggatttg ggttctaaac gaatttctgc acaattaggg aaggatgtat
11341 catgtaaagg ccatctgcac acgacagaag acaaaccgat aatagttcct gacactcgat
11401 atatccaaaa tcatgaatct aataacgata ttttcccaa aaaagagaaa aaattctgca
11461 aacttcacc gtcacggat aatttaacca aaatcatggt gaattcaaaa tggtaacaatc
11521 ctttctttt ttggtttact gtcaagactg aacttagagc ctgccagaag gagaactaca
11581 aaaggaaaa cagaaaattg ggaattatca catcgattaa aggttcatgc tataagttga
11641 tactcaacca gaatctagta gcaatattcg aggaagacag cagtggatc tcagatcata
11701 aaaaagaaa aaaaacgagc tactatctaa ctcccgaat ggctcctatg ttctccgatg
11761 taactgaagg aagattgatg attgatgtg caatgagatt tgacaaaaag taaaaactc
11821 tagagaaaa ggctttgaaa ttatggtttc ttatagacga gttatttctt tctatgggaa
11881 atagagtgt taatattata tccatgcttg agcctttgac tctcgcgata ttacaggtta
11941 aggatgagtc aagggtgttg agaggtgcat tcatgcatca ttgtttaggt gacctcttcg
12001 aagaacttcg agagtccaag aactaccgg aagatgagat caagagattt gccaacgacc
12061 taataaatgt catgacctgt cgggacattc atttagtagc agaattcttc tcattcttta
12121 ggactttcgg acatccaata ttgaacgctc aaactgcagc caggaaagt agagagtaca
12181 tgtagcaga taaaatcctt gagtacgaac ctatcatgaa aggtcatgag attttctgtg
12241 ctataatcat aaatggattt agagatagac atggaggagt ttggcctcct cttgatcttc
12301 caaaacattg ttcaagaac ataatatctc tcaaaaatc aggtgaagg gtaacttatg
12361 aagtagcaat aaacaattgg agatcatttg tcgggttaaa gttcaaatgt tttatgggtc
12421 tcaatttaga caatgatctc agcatgtaca tgaaagataa agcattatca ctttaagggt
12481 atctttggga ttcaatctat tcacgtgaag taatgtccta ccaaccacct agaaaaaaa
12541 aatcaagaag attggttgag gtttctgtg atgatcagga ctttgatccc gttgatatga
12601 taaattatgt tctgaccgga gaatatctca gagatgatga tttcaatgct tcttatagtt

-continued

12661 taaaagagaa agagacaaa caagttggca ggttgtttgc taagatgact tataaaatga
12721 gggcctgtca agttattgct gagaatttaa ttgcacatgg gattgggaga tatttccatg
12781 aaaacgggat ggtaaggat gagcatgagc tcagcaaadc actgtttcaa ttgtctatat
12841 caggaatacc aagaggggaa aaaaacaaca aatcgacgaa cgacacaadc cagaaagca
12901 agatcgagaa taaccattcc tttaaaaaca tccagaatcg atcatttcga aagacggata
12961 acccatacaa tagatttaac attgataacc caactttctt atccccaac tgtaaccca
13021 agtataaccg taagaattca gagacaatag gtatatctc tcgtgcagaa accaaaagca
13081 tgattagaga acagaaaagt cacagagaag tcaaaataaa taagctagat atcggcagtg
13141 ataataga gcaaggaaaa gagatagatg ccgccaagta caaatcacg gacaacccaa
13201 atccacacat aaatcctcaa gatcaaccgc gaatctgtca agaagacaaa ggcaaagaag
13261 gagcaaagtc agatctcaca gaaggcatga gttttctgga gatgcacaca ctctttaacc
13321 cgagtaagag cgatctcaga acaaatctcg aattggaaaa gagttcactt tcaaacctcg
13381 gatttatatc acaaaaagag aaaagaggca aaacttataa tgaatcccat tctctgggaa
13441 agttctctaa agaggatgaa gaaagatacg atgtcatcag tgcattctcg acaacagatt
13501 tacgaaaatt ctgcttaaat tggagacatg aatcaatcgg catttttgca agaaggatgg
13561 acgaaatcta tggtttgcct ggtttcttta attggatgca cagaagacta gagcgatctg
13621 tgttatatgt tgcggaccct cattgcccgc cgtctatcaa tgaacatac gatctaaacg
13681 attcaccgca aagagacata ttatacatc atccgaaagg gggatataga ggatacagcc
13741 aaaaactgtg gacaatagcg actatccctt ttctattcct cagtgtctat gagacaaaca
13801 cccggatagc ggcagttgta caaggtgaca atcaatcaat tgcaattaca cataagggtc
13861 accctcattt gccttacaaa atgaagaaag aactctctgc aatgcaggca aaaaaatatt
13921 tttcaagggt acggcacaaac atgaaggcat tagggcatga attgaaggcg accgagacta
13981 tcattagtag cattttcttc atttattcca agaaaatcca ctatgacggg gctgttttat
14041 cacaatctct gaaatcaatg gcaagggtgtg tattttggtc agaaaccctt gttgatgaaa
14101 ctagagcagc atgcagtaat atcagacaaa caattgcaaa ggctattgag aatgggtata
14161 gcaggagatc tggctatctg ataaatgttc ttaaaacat ccaacaaatt aatatatcat
14221 tgagttttta tataaatgaa tgcagacag atgacataat cagaccgttt agagataatc
14281 caaactggat caaacatgac gcattaatcc ccgacagctt gggaggactc aactatatga
14341 acatgtctcg attgtatgtg aggaatatag gggatccagt cacagcatcg atagcagatg
14401 ttaagagaat gattctcggg ggtgtactac ccattggaat actccacaat atcatgttgc
14461 aagaaccggg tgatgccact tatttggtg ggtgtagtga tccatactcc atcaacctaa
14521 agcagactca aagtatcaca aaagttataa agaacataac ggcaagagtg atactaagga
14581 attcggctca tccactgctc aaaggtctat ttcataagag tgcttatgag gaggacactg
14641 aattagcaac attcattttg gacagagag tcactctacc acgagtcggg cagcagatct
14701 taaacaactc catcacagga gcaagagaag agatctcggg ctactggat accacaaaag
14761 gattgataag aattggcata gcaaggagg gattaactca gagaacatta tctcgaattt
14821 ccaattatga ttatgaaca tttttgaacc taatgaatat gttgaagaac aaagaacaaa
14881 acagtgtcat tccctgtc gcttgcctg ttgactttgc tatagcttta agaagcagga
14941 tgtggaggaa attggcaaaa ggaagattaa tatatggttt agaagtcct gatccaatag

-continued

15001 aagcaatgat tggettttctc attcttggga gtgaaaattg tctactctgt gattcaggaa
15061 gcaaaaacta tacctgggtt ttcataccaa aggatgtaca gttggataag attgataaag
15121 atcacgcac aataagggtt ccctatgtcg gatcaactac cgaagaaaga tcagagataa
15181 agttaggatc cgtgaaaaat ccaagcaaat ccctgaaatc tgctataaga ctcgcaactg
15241 tgtacacttg ggcatttggc acaagtgatg ctgaatgggt ggaggcttgg tacttgtcta
15301 atcaacgagc aaatatatcc ttagatgttc tcaaacgat aacacctata tctacttcaa
15361 cgaatattgc tcatagatta cgagaccgat caacacaggt taaatacgcc agtacatctc
15421 ttaacagagt atcgcgcat gtaacaatta gtaacgataa catgaatttt gaatttgacg
15481 ggggttaaat ggataccaac ttgatttacc aacaagtcac gctgttaggg ctttcatgct
15541 tggagagtgt attccgaat aggaaaatga caaatagtta caatatcgtg taccatttac
15601 acgttcaaga acattgttgt gtaaaaggct tgaatgattt accttataca ccgtcaacac
15661 atccagtgcc aaattatata gaagtttagg ataataaggt aatttacgat cctcaacctc
15721 tattagaatt tgatgagcta agattagcaa ttcagcaaac aaagaaagta gatttggat
15781 tttcattgtg ggatacaaaa gaacttcatg agaatttagc tcaaatgtta gcgattacag
15841 taacggatat tatgacaaaa tctgataaag atcatattaa agaccaaaga agtatagatg
15901 ttgatgataa tattaagaca ctaataactg agtttttatt agtagacct gaaatgtttg
15961 ccgtaaatgt aggttgcac atatcaataa aatggtcatt tgatattcac tttaaaagac
16021 caagaggagc ctatagcatg atagaatact tgactgatct tttggataat acttctctc
16081 atgtttatcg aatccttact aatgtattat ctcatccag agttatgaga aaattcacta
16141 atgcccggct actagtaccg aaatacggct cctaccttac aagtcaagat ttcaaaaaga
16201 tggcggtaga tttcataata acagcgtata ccacatttt gaccaattgg tgtaataata
16261 acaagttttc aattctaata cctgaacaag accctgatat acttgaatta agaaaagaca
16321 tctctcatgc aaggcattta tgtatgatct cggatcttta ctgctactct ttcaagcaac
16381 cttggataaa ggagcttaca ccacaagaga agatctgctg catggaggac ttcatagcca
16441 attgtgttgc taatgatcaa acaagtgcgg gctggaacat aacgccctta agagtttaca
16501 atctccctgc atcgaccaca tacatcagga gagggataat aaaacaatta agaatccgtc
16561 aaagcaatga gcctattgat ctggaagata ttaggattgg tcagaacccc gattttgtga
16621 ataaacctat tgagttttgt agcagtgaat tcgggtatcac aatttataac cttgaagaaa
16681 ttcttcaatc aaatgtgcat ctcatgttaa atatgaacat tgactcctca acaagtaaca
16741 atactgaaaa tcattttatt agaagggtag gcttgaactc tacttcatct tataaagcac
16801 tatctttaac acctgttatt aaaagatata atcaacagaa cactaatagg ctgtttatag
16861 gagaaggatc agggctctatg atgtatcttt accagaaaac cttgggggag acaatatgct
16921 tctttaatc gggagttcag tacaatgagg atctgggtca aaggaacaa tcattatacc
16981 cgagtgaata cagtatctgt gaacaaggag taaaaaaga aaacctctc accgggcatg
17041 ttataccact attcaatgga agaccagaaa ccacatgggt aggcaatgat gattctttca
17101 agtatatatt ggaacatact ataaatagag acatcgggct tgttactcc gatagggaaa
17161 caggaatagg gaaggataat tatactatct taaatgaaca tgcacatctt atagcactga
17221 gccttacagt aatgattgat gatggaatct tgggtgtctaa ggtagcttat gcccctgggt
17281 tttgcatctc ttcattattg aatatgtacc ggacattttt ttcattagtt ctatgtgcgt

-continued

```

17341 ttccaccgta tagcaatddd gaatcaactg aatdddacdt gatttgcttg caaaaaagta
17401 taccgggacc tatcacacca gctagagcca tccaacaaac gacgaagcaa tctagagaag
17461 aggataatag tataactaat aatatcctca aatcaaaaa tcttggtcag aaagaattta
17521 tcaaaacagt aaagaaaaaa tacgaaatcc atccttcgtt taactgtcct atcaacttca
17581 caaaggatga taaatattta atgagtgttg ggtttcaagc caatggctct gatatgatac
17641 gtaaagagac gggctatgac ataggtagca atgtagagaa tctccgagat gtcttaatca
17701 agttgtttgc agatgcagtc accttctatg atgatgtcac aaataaaaag aactttttta
17761 atccttatcc agtctacaca agaactcagt ataaaattct gatggataaa atatgcaaga
17821 aagtcacctt atacacctta atcatatcat gtaaaggatc caatcaatat tgctgggaaa
17881 ttaaatccca aataagaaag cattgtctca tacttgattt gaaaagtaag gtttttacia
17941 aacttattcc aaagggatta agagaaaggg gtgactcaaa agggatgaag agcatatggt
18001 tcactaaact aaccagtcaa gaggtgaaaa gatggtggaa gatgatattt tacatcgtga
18061 taataagcaa tccataacca catccaactt gtcagttaaa cacttaaatc acaataaact
18121 tgtcatcaga ttaagaaaaa cttataattc ccttttttag gt

```

[0029] The present invention provides for nucleic acids related to the CedPV genome. In particular, the present invention provides for nucleic acids with a polynucleotide sequence at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to the polynucleotide sequence of SEQ ID NO:1.

[0030] The present invention also provides for fragments of the polynucleotide of SEQ ID NO:1, for example primers and probes.

[0031] The present invention also comprises vectors containing any of the nucleic acids disclosed herein. As used herein, a “vector” may be any of a number of nucleic acids into which a desired sequence may be inserted by restriction and ligation for transport between different genetic environments or for expression in a host cell. Vectors are typically composed of DNA although RNA vectors are also available. Vectors include, but are not limited to, plasmids and phagemids. A cloning vector is one which is able to replicate in a host cell, and which is further characterized by one or more endonuclease restriction sites at which the vector may be cut in a determinable fashion and into which a desired DNA sequence may be ligated such that the new recombinant vector retains its ability to replicate in the host cell. In the case of plasmids, replication of the desired sequence may occur many times as the plasmid increases in copy number within the host bacterium or just a single time per host before the host reproduces by mitosis. In the case of phage, replication may occur actively during a lytic phase or passively during a lysogenic phase. An expression vector is one into which a desired DNA sequence may be inserted by restriction and ligation such that it is operably joined to regulatory sequences and may be expressed as an RNA transcript. Vectors may further contain one or more marker sequences suitable for use in the identification and selection of cells which have been transformed or transfected with the vector. Markers include, for example, genes encoding proteins which increase or

decrease either resistance or sensitivity to antibiotics or other compounds, genes which encode enzymes whose activities are detectable by standard assays known in the art (e.g., .beta.-galactosidase or alkaline phosphatase), and genes which visibly affect the phenotype of transformed or transfected cells, hosts, colonies or plaques. Examples of vectors include but are not limited to those capable of autonomous replication and expression of the structural gene products present in the DNA segments to which they are operably joined.

[0032] The genomic sequence of SEQ ID NO:1 above codes for the nucleoplasmid protein (“N-protein”), the phosphoprotein (“P-protein”), the matrix protein (“M-protein”), the fusion protein (“F-protein”), the glycoprotein protein or attachment protein (“G-protein”) and the large protein (“L-protein”) of CedPV. In addition, the P gene also codes for the C-protein of CedPV. The terms “protein” and “polypeptide” are under interchangeably herein and refer to a polymer of amino acids.

[0033] As used herein with respect to polypeptides, the term “substantially pure” means that the polypeptides are essentially free of other substances with which they may be found in nature or in vivo systems to an extent practical and appropriate for their intended use. In particular, the polypeptides are sufficiently pure and are sufficiently free from other biological constituents of their host cells so as to be useful in, for example, generating antibodies, sequencing, or producing pharmaceutical preparations. By techniques well known in the art, substantially pure polypeptides may be produced in light of the nucleic acid and amino acid sequences disclosed herein. Because a substantially purified polypeptide of the invention may be admixed with a pharmaceutically acceptable carrier in a pharmaceutical preparation, the polypeptide may comprise only a certain percentage by weight of the preparation. The polypeptide is nonetheless substantially pure in that it has been substantially separated from the substances with which it may be associated in living systems.

[0034] As used herein with respect to nucleic acids and proteins, the term “isolated” means not found in its native

environment and includes but is not limited to such settings : (i) being amplified in vitro by, for example, polymerase chain reaction (PCR); (ii) being recombinantly produced by cloning and/or culturing; (iii) being purified, as by cleavage and gel separation; (iv) being part of a prepared plasmid or expression vector, or (v) synthesized by, for example, chemical synthesis. An isolated nucleic acid is one which is readily manipulable by recombinant DNA techniques well known in the art. Thus, a nucleotide sequence contained in a vector in which 5' and 3' restriction sites are known or for which polymerase chain reaction (PCR) primer sequences have been disclosed is considered isolated but a nucleic acid sequence existing in its native state in its natural host is not. An isolated nucleic acid or protein may be substantially purified, but need not be. For example, a nucleic acid that is isolated within a cloning or expression vector is not pure in that it may comprise only a tiny percentage of the material in the cell in which it resides. Such a nucleic acid is isolated, however, as the term is used herein because it is readily manipulable by standard techniques known to those of ordinary skill in the art.

[0035] Referring to the nucleotide sequence of SEQ ID NO:1 above, the coding sequence for the N-protein begins at position 144 and ends at 1676, resulting in a polypeptide of 510 amino acids long as disclosed in SEQ ID NO:2. The present invention thus provides for nucleic acids that code for the amino acid sequence of SEQ ID NO:2. In addition, the present invention also provides for nucleic acids with a polynucleotide sequence that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%,

[0037] The invention also provides for fragments of the polypeptide of SEQ ID NO:2. As used herein, a fragment of the reference polypeptide is a polypeptide with a length that is less than that of the reference polypeptide. The fragment may be within a larger molecule, such as a chimeric protein, such that the total length of the molecule containing the fragment is larger than the reference protein. The polypeptide fragments of SEQ ID NO:2 can be fragments of at least about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 506, 507, 508 or 509 amino acids in length. As used herein, the length of fragments disclosed above are also used to indicate a polypeptide having a number of amino acids within a certain range. For example, as used herein, a "polypeptide fragment of SEQ ID NO:2 can be fragment of at least about 15, 20, 25, 30 . . . amino acids in length" is used to mean that the fragments can be between 15 and 20 amino acids in length, and that the fragments can be between 20 and 25 amino acids in length, etc. One of skill in the art will recognize that a polypeptide fragment of SEQ ID NO:2 that is, for example, "at least about . . . 440, 445 . . . amino acids in length" will include polypeptide fragments that are between 440 and 445 amino acids in length.

(SEQ ID NO: 2)

```
MSDIFNETQS FRNYQSNLGR DGRASAATTT LTTKVRIFVP ANNNPNLRWR LTLFLMDVVR SPASAESMKV
GAGISLVSMY AEKPGALVRA LLNDPDVEAI IIDVYGFDEG IPIMERRGDK ATDDMDSLRLK IVKAAHDFSR
GRSLFVDQRV QDIVMSDMGS FVNAITSIET QIWILIAKAV TAPDTAESE GRRWAKYVQQ KRVNPLFLIS
PQWINDMRSL IAASLSLRKF MVELLMKAKK GRGTKGRIME IVSDIGNYVE ETGMAGFFAT IKFGLKETKFP
ALALNELQSD LNTMKSLMIL YRSIGPKAPF MVLLDSIQT KFAPGSYPLL WSPAMGVGTT IDRAMGALNI
NRSYLEPVYF RLGGQSAKHQ AGNVDKEMAE KLGLTEDQIV HLSANVKDAS QGRDDNQINI REGKFTNVVD
DIQDHAQSSS EDYNPSKKSF SILTSITSTV DSADSRSAMN ESMTTTSLLK LRQLAEKKK DSKNSQDTPP
KPRAKDQPT DEVSFMDNSNI
```

73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polynucleotide sequence of positions 144-1673 of SEQ ID NO:1.

[0036] The invention also provides for polypeptides, derivatives and fragments of the CedPV N-protein. Specifically, the present invention provides for polypeptides at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polypeptide of SEQ ID NO:2. As used herein, a "derivative" of a reference polypeptide is a polypeptide that has less than 100% amino acid identity with the reference polypeptide. For example, the invention provides for derivatives of the CedPV N-protein as described herein. The invention also provides for polypeptides comprising or consisting of the amino acid sequence of SEQ ID NO:2.

[0038] Referring to the nucleotide sequence of SEQ ID NO:1 above, the coding sequence for the P-protein begins at position 2112 and ends at 4325, resulting in a polypeptide of 737 amino acids long as disclosed in SEQ ID NO:3. The present invention thus provides for nucleic acids that code for the amino acid sequence of SEQ ID NO:3. In addition, the present invention also provides for nucleic acids with a polynucleotide sequence that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polynucleotide sequence of positions 2112-4325 of SEQ ID NO:1.

[0039] The invention also provides for nucleic acid molecules encoding the polypeptides, derivatives and fragments of the CedPV P-protein. Specifically, the present invention provides for polypeptides at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%,

73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polypeptide of SEQ ID NO:3. The invention also provides for polypeptides comprising or consisting of the amino acid sequence of SEQ ID NO:3.

[0040] The polypeptide fragments of SEQ ID NO:3 can be fragments of at least about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 731, 732, 733, 734, 735 or 736 amino acids in length. As used herein, the length of fragments disclosed above are also used to indicate a polypeptide having a number of amino acids within a certain range. For example, as used herein, a “polypeptide fragment of SEQ ID NO:3 can be fragment of at least about 15, 20, 25, 30 . . . amino acids in length” is used to mean that the fragments can be between 15 and 20 amino acids in length, and that the fragments can be between 20 and 25 amino acids in length, etc. One of skill in the art will recognize that a polypeptide fragment of SEQ ID NO:3 that is, for example, “at least about . . . 720, 725 . . . amino acids in length” will include polypeptide fragments that are between 720 and 725 amino acids in length.

that code for the amino acid sequence of SEQ ID NO:4. In addition, the present invention also provides for nucleic acids with a polynucleotide sequence that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polynucleotide sequence of positions 2137-2670 of SEQ ID NO:1.

[0042] The invention also provides for nucleic acid molecules encoding the polypeptides, derivatives and fragments of the CedPV C-protein. Specifically, the present invention provides for polypeptides at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polypeptide of SEQ ID NO:4. The invention also provides for polypeptides comprising or consisting of the amino acid sequence of SEQ ID NO:4.

[0043] The polypeptide fragments of SEQ ID NO:4 can be fragments of at least about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 166, 167, 168, 169, 170, 171, 172, 173, 174, 175 or 176 amino acids in length. As used herein, the length of fragments disclosed above are also used to indicate a polypeptide having a number of amino acids within a certain range. For example, as used herein, a “polypeptide fragment of SEQ ID NO:4 can be fragment of at least about 15, 20, 25, 30 . . . amino acids in length” is used to mean that the fragments can be between 15 and 20 amino acids in length, and that the fragments can be between 20 and

(SEQ ID NO: 3)

```
MDKLQLIEDG LSTINFIQEN KEKLQHSYGR SSIREPPTSV RVEEWEKFIR KIASGPEQVQ GGGSETEITG
DNGDRGNFTN PDQGGGVGTGQ FEERYQKWGS QDSELQLDPM VVHDFFYDER RENPDNGKYD RSSKKRDNIR
EGTRQDKYNN QSTDLLSCL QPSSKNDVIK NESTSVSNLH VTGNKLNPD A KPFEPTSQSK EHPTTTQH NK
NDHQTDDDYK NRRSSENNVI SDHATTMEDN NNFIPATKRK NALSEPIYVQ VLPSNTEGFS GKDYPLLKDN
SVKKRAEPVI LETANHPAGS ADQDTNQIEE NMQFNLPKLL TEDTDDEPED NNDSMPLEED IREIGSMLKD
GTKDIKTRMN EIDDAIKKIN KSKNRSLLD ESDGKDQGRR DPSVDLGIKK RKEGLKAAMQ KTKEQLSIKV
EREIGLNDRI CQNSKMSTK KLIYAGMEME YGQTSTGSGG PQGSKDGTSD DVQVDEYDE GEDYEAMPSD
RFYTTLSGEQ KDRFDLDANQ MSQYDLEAQQ DELTRMNLIL YSRLETTNKL LIDILDLAKE MPKLVKVDN
LERQMGNLNM LTSTLEGLHS SVMIMIPGKD KSEKEIPKNP DLRPILGRSN TSLTDVIDLD HYPDKGSKGI
KPSGSGDRQY IGSLESKF SI NDEYNFAPYP IRDELLLPGL RDDKTNASSF IPDDTDRSPM VLKIIIRQNI
HDEEVKDELL SILEQHNTVE ELNEIWNTVN DYLDGNI
```

[0041] The coding sequence for the C-protein is within the P-protein coding sequence and begins at position 2137 (of SEQ ID NO:1) and ends at position 2670, resulting in a polypeptide of 177 amino acids long as disclosed in SEQ ID NO:4. The present invention thus provides for nucleic acids

25 amino acids in length, etc. One of skill in the art will recognize that a polypeptide fragment of SEQ ID NO:4 that is, for example, “at least about . . . 140, 145 . . . amino acids in length” will include polypeptide fragments that are between 140 and 145 amino acids in length.

(SEQ ID NO: 4)

MASLLSILYR KIRKNYSILT EDPPSESHQ VSGLKSGRNL FERSLLDLNK FKGEDLRLRS QAIMEIEAIL

PILIREAESQ DNSKKGKING GHKIQYNWT QWLYTSSMT REGRIPTMEN MTAALKNGII SEKEHDRIST

IISLLMNYCP AYNHLLRTMS SRMKVHCQCI CMLQEIN

[0044] Referring to the nucleotide sequence of SEQ ID NO:1 above, the coding sequence for the M-protein begins at position 4635 and ends at 5717, resulting in a polypeptide of 360 amino acids long as disclosed in SEQ ID NO:5. The present invention thus provides for nucleic acids that code for the amino acid sequence of SEQ ID NO:5. In addition, the present invention also provides for nucleic acids with a polynucleotide sequence that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polynucleotide sequence of positions 4635-5717 of SEQ ID NO:1.

[0045] The invention also provides for nucleic acid molecules encoding the polypeptides, derivatives and fragments of the CedPV M-protein. Specifically, the present invention provides for polypeptides at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polypeptide of SEQ ID NO:5. The invention also provides for polypeptides comprising or consisting of the amino acid sequence of SEQ ID NO:5.

[0046] The polypeptide fragments of SEQ ID NO:5 can be fragments of at least about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 356, 357, 358 or 359 amino acids in length. As used herein, the length of fragments disclosed above are also used to indicate a polypeptide having a number of amino acids within a certain range. For example, as used herein, a “polypeptide fragment of SEQ ID NO:5 can be fragment of at least about 15, 20, 25, 30 . . . amino acids in length” is used to mean that the fragments can be between 15 and 20 amino acids in length, and that the fragments can be between 20 and 25 amino acids in length, etc. One of skill in the art will recognize that a polypeptide fragment of SEQ ID NO:5 that is, for example, “at least about . . . 280, 285 . . . amino acids in length” will include polypeptide fragments that are between 280 and 285 amino acids in length.

[0047] Referring to the nucleotide sequence of SEQ ID NO:1 above, the coding sequence for the F-protein begins at position 6405 and ends at 8078, resulting in a polypeptide of 557 amino acids long as disclosed in SEQ ID NO:6. The present invention thus provides for nucleic acids that code for the amino acid sequence of SEQ ID NO:6. In addition, the present invention also provides for nucleic acids with a polynucleotide sequence that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polynucleotide sequence of positions 6405-8078 of SEQ ID NO:1.

[0048] The invention also provides for nucleic acid molecules encoding the polypeptides, derivatives and fragments of the CedPV F-protein. Specifically, the present invention provides for polypeptides at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polypeptide of SEQ ID NO:6. The invention also provides for polypeptides comprising or consisting of the amino acid sequence of SEQ ID NO:6.

[0049] The polypeptide fragments of SEQ ID NO:6 can be fragments of at least about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 546, 547, 548, 549, 550, 551, 552, 553, 554, 555 or 556 amino acids in length. As used herein, the length of fragments disclosed above are also used to indicate a polypeptide having a number of amino acids within a certain range. For example, as used herein, a “polypeptide fragment of SEQ ID NO:6 can be fragment of at least about 15, 20, 25, 30 . . . amino acids in length” is used to mean that the fragments can be between 15 and 20 amino acids in length, and that the fragments can be between 20 and 25 amino acids in length, etc. One of skill in the art will recognize that a polypeptide fragment of SEQ ID

(SEQ ID NO: 5)

MDPSDLRRRII MEDDKSLVNN DDSTETDFLE KTWREGSKID KITPEVDENG NMVPKYVVFN PGKNERKTSG

YQYMICYGFI EDGPINGSR VKGNIRTTAS FPLGVGKTY S PEEILQELT TLKITVRRTA GSNEKLVYGI

TGPLNHLYPW YKVLTTGGSIF SAVKVCNRVD QILLDRPQIL RVFFLSITKL TDKGVYMIKP SVLDFRSDNS

MAFNLLVYLK IDTDITKAGI RGIWNKEGER ITSPMLHIGN FTRRGKHY S VEYCKRKIDK MKLTFALGTI

GGLSLHIRID GRISKRLQAO VGFQRNICYS LMDTNPWLNK LTWNNSCEIH KVTAVIQPSV PKDFMLYEDI

LIDNTGKILK

NO:6 that is, for example, “at least about . . . 515, 520 . . . amino acids in length” will include polypeptide fragments that are between 515 and 520 amino acids in length.

[0053] Referring to the nucleotide sequence of SEQ ID NO:1 above, the coding sequence for the G-protein begins at position 8268 and ends at 10136, resulting in a polypeptide of

(SEQ ID NO: 6)

```

MSNKRTTVLI IISYTLFYLN NAAIVGFDFD KLNKIGVVQG RVLNYKIKGD PMTKDLVLKF IPNIVNITEC
VREPLSRYN TVRRLLLPIH NMLGLYLNNT NAKMTGLMIA GVIMGGIAIG IATAAQITAG FALYEAKKNT
ENIQKLTDSI MKTQDSIDKL TDSVGTSLIL LNKLTQTYINN QLVPNLELLS CRQNKIEFDL MLTKYLVLDL
TVIGPNINNP VNKDMTIQSL SLLFDGNYDI MMSELGYTPQ DFLDLIESKS ITGQIIYVDM ENLYVVIRTY
LPTLIEVPDA QIYEFNKITM SSNGGEYLSL IPNFILIRGN YMSNIDVATC YMTKASVICN QDYSLPMSQN
LRSCYQGETE YCPVEAVIAS HSPRFALTNG VIFANCINTI CRCQDNGKTI TQNIHQFVSM IDNSTCNDVM
VDKFTIKVGK YMGRKDINNI NIQIGPQIII DKVDLSNEIN KMNQSLKDSI FYLREAKRIL DSVNISLISP
SVQLFLIIIS VLSFIILLII IVYLYCKSKH SYKYNKFIDD PDYNDYKRE RINGKASKSN NIYYVGD

```

[0050] One example of a fragment of an F protein is a soluble CedPV F glycoprotein comprising all or part of the extracellular domain of F glycoprotein of CedPV. The soluble forms of F glycoprotein may be produced by deleting all or part of the transmembrane and/or cytoplasmic tail domains of the F glycoprotein. By way of example, a soluble F glycoprotein may comprise the complete extracellular region of a CedPV F glycoprotein. In some embodiments, the soluble F glycoprotein may be truncated at after K490 in SEQ ID NO:6. Also, by way of example, a soluble F glycoprotein may comprise all or part of the extracellular region and part of the transmembrane domain of a CedPV F glycoprotein. By way of further example, several versions of a soluble F (sF) glycoprotein can be constructed, primarily through removing the cytoplasmic tail and/or transmembrane domain that anchor the protein. As used herein, “soluble F glycoprotein” or “soluble form of F glycoprotein” or “sF glycoprotein” refers to an amino acid sequence for a fragment or portion of native F glycoprotein that contains the extracellular domain or a portion thereof. The sF glycoprotein is structurally similar to the native viral F glycoprotein.

[0051] The sF glycoproteins of the invention are structurally similar to the native viral F glycoprotein. By way of example, the sF glycoproteins of the invention may be recognized by polyclonal antibodies directed to CedPV. By way of example, the sF glycoproteins of the invention may assemble in the oligomeric form or forms (such as a trimer), comparable to native CedPV F glycoprotein.

[0052] The sF or sG glycoproteins of the present invention are suitable, for example, for vaccine development and for acting as an antigen to generate anti-viral antibodies when used as a vaccine or in the isolation of recombinant monoclonal antibodies. The sF or sG glycoproteins are suitable to generate antibodies capable of recognizing native F or G glycoprotein. The sF or sG glycoproteins of the present invention that assemble in monomeric or oligomeric forms, such as trimers, can be of further use, such as, for example, for crystallization and structural determination to provide further information to aid structural-based antiviral research. The oligomeric forms of sF or sG glycoprotein of the present invention may also generate further antibodies capable of recognizing native F or G glycoprotein and its native oligomeric forms. The term “soluble” has no bearing on the protein’s ability to dissolve in an aqueous or non-aqueous solvent.

622 amino acids long as disclosed in SEQ ID NO:7. The present invention thus provides for nucleic acids that code for the amino acid sequence of SEQ ID NO:7. In addition, the present invention also provides for nucleic acids with a polynucleotide sequence that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polynucleotide sequence of positions 8268-10136 of SEQ ID NO:1.

[0054] The invention also provides for nucleic acid molecules encoding the polypeptides, derivatives and fragments of the CedPV G-protein. Specifically, the present invention provides for polypeptides at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polypeptide of SEQ ID NO:7. The invention also provides for polypeptides comprising or consisting of the amino acid sequence of SEQ ID NO:7.

[0055] The polypeptide fragments of SEQ ID NO:7 can be fragments of at least about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795, 800, 805, 810, 815, 820, 825, 830, 835, 840, 845, 850, 855, 860, 865, 870, 875, 880, 885, 890, 895, 900, 905, 910, 915, 920, 925, 930, 935, 940, 945, 950, 955, 960, 965, 970, 975, 980, 985, 990, 995, 1000, 1005, 1010, 1015, 1020, 1025, 1030, 1035, 1040, 1045, 1050, 1055, 1060, 1065, 1070, 1075, 1080, 1085, 1090, 1095, 1100, 1105, 1110, 1115, 1120, 1125, 1130, 1135, 1140, 1145, 1150, 1155, 1160, 1165, 1170, 1175, 1180, 1185, 1190, 1195, 1200, 1205, 1210, 1215, 1220, 1225, 1230, 1235, 1240, 1245, 1250, 1255, 1260, 1265, 1270, 1275, 1280, 1285, 1290, 1295, 1300, 1305, 1310, 1315, 1320, 1325, 1330, 1335, 1340, 1345, 1350, 1355, 1360, 1365, 1370, 1375, 1380, 1385, 1390, 1395, 1400, 1405, 1410, 1415, 1420, 1425, 1430, 1435, 1440, 1445, 1450, 1455, 1460, 1465, 1470, 1475, 1480, 1485, 1490, 1495, 1500, 1505, 1510, 1515, 1520, 1525, 1530, 1535, 1540, 1545, 1550, 1555, 1560, 1565, 1570, 1575, 1580, 1585, 1590, 1595, 1600, 1605, 1610, 1615, 1620, 1625, 1630, 1635, 1640, 1645, 1650, 1655, 1660, 1665, 1670, 1675, 1680, 1685, 1690, 1695, 1700, 1705, 1710, 1715, 1720, 1725, 1730, 1735, 1740, 1745, 1750, 1755, 1760, 1765, 1770, 1775, 1780, 1785, 1790, 1795, 1800, 1805, 1810, 1815, 1820, 1825, 1830, 1835, 1840, 1845, 1850, 1855, 1860, 1865, 1870, 1875, 1880, 1885, 1890, 1895, 1900, 1905, 1910, 1915, 1920, 1925, 1930, 1935, 1940, 1945, 1950, 1955, 1960, 1965, 1970, 1975, 1980, 1985, 1990, 1995, 2000, 2005, 2010, 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050, 2055, 2060, 2065, 2070, 2075, 2080, 2085, 2090, 2095, 2100, 2105, 2110, 2115, 2120, 2125, 2130, 2135, 2140, 2145, 2150, 2155, 2160, 2165, 2170, 2175, 2180, 2185, 2190, 2195, 2200, 2205, 2210, 2215, 2220, 2225, 2230, 2235, 2240, 2245, 2250, 2255, 2260, 2265, 2270, 2275, 2280, 2285, 2290, 2295, 2300, 2305, 2310, 2315, 2320, 2325, 2330, 2335, 2340, 2345, 2350, 2355, 2360, 2365, 2370, 2375, 2380, 2385, 2390, 2395, 2400, 2405, 2410, 2415, 2420, 2425, 2430, 2435, 2440, 2445, 2450, 2455, 2460, 2465, 2470, 2475, 2480, 2485, 2490, 2495, 2500, 2505, 2510, 2515, 2520, 2525, 2530, 2535, 2540, 2545, 2550, 2555, 2560, 2565, 2570, 2575, 2580, 2585, 2590, 2595, 2600, 2605, 2610, 2615, 2620, 2625, 2630, 2635, 2640, 2645, 2650, 2655, 2660, 2665, 2670, 2675, 2680, 2685, 2690, 2695, 2700, 2705, 2710, 2715, 2720, 2725, 2730, 2735, 2740, 2745, 2750, 2755, 2760, 2765, 2770, 2775, 2780, 2785, 2790, 2795, 2800, 2805, 2810, 2815, 2820, 2825, 2830, 2835, 2840, 2845, 2850, 2855, 2860, 2865, 2870, 2875, 2880, 2885, 2890, 2895, 2900, 2905, 2910, 2915, 2920, 2925, 2930, 2935, 2940, 2945, 2950, 2955, 2960, 2965, 2970, 2975, 2980, 2985, 2990, 2995, 3000, 3005, 3010, 3015, 3020, 3025, 3030, 3035, 3040, 3045, 3050, 3055, 3060, 3065, 3070, 3075, 3080, 3085, 3090, 3095, 3100, 3105, 3110, 3115, 3120, 3125, 3130, 3135, 3140, 3145, 3150, 3155, 3160, 3165, 3170, 3175, 3180, 3185, 3190, 3195, 3200, 3205, 3210, 3215, 3220, 3225, 3230, 3235, 3240, 3245, 3250, 3255, 3260, 3265, 3270, 3275, 3280, 3285, 3290, 3295, 3300, 3305, 3310, 3315, 3320, 3325, 3330, 3335, 3340, 3345, 3350, 3355, 3360, 3365, 3370, 3375, 3380, 3385, 3390, 3395, 3400, 3405, 3410, 3415, 3420, 3425, 3430, 3435, 3440, 3445, 3450, 3455, 3460, 3465, 3470, 3475, 3480, 3485, 3490, 3495, 3500, 3505, 3510, 3515, 3520, 3525, 3530, 3535, 3540, 3545, 3550, 3555, 3560, 3565, 3570, 3575, 3580, 3585, 3590, 3595, 3600, 3605, 3610, 3615, 3620, 3625, 3630, 3635, 3640, 3645, 3650, 3655, 3660, 3665, 3670, 3675, 3680, 3685, 3690, 3695, 3700, 3705, 3710, 3715, 3720, 3725, 3730, 3735, 3740, 3745, 3750, 3755, 3760, 3765, 3770, 3775, 3780, 3785, 3790, 3795, 3800, 3805, 3810, 3815, 3820, 3825, 3830, 3835, 3840, 3845, 3850, 3855, 3860, 3865, 3870, 3875, 3880, 3885, 3890, 3895, 3900, 3905, 3910, 3915, 3920, 3925, 3930, 3935, 3940, 3945, 3950, 3955, 3960, 3965, 3970, 3975, 3980, 3985, 3990, 3995, 4000, 4005, 4010, 4015, 4020, 4025, 4030, 4035, 4040, 4045, 4050, 4055, 4060, 4065, 4070, 4075, 4080, 4085, 4090, 4095, 4100, 4105, 4110, 4115, 4120, 4125, 4130, 4135, 4140, 4145, 4150, 4155, 4160, 4165, 4170, 4175, 4180, 4185, 4190, 4195, 4200, 4205, 4210, 4215, 4220, 4225, 4230, 4235, 4240, 4245, 4250, 4255, 4260, 4265, 4270, 4275, 4280, 4285, 4290, 4295, 4300, 4305, 4310, 4315, 4320, 4325, 4330, 4335, 4340, 4345, 4350, 4355, 4360, 4365, 4370, 4375, 4380, 4385, 4390, 4395, 4400, 4405, 4410, 4415, 4420, 4425, 4430, 4435, 4440, 4445, 4450, 4455, 4460, 4465, 4470, 4475, 4480, 4485, 4490, 4495, 4500, 4505, 4510, 4515, 4520, 4525, 4530, 4535, 4540, 4545, 4550, 4555, 4560, 4565, 4570, 4575, 4580, 4585, 4590, 4595, 4600, 4605, 4610, 4615, 4620, 4625, 4630, 4635, 4640, 4645, 4650, 4655, 4660, 4665, 4670, 4675, 4680, 4685, 4690, 4695, 4700, 4705, 4710, 4715, 4720, 4725, 4730, 4735, 4740, 4745, 4750, 4755, 4760, 4765, 4770, 4775, 4780, 4785, 4790, 4795, 4800, 4805, 4810, 4815, 4820, 4825, 4830, 4835, 4840, 4845, 4850, 4855, 4860, 4865, 4870, 4875, 4880, 4885, 4890, 4895, 4900, 4905, 4910, 4915, 4920, 4925, 4930, 4935, 4940, 4945, 4950, 4955, 4960, 4965, 4970, 4975, 4980, 4985, 4990, 4995, 5000, 5005, 5010, 5015, 5020, 5025, 5030, 5035, 5040, 5045, 5050, 5055, 5060, 5065, 5070, 5075, 5080, 5085, 5090, 5095, 5100, 5105, 5110, 5115, 5120, 5125, 5130, 5135, 5140, 5145, 5150, 5155, 5160, 5165, 5170, 5175, 5180, 5185, 5190, 5195, 5200, 5205, 5210, 5215, 5220, 5225, 5230, 5235, 5240, 5245, 5250, 5255, 5260, 5265, 5270, 5275, 5280, 5285, 5290, 5295, 5300, 5305, 5310, 5315, 5320, 5325, 5330, 5335, 5340, 5345, 5350, 5355, 5360, 5365, 5370, 5375, 5380, 5385, 5390, 5395, 5400, 5405, 5410, 5415, 5420, 5425, 5430, 5435, 5440, 5445, 5450, 5455, 5460, 5465, 5470, 5475, 5480, 5485, 5490, 5495, 5500, 5505, 5510, 5515, 5520, 5525, 5530, 5535, 5540, 5545, 5550, 5555, 5560, 5565, 5570, 5575, 5580, 5585, 5590, 5595, 5600, 5605, 5610, 5615, 5620, 5625, 5630, 5635, 5640, 5645, 5650, 5655, 5660, 5665, 5670, 5675, 5680, 5685, 5690, 5695, 5700, 5705, 5710, 5715, 5720, 5725, 5730, 5735, 5740, 5745, 5750, 5755, 5760, 5765, 5770, 5775, 5780, 5785, 5790, 5795, 5800, 5805, 5810, 5815, 5820, 5825, 5830, 5835, 5840, 5845, 5850, 5855, 5860, 5865, 5870, 5875, 5880, 5885, 5890, 5895, 5900, 5905, 5910, 5915, 5920, 5925, 5930, 5935, 5940, 5945, 5950, 5955, 5960, 5965, 5970, 5975, 5980, 5985, 5990, 5995, 6000, 6005, 6010, 6015, 6020, 6025, 6030, 6035, 6040, 6045, 6050, 6055, 6060, 6065, 6070, 6075, 6080, 6085, 6090, 6095, 6100, 6105, 6110, 6115, 6120, 6125, 6130, 6135, 6140, 6145, 6150, 6155, 6160, 6165, 6170, 6175, 6180, 6185, 6190, 6195, 6200, 6205, 6210, 6215, 6220, 6225, 6230, 6235, 6240, 6245, 6250, 6255, 6260, 6265, 6270, 6275, 6280, 6285, 6290, 6295, 6300, 6305, 6310, 6315, 6320, 6325, 6330, 6335, 6340, 6345, 6350, 6355, 6360, 6365, 6370, 6375, 6380, 6385, 6390, 6395, 6400, 6405, 6410, 6415, 6420, 6425, 6430, 6435, 6440, 6445, 6450, 6455, 6460, 6465, 6470, 6475, 6480, 6485, 6490, 6495, 6500, 6505, 6510, 6515, 6520, 6525, 6530, 6535, 6540, 6545, 6550, 6555, 6560, 6565, 6570, 6575, 6580, 6585, 6590, 6595, 6600, 6605, 6610, 6615, 6620, 6625, 6630, 6635, 6640, 6645, 6650, 6655, 6660, 6665, 6670, 6675, 6680, 6685, 6690, 6695, 6700, 6705, 6710, 6715, 6720, 6725, 6730, 6735, 6740, 6745, 6750, 6755, 6760, 6765, 6770, 6775, 6780, 6785, 6790, 6795, 6800, 6805, 6810, 6815, 6820, 6825, 6830, 6835, 6840, 6845, 6850, 6855, 6860, 6865, 6870, 6875, 6880, 6885, 6890, 6895, 6900, 6905, 6910, 6915, 6920, 6925, 6930, 6935, 6940, 6945, 6950, 6955, 6960, 6965, 6970, 6975, 6980, 6985, 6990, 6995, 7000, 7005, 7010, 7015, 7020, 7025, 7030, 7035, 7040, 7045, 7050, 7055, 7060, 7065, 7070, 7075, 7080, 7085, 7090, 7095, 7100, 7105, 7110, 7115, 7120, 7125, 7130, 7135, 7140, 7145, 7150, 7155, 7160, 7165, 7170, 7175, 7180, 7185, 7190, 7195, 7200, 7205, 7210, 7215, 7220, 7225, 7230, 7235, 7240, 7245, 7250, 7255, 7260, 7265, 7270, 7275, 7280, 7285, 7290, 7295, 7300, 7305, 7310, 7315, 7320, 7325, 7330, 7335, 7340, 7345, 7350, 7355, 7360, 7365, 7370, 7375, 7380, 7385, 7390, 7395, 7400, 7405, 7410, 7415, 7420, 7425, 7430, 7435, 7440, 7445, 7450, 7455, 7460, 7465, 7470, 7475, 7480, 7485, 7490, 7495, 7500, 7505, 7510, 7515, 7520, 7525, 7530, 7535, 7540, 7545, 7550, 7555, 7560, 7565, 7570, 7575, 7580, 7585, 7590, 7595, 7600, 7605, 7610, 7615, 7620, 7625, 7630, 7635, 7640, 7645, 7650, 7655, 7660, 7665, 7670, 7675, 7680, 7685, 7690, 7695, 7700, 7705, 7710, 7715, 7720, 7725, 7730, 7735, 7740, 7745, 7750, 7755, 7760, 7765, 7770, 7775, 7780, 7785, 7790, 7795, 7800, 7805, 7810, 7815, 7820, 7825, 7830, 7835, 7840, 7845, 7850, 7855, 7860, 7865, 7870, 7875, 7880, 7885, 7890, 7895, 7900, 7905, 7910, 7915, 7920, 7925, 7930, 7935, 7940, 7945, 7950, 7955, 7960, 7965, 7970, 7975, 7980, 7985, 7990, 7995, 8000, 8005, 8010, 8015, 8020, 8025, 8030, 8035, 8040, 8045, 8050, 8055, 8060, 8065, 8070, 8075, 8080, 8085, 8090, 8095, 8100, 8105, 8110, 8115, 8120, 8125, 8130, 8135, 8140, 8145, 8150, 8155, 8160, 8165, 8170, 8175, 8180, 8185, 8190, 8195, 8200, 8205, 8210, 8215, 8220, 8225, 8230, 8235, 8240, 8245, 8250, 8255, 8260, 8265, 8270, 8275, 8280, 8285, 8290, 8295, 8300, 8305, 8310, 8315, 8320, 8325, 8330, 8335, 8340, 8345, 8350, 8355, 8360, 8365, 8370, 8375, 8380, 8385, 8390, 8395, 8400, 8405, 8410, 8415, 8420, 8425, 8430, 8435, 8440, 8445, 8450, 8455, 8460, 8465, 8470, 8475, 8480, 8485, 8490, 8495, 8500, 8505, 8510, 8515, 8520, 8525, 8530, 8535, 8540, 8545, 8550, 8555, 8560, 8565, 8570, 8575, 8580, 8585, 8590, 8595, 8600, 8605, 8610, 8615, 8620, 8625, 8630, 8635, 8640, 8645, 8650, 8655, 8660, 8665, 8670, 8675, 8680, 8685, 8690, 8695, 8700, 8705, 8710, 8715, 8720, 8725, 8730, 8735, 8740, 8745, 8750, 8755, 8760, 8765, 8770, 8775, 8780, 8785, 8790, 8795, 8800, 8805,

amino acids in length” will include polypeptide fragments that are between 300 and 305 amino acids in length.

nucleotide sequence that is at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%,

(SEQ ID NO: 7)

MLSQQLQKNYL DNSNQQGDKM NNPDKKLSVN FNPLELDKGQ KDLNKSYYVK NKNYNVSNLL NESLHDIKFC
IYCIFSLII ITIINIITIS IVITRLKVHE ENNGMESPNL QSIQDSLSSL TNMINTEITP RIGILVTATS
VTLSSSINYV GTKTNQLVNE LKDYITKSCG FKVPELKLHE CNISCADPKI SKSAMYSTNA YAELAGPPKI
FCKSVSKDPD FRLKQIDYVI PVQQDRSICM NNPLLDISDG FFTYIHYEGI NSCKKSDSFK VLLSHGEIVD
RGDYRPSLYL LSSHYHPYSM QVINCVPVTC NQSSFVFCI SMNTKTLDNS DYSSDEYYIT YFNGIDRPKT
KKIPINMNTA DNRYIHFTFS GGGGVCLGEE FIIPVTTVIN TDVPTHDYCE SFNCVSQTKG SLKEICSESL
RSPTNSSRYN LNGIMIISQN NMTDFKIQLN GITYNKLSFG SPGRLSKTLG QVLYYQSSMS WDTYKAGFV
EKWKPFPTNW MNNTVISRPN QGNCPRYHKC PEICYGGTYN DIAPLDLGKD MYVSVILDSD QLAENPEITV
FNSTTILYKE RVSKDELNTR STTSCFLFL DEPWCISVLE TNRFNGKSIR PEIYSYKIPK YC

[0056] Examples of fragments of G proteins CedPV include soluble forms of CedPV G-protein that retain characteristics of the native viral G glycoprotein allowing for rapid high throughput production of vaccines, diagnostics and screening.

[0057] Soluble forms of CedPV G glycoproteins comprise at least a portion of the ectodomain (e.g. extracellular) of the G glycoprotein. In select embodiments, CedPV are generally produced by deleting all or part of the transmembrane domain of the G glycoprotein and all or part of the cytoplasmic tail of the G glycoprotein. In one embodiment, the soluble G protein of CedPV does not comprise any portion of the cytoplasmic region of the full length G protein. In another embodiment, the soluble G protein of CedPV does not comprise any portion of the transmembrane domain. In yet another embodiment, the soluble G protein of CedPV comprises no portion of the transmembrane domain and the cytoplasmic domain. As used herein, the term “soluble” simply means that the G protein is missing a portion or all of its cytoplasmic tail or that the G protein is missing all or part of its transmembrane domain, or both. In some embodiments, the soluble G glycoprotein is truncated after K87 in SEQ ID NO:7. The term “soluble” has no bearing on the protein’s ability to dissolve in an aqueous or non-aqueous solvent.

[0058] The soluble CedPV G glycoproteins of the invention, generally retain one or more characteristics of the corresponding native viral glycoprotein, such as, ability to interact or bind the viral host cell receptor, can be produced in monomeric and/or oligomeric form or forms, or the ability to elicit antibodies (including, but not limited to, viral neutralizing antibodies) capable of recognizing native G glycoprotein. Examples of additional characteristics include, but are not limited to, the ability to block or prevent infection of a host cell. Conventional methodology may be utilized to evaluate soluble CedPV G glycoproteins for one of more of the characteristics. Examples of methodology that may be used include, but are not limited to, the assays described herein in the Examples.

[0059] Referring to the nucleotide sequence of SEQ ID NO:1 above, the coding sequence for the L-protein begins at position 10572 and ends at 18077, resulting in a polypeptide of 2501 amino acids long as disclosed in SEQ ID NO:8. The present invention thus provides for nucleic acids that code for the amino acid sequence of SEQ ID NO:8. In addition, the present invention also provides for nucleic acids with a poly-

73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polynucleotide sequence of positions 10572-18077 of SEQ ID NO:1.

[0060] The invention also provides for nucleic acid molecules encoding the polypeptides, derivatives and fragments of the CedPV L-protein. Specifically, the present invention provides for polypeptides at least about 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identical to the polypeptide of SEQ ID NO:8. The invention also provides for polypeptides comprising or consisting of the amino acid sequence of SEQ ID NO:8.

[0061] The polypeptide fragments of SEQ ID NO:8 can be fragments of at least about 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 255, 260, 265, 270, 275, 280, 285, 290, 295, 300, 305, 310, 315, 320, 325, 330, 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 395, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545, 550, 555, 560, 565, 570, 575, 580, 585, 590, 595, 600, 605, 610, 615, 620, 625, 630, 635, 640, 645, 650, 655, 660, 665, 670, 675, 680, 685, 690, 695, 700, 705, 710, 715, 720, 725, 730, 735, 740, 745, 750, 755, 760, 765, 770, 775, 780, 785, 790, 795, 800, 805, 810, 815, 820, 825, 830, 835, 840, 845, 850, 855, 860, 865, 870, 875, 880, 885, 890, 895, 900, 905, 910, 915, 920, 925, 930, 935, 940, 945, 950, 955, 960, 965, 970, 975, 980, 985, 990, 995, 1000, 1005, 1010, 1015, 1020, 1025, 1030, 1035, 1040, 1045, 1050, 1055, 1060, 1065, 1070, 1075, 1080, 1085, 1090, 1095, 1100, 1105, 1110, 1115, 1120, 1125, 1130, 1135, 1140, 1145, 1150, 1155, 1160, 1165, 1170, 1175, 1180, 1185, 1190, 1195, 1200, 1205, 1210, 1215, 1220, 1225, 1230, 1235, 1240, 1245, 1250, 1255, 1260, 1265, 1270, 1275, 1280, 1285, 1290, 1295, 1300, 1305, 1310, 1315, 1320, 1325, 1330, 1335, 1340, 1345, 1350, 1355, 1360, 1365, 1370, 1375, 1380, 1385, 1390, 1395, 1400, 1405, 1410, 1415, 1420, 1425, 1430, 1435, 1440, 1445, 1450, 1455, 1460, 1465, 1470, 1475, 1480, 1485, 1490, 1495, 1500, 1505, 1510, 1515, 1520, 1525, 1530, 1535, 1540, 1545, 1550, 1555, 1560, 1565, 1570,

1575, 1580, 1585, 1590, 1595, 1600, 1605, 1610, 1615, 1620, 1625, 1630, 1635, 1640, 1645, 1650, 1655, 1660, 1665, 1670, 1675, 1680, 1685, 1690, 1695, 1700, 1705, 1710, 1715, 1720, 1725, 1730, 1735, 1740, 1745, 1750, 1755, 1760, 1765, 1770, 1775, 1780, 1785, 1790, 1795, 1800, 1805, 1810, 1815, 1820, 1825, 1830, 1835, 1840, 1845, 1850, 1855, 1860, 1865, 1870, 1875, 1880, 1885, 1890, 1895, 1900, 1905, 1910, 1915, 1920, 1925, 1930, 1935, 1940, 1945, 1950, 1955, 1960, 1965, 1970, 1975, 1980, 1985, 1990, 1995, 2000, 2005, 2010, 2015, 2020, 2025, 2030, 2035, 2040, 2045, 2050, 2055, 2060, 2065, 2070, 2075, 2080, 2085, 2090, 2095, 2100, 2105, 2110, 2115, 2120, 2125, 2130, 2135, 2140, 2145, 2150, 2155, 2160, 2165, 2170, 2175, 2180, 2185, 2190, 2195, 2200, 2205, 2210, 2215, 2220, 2225, 2230, 2235, 2240, 2245, 2250, 2255, 2260, 2265, 2270, 2275, 2280, 2285, 2290, 2295, 2300, 2305, 2310, 2315, 2320, 2325, 2330, 2335, 2340, 2345, 2350, 2355, 2360, 2365, 2370,

2375, 2380, 2385, 2390, 2395, 2400, 2405, 2410, 2415, 2420, 2425, 2430, 2435, 2440, 2445, 2450, 2455, 2460, 2465, 2470, 2475, 2480, 2485, 2490, 2491, 2492, 2593, 2494, 2495, 2496, 2497, 2498, 2499 or 2500 amino acids in length. As used herein, the length of fragments disclosed above are also used to indicate a polypeptide having a number of amino acids within a certain range. For example, as used herein, a “polypeptide fragment of SEQ ID NO:8 can be fragment of at least about 15, 20, 25, 30 . . . amino acids in length” is used to mean that the fragments can be between 15 and 20 amino acids in length, and that the fragments can be between 20 and 25 amino acids in length, etc. One of skill in the art will recognize that a polypeptide fragment of SEQ ID NO:8 that is, for example, “at least about . . . 2050, 2055 . . . amino acids in length” will include polypeptide fragments that are between 2050 and 2055 amino acids in length.

(SEQ ID NO: 8)

MESDFDISVS DVLYPECHLD SPIVGGLIT SLEYANLTHN QPHEDQTLT NINVNKKKKI KSP LISQQSL

FGNEVNKEIF DLKNYYHVPY PECNRDLFLI SDDKIAFKLS KIMDNSNKL F DGLERKLSRL ISNVNDQLLN

ATSLHNNSEM DRKGKEHPCF PEKSTIDDVR QQRQTRDFPK NSTREGRSPK HPDAGPTPEN SAKNDLHRDN

TDNMPTGHSS TSMKKPKISG EYLSMWLDS EDLGSKRISA QLGKDVSCG HLHTTEDKPI IVPDTRYIQN

HESNNDIFPK KEKFKLPP SSDNLTKIMV NSKWYNPFLF WFTVKTELRA CQKENYKRKN RKLGIITSIK

GSCYKLILNQ NLVAIFEEDS SGYSDHKRRK KRCYYLTPEM VLMFSDVTEG RLMIDVAMRF DKKYKTLKEK

ALKLWFLIDE LFPSMGNRVY NIISMLEPLT LAILQVKDES RLLRGAFMH CLGDLFEELR ESKNYPEDEI

KRFANDLINV MTCRDIHLVA EFFFSTFTFG HPILNAQTAA RKVREYMLAD KILEYEPIMK GHAIFCAIII

NGFRDRHGGV WPPLDLPKHC SKNIISLKNT GEGVTYEVAI NNWRSFVGLK FKCMPGLNLD NDLSMYMKDK

ALSPLRDLWD SIYSREVMSY QPPRNKKSRR LVEVFVDDQD FDPVDMINYV LTGEYLRDD FNASYSLKEK

ETKQVGRLEA KMTYKMRACQ VIAENLIAHG IGRYFHENG M VKDEHELKSK LFQLSISGIP RGNKNNKSTN

DTIHESKIEN NHSFKNIQNR SFRKTDNPYN RFNIDNPTFL SPNCNPKYNR KNSETIGIFS RAETKSMIRE

QKSHREVKIN KLDIGSDNEE QGKEIDAAKY KITDNPNP HI NPQDQPGICQ EDKGKEGAKS DLTEGMSFLE

MHTLFNPSKS DIRTNLELEK SLSNPGFIS QKEKRKGTYN ESHSLGKFSK EDEERYDVIS AFLTTDLRKF

CLNWRHESIG IFARRMDEIY GLPGFFNMW RRLERSVLYV ADPHCPPSIN EHIDLND SPE RDI FHHHPKG

GIEGYSQKLW TIATIPFLFL SAHETNTRIA AVVQGDNQSI AITHKVHPL PYKMKKELSA MQAKKYFSRL

RHNMKALGHE LKATETIIST HFFIYKKI H YDGA VLSQSL KSMARCVFWS ETLVDETAA CSNISTTIAK

AIENGYSRRS GYLINVLKTI QQINISLSFN INECMTDDII RPFDRNPNWI KHAALIPASL GGLNYMMSR

LYVRNIGDPV TASIADVKRM ILGGVLP IGI LHNIMLQEPG DATYLDWCS D PYSINLKQTQ SITKVIKNIT

ARVILRNSVN PLLKGLFHEG AYEEDTELAT FILD RR VILP RVGHEILNNS ITGAREEISG LLDTTKGLIR

IGIAKGGLTQ RTLRSISNYD YEQFLNLMNM LKNKEQNSVI SLSACSV DFA IALRSRMWRK LAKGR LIYGL

EVPDPIEAMI GFLILGSENC LLCDSGSKNY TWFFIPKDVQ LDKIDKDHAS IRVPYVGSTT EERSEIKLGS

VKNPSKSLKS AIRLATVYTW AFGTSDAEWW EAWYLSNQRA NIPLDVLKTI TPISTSTNIA HRLRDRSTQV

KYASTSLNRV SRHVTISNDN MNFEFDGVKM DTNLIYQQVM LLGLSCLES L FRNRKMTNSY NIVYHLHVQE

HCCVKALNDL PYTPSTHVPV NYTEVRDNRL IYDPQPILEF DELRLAIQQT KKVDLEFSLW DTKE LHENLA

QSLAITVTDI MTKSDKHIK DQSIDVDDN IKTLITEFL L VDPEMFAVNL GLHISIKWSF DIHFKRPRGR

YSMIEYLTDL LDNTSSHVYR ILTNVLSHPR VMRKFTNAGL LVPKYGPYLT SQDFKKMAVD FIITAYTTFL

TNWCNNKFS ILIPEQDPDI LELRKDITHA RHLCMISDLY CYSFKQPWIK ELTPQEKICV MEDFIANCVA

-continued

NDQTSAGWNI TPLRVYNLPA STTYIRRGII KQLRIRQSNE PIDLEDIRIG QNPDFVNKPI EFCSSSEFGIT
 IYNLEEILQS NVHLSVMNMI DSSTSNNTEN HLFRRVGLNS TSSYKALSLT PVIKRYHQQN TNRLFIGEGS
 GSM MYLYQKT LGETICFFNS GVQYNEDLGQ REQSLYPSEY SICEQGVKKE NPLTGHVPIPL FNGRPETTWV
 GNDDSFKYIL EHTINRDIGL VHSDMETGIG KDNYTILNEH AHLIALSLTV MIDDGILVSK VAYAPGFCIS
 SLLNMYRTFF SLVLCAPPPY SNFESTEFYL ICLQKSIPGP ITPARAIQQT TKQSREEDNS ITNNILKIKN
 LVQKEFIKT V KKKYEIHPSF NCPINF TKDD KYLMSVGFQA NGPDMIRKET GYDIGSNVEN LRDVLIKLFA
 DAVTFYDDVT NKKNFLNPYP VYTRTQYKIL MDKICKKVT L YTLIISCKGS NQYCWEIKSQ IRKHCLILD L
 KSKVFTKLIP KGLRERGDSK GMKSIWFTKL TSQEVKRWK MISYIVIISN P

[0062] A polypeptide having an amino acid sequence at least, for example, about 95% “identical” to a reference amino acid sequence, e.g., SEQ ID NO:7, is understood to mean that the amino acid sequence of the polypeptide is identical to the reference sequence except that the amino acid sequence may include up to about five modifications per each 100 amino acids of the reference amino acid sequence. In other words, to obtain a peptide having an amino acid sequence at least about 95% identical to a reference amino acid sequence, up to about 5% of the amino acid residues of the reference sequence may be deleted or substituted with another amino acid or a number of amino acids up to about 5% of the total amino acids in the reference sequence may be inserted into the reference sequence. These modifications of the reference sequence may occur at the N-terminus or C-terminus positions of the reference amino acid sequence or anywhere between those terminal positions, interspersed either individually among amino acids in the reference sequence or in one or more contiguous groups within the reference sequence.

[0063] As used herein, “identity” is a measure of the identity of nucleotide sequences or amino acid sequences compared to a reference nucleotide or amino acid sequence. In general, the sequences are aligned so that the highest order match is obtained. “Identity” per se has an art-recognized meaning and can be calculated using published techniques. (See, e.g., Computational Molecular Biology, Lesk, A. M., ed., Oxford University Press, New York (1988); Biocomputing: Informatics And Genome Projects, Smith, D. W., ed., Academic Press, New York (1993); Computer Analysis of Sequence Data, Part I, Griffin, A. M., and Griffin, H. G., eds., Humana Press, New Jersey (1994); von Heinje, G., Sequence Analysis In Molecular Biology, Academic Press (1987); and Sequence Analysis Primer, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York (1991)). While there are several methods to measure identity between two polynucleotide or polypeptide sequences, the term “identity” is well known to skilled artisans (Carillo, H. & Lipton, D., Siam J Applied Math 48:1073 (1988)). Methods commonly employed to determine identity or similarity between two sequences include, but are not limited to, those disclosed in Guide to Huge Computers, Martin J. Bishop, ed., Academic Press, San Diego (1994) and Carillo, H. & Lipton, D., Siam J Applied Math 48:1073 (1988). Computer programs may also contain methods and algorithms that calculate identity and similarity. Examples of computer program methods to determine identity and similarity between two sequences include, but are not limited to, GCG program package (Devereux, J., et al., Nucleic Acids Research 12(i):387 (1984)), BLASTP, ExPASy, BLASTN, FASTA (Atschul, S. F., et al., J Molec

Biol 215:403 (1990)) and FASTDB. Examples of methods to determine identity and similarity are discussed in Michaels, G. and Garian, R., Current Protocols in Protein Science, Vol 1, John Wiley & Sons, Inc. (2000), which is incorporated by reference.

[0064] In one embodiment of the present invention, the algorithm used to determine identity between two or more polypeptides is BLASTP. In another embodiment of the present invention, the algorithm used to determine identity between two or more polypeptides is FASTDB, which is based upon the algorithm of Brutlag et al. (Comp. App. Biosci. 6:237-245 (1990), incorporated by reference). In a FASTDB sequence alignment, the query and reference sequences are amino sequences. The result of sequence alignment is in percent identity. In one embodiment, parameters that may be used in a FASTDB alignment of amino acid sequences to calculate percent identity include, but are not limited to: Matrix=PAM, k-tuple=2, Mismatch Penalty=1, Joining Penalty=20, Randomization Group Length=0, Cutoff Score=1, Gap Penalty=5, Gap Size Penalty 0.05, Window Size=500 or the length of the subject amino sequence, whichever is shorter.

[0065] If the reference sequence is shorter or longer than the query sequence because of N-terminus or C-terminus additions or deletions, but not because of internal additions or deletions, a manual correction can be made, because the FASTDB program does not account for N-terminus and C-terminus truncations or additions of the reference sequence when calculating percent identity. For query sequences truncated at the N- or C-termini, relative to the reference sequence, the percent identity is corrected by calculating the number of residues of the query sequence that are N- and C-terminus to the reference sequence that are not matched/aligned, as a percent of the total bases of the query sequence. The results of the FASTDB sequence alignment determine matching/alignment. The alignment percentage is then subtracted from the percent identity, calculated by the above FASTDB program using the specified parameters, to arrive at a final percent identity score. This corrected score can be used for the purposes of determining how alignments “correspond” to each other, as well as percentage identity. Residues of the reference sequence that extend past the N- or C-termini of the query sequence may be considered for the purposes of manually adjusting the percent identity score. That is, residues that are not matched/aligned with the N- or C-termini of the comparison sequence may be counted when manually adjusting the percent identity score or alignment numbering.

[0066] For example, a 90 amino acid residue query sequence is aligned with a 100 residue reference sequence to determine percent identity. The deletion occurs at the N-ter-

minus of the query sequence and therefore, the FASTDB alignment does not show a match/alignment of the first 10 residues at the N-terminus. The 10 unpaired residues represent 10% of the reference sequence (number of residues at the N- and C-termini not matched/total number of residues in the reference sequence) so 10% is subtracted from the percent identity score calculated by the FASTDB program. If the remaining 90 residues were perfectly matched (100% alignment) the final percent identity would be 90% (100% alignment-10% unmatched overhang). In another example, a 90 residue query sequence is compared with a 100 reference sequence, except that the deletions are internal deletions. In this case the percent identity calculated by FASTDB is not manually corrected, since there are no residues at the N- or C-termini of the subject sequence that are not matched/aligned with the query. In still another example, a 110 amino acid query sequence is aligned with a 100 residue reference sequence to determine percent identity. The addition in the query occurs at the N-terminus of the query sequence and therefore, the FASTDB alignment may not show a match/alignment of the first 10 residues at the N-terminus. If the remaining 100 amino acid residues of the query sequence have 95% identity to the entire length of the reference sequence, the N-terminal addition of the query would be ignored and the percent identity of the query to the reference sequence would be 95%.

[0067] As used herein, the terms “correspond(s) to” and “corresponding to,” as they relate to sequence alignment, are intended to mean enumerated positions within the reference protein, e.g., CedPV G protein, and those positions in the modified CedPV G protein that align with the positions on the reference protein. Thus, when the amino acid sequence of a subject CedPV G protein is aligned with the amino acid sequence of a reference CedPV G protein, e.g., SEQ ID NO:7, the amino acids in the subject sequence that “correspond to” certain enumerated positions of the reference sequence are those that align with these positions of the reference sequence, e.g., SEQ ID NO:7, but are not necessarily in these exact numerical positions of the reference sequence. Methods for aligning sequences for determining corresponding amino acids between sequences are described herein. Accordingly, the invention provides novel peptides whose sequences correspond to the sequence of SEQ ID NO:7.

[0068] Variants resulting from insertion of the polynucleotide encoding a protein disclosed herein into an expression vector system are also contemplated. For example, variants (usually insertions) may arise from when the amino terminus and/or the carboxy terminus of a modified protein is/are fused to another polypeptide.

[0069] In another aspect, the invention provides deletion variants wherein one or more amino acid residues in the modified protein are removed. Deletions can be effected at one or both termini of the modified protein, or with removal of one or more non-terminal amino acid residues of the modified protein. Deletion variants, therefore, include all fragments of the modified protein.

[0070] Within the confines of the disclosed percent identity, the invention also relates to substitution variants of disclosed polypeptides of the invention. Substitution variants include those polypeptides wherein one or more amino acid residues of a modified protein are removed and replaced with alternative residues. In one aspect, the substitutions are conservative in nature; however, the invention embraces substitutions that are also non-conservative. Conservative substitutions for this

purpose may be defined as set out in the tables below. Amino acids can be classified according to physical properties and contribution to secondary and tertiary protein structure. A conservative substitution is recognized in the art as a substitution of one amino acid for another amino acid that has similar properties. Exemplary conservative substitutions are set out in below.

TABLE I

Conservative Substitutions	
SIDE CHAIN CHARACTERISTIC	AMINO ACID
<u>Aliphatic</u>	
Non-polar	G, A, P, I, L, V
Polar - uncharged	C, S, T, M, N, Q
Polar - charged	D, E, K, R
Aromatic	H, F, W, Y
Other	N, Q, D, E

[0071] Alternatively, conservative amino acids can be grouped as described in Lehninger, [Biochemistry, Second Edition; Worth Publishers, Inc. NY, N.Y. (1975), pp. 71 77] as set out below.

TABLE II

Conservative Substitutions	
SIDE CHAIN CHARACTERISTIC	AMINO ACID
<u>Non-polar (hydrophobic)</u>	
A. Aliphatic:	A, L, I, V, P
B. Aromatic:	F, W
C. Sulfur-containing:	M
D. Borderline:	G
<u>Uncharged-polar</u>	
A. Hydroxyl:	S, T, Y
B. Amides:	N, Q
C. Sulfhydryl:	C
D. Borderline:	G
Positively Charged (Basic):	K, R, H
Negatively Charged (Acidic)	D, E

[0072] And still other alternative, exemplary conservative substitutions are set out below.

TABLE III

Conservative Substitutions	
Original Residue	Exemplary Substitution
Ala (A)	Val, Leu, Ile
Arg (R)	Lys, Gln, Asn
Asn (N)	Gln, His, Lys, Arg
Asp (D)	Glu
Cys (C)	Ser
Gln (Q)	Asn
Glu (E)	Asp
His (H)	Asn, Gln, Lys, Arg
Ile (I)	Leu, Val, Met, Ala, Phe
Leu (L)	Ile, Val, Met, Ala, Phe
Lys (K)	Arg, Gln, Asn
Met (M)	Leu, Phe, Ile
Phe (F)	Leu, Val, Ile, Ala
Pro (P)	Gly
Ser (S)	Thr
Thr (T)	Ser

TABLE III-continued

Conservative Substitutions	
Original Residue	Exemplary Substitution
Trp (W)	Tyr
Tyr (Y)	Trp, Phe, Thr, Ser
Val (V)	Ile, Leu, Met, Phe, Ala

[0073] It should be understood that the definition of peptides or polypeptides of the invention is intended to include polypeptides bearing modifications other than insertion, deletion, or substitution of amino acid residues. By way of example, the modifications may be covalent in nature, and include for example, chemical bonding with polymers, lipids, other organic and inorganic moieties. Such derivatives may be prepared to increase circulating half-life of a polypeptide, or may be designed to improve the targeting capacity of the polypeptide for desired cells, tissues or organs. Similarly, the invention further embraces modified peptides that have been covalently modified to include one or more water-soluble polymer attachments such as polyethylene glycol, polyoxyethylene glycol or polypropylene glycol.

[0074] The present invention is also directed to antibodies or fragments thereof that specifically bind to CedPV or fragments of any of the CedPV proteins disclosed herein.

[0075] In particular, the present invention provides antibodies or antibody fragments that bind to the four hydrophobic pockets in the head of the G glycoprotein of the Cedar virus. The antibodies may be monoclonal or polyclonal. Cedar virus likely begins the infection process by binding to the ephrin B2 transmembrane protein that is present on at least endothelial cells, among others. Specifically, the ephrin B2 protein contains a "GH-loop region" that inserts into the 4 hydrophobic binding pockets on the head of the G glycoprotein of Cedar virus, thus allowing the virus to bind specifically to the cell surface protein and begin the infection process. The contact residues of Cedar virus that bind the ephrin B2 are V507, F458 and 1401, with the letters referring to the standard one-letter abbreviation of standard amino acids and the numbering referring to the amino acid numbering of SEQ ID NO:7 according to the sequences disclosed herein. As such, the present invention provides antibodies or antibody fragments that bind the non-linear epitope of Cedar virus defined by V507/F458/1401, provided the antibodies or antibody fragments, provided that the antibodies are not any of the antibodies disclosed in PCT/US05/040050 and PCT/US12/35806 which are hereby incorporated by reference in their entirety.

[0076] For example, antibodies encompassed by the present invention, include, but are not limited to, antibodies specific for CedPV G glycoprotein, antibodies that cross react with Hendra Virus G glycoprotein and/or Nipah Virus G Glycoprotein and neutralizing antibodies. By way of example a characteristic of a neutralizing antibody includes, but is not limited to, the ability to block or prevent infection of a host cell. The antibodies of the invention may be characterized using methods well known in the art.

[0077] The antibodies useful in the present invention can encompass monoclonal antibodies, polyclonal antibodies, antibody fragments (e.g., Fab, Fab', F(ab')₂, Fv, Fc, etc.), chimeric antibodies, bispecific antibodies, heteroconjugate antibodies, single chain (ScFv), mutants thereof, fusion proteins comprising an antibody portion, humanized antibodies,

and any other modified configuration of the immunoglobulin molecule that comprises an antigen recognition site of the required specificity, including glycosylation variants of antibodies, amino acid sequence variants of antibodies, and covalently modified antibodies. Examples of antibodies are derived from murine, rat, human, primate, or any other origin (including chimeric or humanized antibodies).

[0078] Methods of preparing monoclonal and polyclonal antibodies are well known in the art. Polyclonal antibodies can be raised in a mammal, for example, by one or more injections of an immunizing agent and, if desired an adjuvant. Examples of adjuvants include, but are not limited to, keyhole limpet, hemocyanin, serum albumin, bovine thyroglobulin, soybean trypsin inhibitor, Freund complete adjuvant and MPL-TDM adjuvant. The immunization protocol can be determined by one of skill in the art.

[0079] The antibodies may alternatively be monoclonal antibodies. Monoclonal antibodies may be produced using hybridoma methods (see, e.g., Kohler, B. and Milstein, C. (1975) *Nature* 256:495-497 or as modified by Buck, D. W., et al., *In Vitro*, 18:377-381 (1982).

[0080] If desired, the antibody of interest may be sequenced and the polynucleotide sequence may then be cloned into a vector for expression or propagation. The sequence encoding the antibody of interest may be maintained in vector in a host cell and the host cell can then be expanded and frozen for future use. In an alternative, the polynucleotide sequence may be used for genetic manipulation to "humanize" the antibody or to improve the affinity, or other characteristics of the antibody (e.g., genetically manipulate the antibody sequence to obtain greater affinity to the G glycoprotein and/or greater efficacy in inhibiting the fusion of a Cedar Virus, Hendra or Nipah virus to the host cell receptor.).

[0081] The antibodies may also be humanized by methods known in the art. See, for example, U.S. Pat. Nos. 4,816,567; 5,807,715; 5,866,692; 6,331,415; 5,530,101; 5,693,761; 5,693,762; 5,585,089; and 6,180,370, which are incorporated by reference. In yet another embodiment, fully human antibodies may be obtained by using commercially available mice that have been engineered to express specific human immunoglobulin proteins.

[0082] In another embodiment, antibodies may be made recombinantly and expressed using any method known in the art. By way of example, antibodies may be made recombinantly by phage display technology. See, for example, U.S. Pat. Nos. 5,565,332; 5,580,717; 5,733,743; and 6,265,150; and Winter et al., *Annu. Rev. Immunol.* 12:433-455 (1994). Alternatively, the phage display technology (McCafferty et al., *Nature* 348:552-553 (1990)) can be used to produce human antibodies and antibody fragments in vitro. Phage display can be performed in a variety of formats; for review see, e.g., Johnson, Kevin S, and Chiswell, David J., *Current Opinion in Structural Biology* 3:564-571 (1993). By way of example, a soluble G glycoprotein as described herein may be used as an antigen for the purposes of isolating recombinant antibodies by these techniques.

[0083] Antibodies may be made recombinantly by first isolating the antibodies and antibody producing cells from host animals, obtaining the gene sequence, and using the gene sequence to express the antibody recombinantly in host cells (e.g., CHO cells). Another method which may be employed is to express the antibody sequence in plants (e.g., tobacco) or transgenic milk. Methods for expressing antibodies recombinantly in plants or milk have been disclosed. See, for

example, Peeters, et al. Vaccine 19:2756 (2001); Lonberg, N. and D. Huszar Int. Rev. Immunol 13:65 (1995); and Pollock, et al., J Immunol Methods 231:147 (1999), which are incorporated by reference. Methods for making derivatives of antibodies, e.g., humanized, single chain, etc. are known in the art.

[0084] The antibodies of the invention can be bound to a carrier by conventional methods, for use in, for example, isolating or purifying CedPV G glycoproteins or detecting Hendra or Nipah G glycoproteins in a biological sample or specimen. Alternatively, by way of example, the neutralizing antibodies of the invention may be administered as passive immunotherapy to a subject infected with or suspected of being infected with Hendra, Nipah and/or Cedar virus. The terms "subject" and "patient" are used interchangeably and include but are not limited to humans, simians, farm animals, sport animals and pets. Veterinary uses are also encompassed by the invention.

[0085] Diagnostics

[0086] The proteins, protein fragment and/or antibodies of the invention may be used in a variety of immunoassays for Cedar virus. The recombinant expressed protein fragments of the invention can be produced with high quality control and are suitable as an antigen for the purposes of detecting antibody in biological samples. By way of example, and not limitation, a soluble CedPV G glycoprotein could be used as an antigen in an ELISA assay to detect antibody in a biological sample from a subject.

[0087] The nucleic acids, including primers and probes, of the invention are also be used in a variety of assays for Cedar virus. The primers and probes of the invention are used to detect the presence of ribonucleic acids encoding the Cedar virus in a subject. The present invention also includes a method for detecting the presence of Cedar virus utilizing nucleic acid amplification techniques, for example reverse transcriptase-PCR methods, utilizing repeated cycles of denaturations, primer annealing and extension carried out with DNA polymerase, for example Taq polymerase, to lead to exponential increases in derived nucleic acid, so as to facilitate detection of the presence of the virus.

[0088] Vaccines

[0089] This invention also relates to vaccines for Cedar virus. In one aspect the vaccines are DNA based vaccines. One skilled in the art is familiar with administration of expression vectors to obtain expression of an exogenous protein in vivo. See, e.g., U.S. Pat. Nos. 6,436,908; 6,413,942; and 6,376,471. Viral-based vectors for delivery of a desired polynucleotide and expression in a desired cell are well known in the art and non-limiting examples are described herein. In another aspect, the vaccines are protein-based and comprise one or more fragments of the proteins or protein fragment of the invention. Examples of protein fragments include but are not limited to ectodomains, transmembrane domains, cytoplasmic domains and functional portions thereof, as well as portions that are specifically reactive to neutralizing antibodies. Vaccines may also be antibody-based vaccines for more immediate treatment as well as prophylaxis against infection.

[0090] Administration of expression vectors includes but is not limited to local or systemic administration, including injection, oral administration, particle gun or catheterized administration, and topical administration. Targeted delivery of therapeutic compositions containing an expression vector, or subgenomic polynucleotides can also be used. Receptor-

mediated DNA delivery techniques are described in, for example, Findeis et al., Trends Biotechnol. (1993) 11:202; Chiou et al., Gene Therapeutics: Methods And Applications Of Direct Gene Transfer (J. A. Wolff, ed.) (1994); Wu et al., J. Biol. Chem. (1988) 263:621; Wu et al., J. Biol. Chem. (1994) 269:542; Zenke et al., Proc. Natl. Acad. Sci. USA (1990) 87:3655; Wu et al., J. Biol. Chem. (1991) 266:338.

[0091] Non-viral delivery vehicles and methods can also be employed, including, but not limited to, polyelectrolytic condensed DNA linked or unlinked to killed adenovirus alone (see, e.g., Curiel, Hum. Gene Ther. (1992) 3:147); ligand-linked DNA (see, e.g., Wu, J. Biol. Chem. (1989) 264:16985); eukaryotic cell delivery vehicles cells (see, e.g., U.S. Pat. No. 5,814,482; PCT Publication Nos. WO 95/07994; WO 96/17072; WO 95/30763; and WO 97/42338) (all of which are incorporated by reference) and nucleic charge neutralization or fusion with cell membranes. Naked DNA can also be employed. Exemplary naked DNA introduction methods are described in PCT Publication No. WO 90/11092 and U.S. Pat. No. 5,580,859, which are incorporated by reference. Liposomes that can act as gene delivery vehicles are described in U.S. Pat. No. 5,422,120; PCT Publication Nos. WO 95/13796; WO 94/23697; WO 91/14445; and EP 0524968, which are incorporated by reference. Additional approaches are described in Philip, Mol. Cell. Biol. (1994) 14:2411, and in Woffendin, Proc. Natl. Acad. Sci. (1994) 91:1581, which are incorporated by reference.

[0092] For human administration, codons comprising a polynucleotide encoding a protein or fragment thereof may be optimized for human use.

[0093] In another aspect of the invention, a soluble CedPV G glycoprotein is used as a subunit vaccine. The soluble CedPV glycoprotein or combination thereof may be administered by itself or in combination with an adjuvant. Examples of adjuvants include, but are not limited, aluminum salts, water-in-oil emulsions, oil-in-water emulsions, saponin, QuilA and derivatives, iscoms, liposomes, cytokines including gamma interferon or interleukin 12, DNA, microencapsulation in a solid or semi-solid particle, Freund's complete and incomplete adjuvant or active ingredients thereof including muramyl dipeptide and analogues, DEAE dextran/mineral oil, Alhydrogel, Auspharm adjuvant, and Algamulin.

[0094] The subunit vaccine comprising soluble CedPV G glycoprotein or combinations thereof can be administered orally, intravenously, subcutaneously, intraarterially, intramuscularly, intracardially, intraspinal, intrathoracically, intraperitoneally, intraventricularly, sublingually, and/or transdermally.

[0095] Dosage and schedule of administration can be determined by methods known in the art. Efficacy of the soluble CedPV G glycoprotein or combinations thereof as a vaccine for Cedar, Hendra, Nipah or related Henipavirus viruses may also be evaluated by methods known in the art.

EXAMPLES

Example 1

[0096] Urine (approximately 0.5-1 ml) was collected off plastic sheets placed underneath a colony of flying foxes (predominantly *Pteropus alecto* with some *P. Poliocephalus* in the mixed population) in Cedar Grove, South East Queensland, Australia and pooled into 2 ml tubes containing 0.5 ml of viral transport medium (SPGA: a mix of sucrose, phosphate, glutamate and albumin plus penicillin, streptomycin

and fungizone). The tubes were temporarily stored on ice after collection and transported to a laboratory in Queensland, frozen at -80°C . The samples were thawed at 4°C and centrifuged at $16,000\times g$ for 1 min to pellet debris. Urine in the supernatant (approximately 0.5-1 ml) was diluted 1:10 in cell culture media.

[0097] The diluted urine was centrifuged at $1,200\times g$ for 5 min and split evenly over Vero, PaKi, PaBr, PaSp and PaPI cell monolayers in 75-cm^2 tissue culture flasks. Cell lines used this study were Vero (ATCC), HeLa-USU (22), and the P. alecto primary cell lines derived from kidney (PaKi), brain (PaBr), (spleen) PaSp and placenta (PaPI). Cells were grown in Dulbecco's Modified Eagle's Medium Nutrient Mixture F-12 Ham supplemented with double strength antibiotic-antimycotic (Invitrogen), $10\text{ }\mu\text{g/ml}$ ciprofloxacin (MP Biomedicals) and 10% fetal calf serum at 37°C in the presence of 5% CO_2 . The flasks were rocked for 2 h at 37°C , 14 ml of fresh cell culture media was added and then incubated for 7 days at 37°C . The flasks were observed daily for toxicity, contamination, or viral cytopathic effect (CPE).

[0098] Syncytial CPE was observed in kidney cell (PaKi) monolayers 5 days post inoculation (dpi) with two different urine samples. No CPE was observed in any of the four other cell lines. Supernatant harvested 6 dpi was used to inoculate fresh PaKi cell monolayers. After two passages in PaKi cells, the virus was able to infect and cause CPE in Vero cells. The CPE morphology of the virus, however, in Vero cells was different from that of HeV infection. Further analysis using HeV-specific PCR primers indicated that the new bat virus was not an isolate of HeV.

Example 2

[0099] Cells from Example 1 showing syncytial CPE were screened using published broadly reactive primers (31) for all known paramyxoviruses and a subset of paramyxoviruses. PCR products were gel extracted and cloned into pGEM T-Easy (Promega) to facilitate sequencing using M13 primers. Sequences were obtained and aligned with known paramyxovirus sequences allowing for initial classification.

[0100] The entire genomic sequence was analyzed using a combination of 454 sequencing (43) and conventional Sanger sequencing. Virions from tissue culture supernatant were collected by centrifugation at $30,000\times g$ for 60 min and resuspended in $140\text{ }\mu\text{l}$ of PBS and mixed with $560\text{ }\mu\text{l}$ of freshly made AVL for RNA extraction using QIAamp Viral RNA mini kit (Qiagen). Synthesis of cDNA and random amplification was conducted using a modification of a published procedure (44). Briefly, cDNA synthesis was performed using a random octamer-linked to a 17-mer defined primer sequence: (5'-GTTTCCCAGTAGGTCTC NNN NNNN-3') and SuperScript III Reverse Transcriptase (Life Technologies). $8\text{ }\mu\text{l}$ of ds-cDNA was amplified in $200\text{ }\mu\text{l}$ PCR reactions with hot-start Taq polymerase enzyme (Promega) and 5'-A*G*(C*A*C TGTAGGTTTCCCAGTAGGTCTC-3' (where * denotes thiol modifications) as amplification primers for 40 cycles of $95^{\circ}\text{C}/1\text{ min}$, $48^{\circ}\text{C}/1\text{ min}$, $72^{\circ}\text{C}/1\text{ min}$ after an initial denaturation step of 5 min at 95°C and followed by purification with the QIAquick PCR purification kit (Qiagen). Sample preparation for Roche 454 sequencing (454 Life Sciences Branford, Conn., USA) was performed according to the manufacturer's suggested protocol (Rapid Library Preparation and emPCR Lib-L SV).

[0101] To obtain an accurate CedPV genome sequence, 454 generated data (after removing low quality, ambiguous and

adapter sequences) was analysed by both de novo assembly and read mapping of raw reads onto the CedPV draft genome sequence derived from Sanger sequencing. For 454 read mapping, SNPs and DIPs generated with the CLC software were manually assessed for accuracy by visualising the mapped raw reads (random PCR errors are obvious compared to real SNPs and DIPs especially when read coverage is deep). Consensus sequences for both 454 de novo and read mapping assembly methods were then compared to the Sanger sequence with the latter used to resolve conflicts within the low coverage regions as well as to resolve 454 homopolymer errors.

[0102] Sequences of genome termini were determined by 3'- and 5'-RACE using a previously published protocol (45). Briefly, approximately 100 ng of RNA was ligated with adaptor DT88 (see reference for sequence information) using T4 RNA ligase (Promega) followed by cDNA synthesis using the SuperScript III RT kit (Life Technologies) and an adaptor-specific primer, DT89. PCR amplification was then carried out using DT89 and one or more genome-specific primers. PCR products were sequenced directly using either DT89 or genome specific primers by an in-house service group on the ABI Sequencer 3100.

[0103] The CLC Genomics Workbench v4.5.1 (CLC Inc, Aarhus, Denmark) was used to trim 454 adapter and cDNA/PCR primer sequences, to remove low quality, ambiguous and small reads $<15\text{ bp}$ and to perform de novo and read mapping assemblies all with default parameters. Clone Manager

[0104] Professional version 9.11 (Scientific and Educational Software, Cary, N.C., USA) was used to join overlapping contigs generated by de novo assembly. Phylogenetic trees were constructed using the neighbor-joining algorithm with bootstrap values determined by 1,000 replicates in the MEGA4 software package (46).

[0105] Considering the formation of syncytial CPE by this new virus and the previous success in isolating paramyxoviruses from bat urine, paramyxovirus family-specific and genus-specific primers were used to determine whether this new virus was a member of the family Paramyxoviridae. Positive PCR fragments of the expected sizes were obtained from the Paramyxovirinae and Respirovirus/Morbillivirus/Henipavirus primer sets developed by Tong et al (31).

[0106] Sequencing of the PCR products indicated that it was a new paramyxovirus most closely related to HeV and NiV. Based on these preliminary data, the virus was named Cedar virus (CedPV) after the location of the bat colony sampled.

[0107] As shown in FIG. 1, the genome of CedPV is 18,162 nt in length and is most similar to that of HeV in the family. The full genome sequence has been deposited to GenBank (Accession No. JQ001776). The genome size is a multiple of 6, which is in perfect agreement with the Rule-of-Six observed for all known members of the subfamily Paramyxovirinae (3). The genome of CedPV has a 3-nt intergenic sequence of CTT absolutely conserved at all seven positions and highly conserved gene start and stop signals similar to those present in HeV and NiV (FIG. 2).

[0108] Also similar to the HeV genome is the presence of relatively large non-coding regions in the CedPV genome (FIG. 1 and Table 1). The overall protein-coding capacity of the CedPV genome is 87.41% which is higher than HeV at 82.12%. As the genome size of CedPV and HeV is very similar, the increased coding capacity of CedPV is attributed

to an increase in protein sizes for five of the six major proteins, with the L protein being 257-aa larger (Table 1). At 2,501 aa, the CedPV L protein is the largest, not only in the family Paramyxoviridae but also for all known viruses in the order Mononegavirale.

[0112] To verify that there are no multiple mRNAs produced from the CedPV P gene, direct sequencing of P gene transcripts was conducted from CedPV-infected Vero cells using multiple sets of primers generating overlapping fragments covering the entire coding region of the P gene. Briefly,

TABLE 1

Comparison of common genes among CedPV, HeV and NiV						
Gene	Virus	Open Reading Frame			Length of Untranslated Regions (nt)	
		Length (aa)	% sequence identity to CedPV	% sequence identity to HeV	5' UTR	3'UTR
N	CedPV	510			88	334
	HeV	532	58		57	568
	NiV	532	59	92	57	586
P	CedPV	737			98	192
	HeV	707	25		105	469
	NiV	709	27	65	105	469
C	CedPV	177				
	HeV	166	26			
	NiV	166	25	83		
M	CedPV	359			114	408
	HeV	352	60		100	200
	NiV	352	60	89	100	200
F	CedPV	557			276	88
	HeV	546	42		272	418
	NiV	546	43	87	284	412
G	CedPV	622			98	139
	HeV	604	29		233	516
	NiV	602	30	78	233	504
L	CedPV	2501			293	63
	HeV	2244	50		153	67
	NiV	2244	50	86	153	67

[0109] Phylogenetic analysis based on the full length genome sequence and the deduced amino acid sequences of each structural protein confirmed the initial observation that CedPV is most closely related to henipaviruses in the family. A phylogenetic tree based on the deduced sequences of the nucleocapsid protein (N) is presented in FIG. 3A. A phylogenetic tree analysis based on whole genome sequences gave similar results (FIG. 3B). Indeed, CedPV is more closely related to HeV and NiV than henipavirus-like sequences detected in African bats (26, 32) as shown in a phylogenetic tree based on the only sequences available of a 550-nt L gene fragment (FIG. 3C).

Example 3

[0110] First discovered for the parainfluenza virus 5 (PIV5, previously known as simian virus 5), almost all members of Paramyxovirinae have a P gene which produces multiple proteins through an RNA editing mechanism by addition of non-templated G residues leading to production of N-terminal co-linear proteins from different reading frames downstream from the editing site (3, 33). These multiple gene products are known to play a key role in antagonizing the innate response of susceptible hosts (3).

[0111] The CedPV genome codes for P protein of 737-aa and a C protein of 177-aa. PCR analysis, however, failed to find the highly conserved, cysteine-rich V protein ORF that is present in most other paramyxoviruses. The absence of the V protein ORF is attributed to the RNA editing site, with a sequence of AAAAGGG that is conserved in all other known HeV and NiV isolates discovered to date, is missing from the CedPV P gene sequence.

quantitative PCR assays (qPCR) were established based on CedPV-specific sequences obtained from the high throughput sequencing. A TaqMan assay on the P gene was developed and used for all subsequent studies. The sequences of the primer/probe were as follows: forward primer, 5'-TGCAT TGAGC GAACC CATAT AC; reverse primer, 5'-GCACG CTTCT TGACA GAGTT GT; probe, 5'-TCCCG AGAAA CCCTC TGTGT TTGA-MGB.

[0113] Each produced uniform trace files indicating a lack of RNA editing activities, which is very different from the mixed peaks generated by HeV and NiV immediately after the editing site (FIG. 4). It appears that CedPV is the first-identified member of Paramyxovirinae that lacks both RNA editing and any V-related coding sequence in its P gene.

Example 4

[0114] The striking similarity in genome size and organization and the presence of highly conserved protein domains among the N, M and L proteins between CedPV and henipaviruses would indicate that CedPV may be antigenically related to HeV and/or NiV. To prepare antibodies directed against CedPV, the coding region for the CedPV N protein was amplified by PCR with a pair of primers flanked by AscI (5' end) and NotI (3' end) sites for cloning into a previously described GST-fusion expression vector (47). The expression and purification by gel elution was conducted as previously described (48). For antibody production, purified protein was injected subcutaneously into 4 different sites of 2 adult (at a dose of 100 µg per animal) New Zealand white female rabbits at days 0 and 27. A previously published triple adjuvant (49)

was used for the immunization. Animals were checked for specific antibodies after days 5 and 42 and euthanized at day 69 for the final blood collection.

[0115] For immunofluorescence antibody test, Vero cell monolayers were prepared in 8-well chamber slides by seeding at a concentration of 30,000 cells/well in 300 μ l of cell media and incubating over night at 37° C. The cell monolayers were infected with an MOI of 0.01 of CedPV, HeV or NiV and fixed with 100% ice-cold methanol at 24 hours post-infection. The chamber slides were blocked with 100 μ l/well of 1%BSA in PBS for 30 min at 37° C. before adding 50 μ l/well of rabbit sera against CedPV N or NiV N diluted 1:1000. After incubation at 37° C. for 30 min, the slides were washed three times in PBS-T and incubated with 50 μ l/well of anti-rabbit 488 Alexafluore conjugate (Life Technologies) diluted 1:1000 at 37° C. for 30 min. The slides were then washed three times in PBS-T and mounted in 50% glycerol/PBS for observation under a fluorescence microscope.

[0116] For virus neutralization test, serial two-fold dilutions of sera were prepared in duplicate in a 96-well tissue culture plate in 50 μ l cell media (Minimal Essential Medium containing Earle's salts and supplemented with 2 mM glutamine, antibiotic-antimycotic and 10% fetal calf serum). An equal volume containing 200 TCID₅₀ of target virus was added and the virus-sera mix incubated for 30 min at 37° C. in a humidified 5% CO₂ incubator. 100 μ l of Vero cell suspension containing 2 $\times$ 10⁵ cells/ml was added and the plate incubated at 37° C. in a humidified 5% CO₂ incubator. After 4 days, the plate was examined for viral CPE. The highest serum dilution generating complete inhibition of CPE was defined as the final neutralizing titer.

[0117] Staining of CedPV-infected Vero cells using rabbit anti-henipavirus antibodies indicated the presence of cross-reactivity. This cross-reactivity was further confirmed in reverse by staining of HeV-infected Vero cells using a rabbit serum raised against a recombinant CedPV N protein (FIG. 5). Analysis by virus neutralization test, however, found that henipavirus-neutralizing antibodies were unable to neutralize CedPV and vice versa. See also FIG. 6 which shows IFAT conducted with anti-CedPV serum on Vero cells infected with J paramyxovirus (JPV), Rinderpest virus (RPV), Sendai virus (SeV), Menangle virus (MenPV) and CedPV, respectively. Mock infected cell monolayer was included as a negative control

Example 5

[0118] To further investigate the relationship between CedPV and recognized henipaviruses, CedPV's use of the ephrin-B2 and -B3 host cell proteins was examined. Typically, HeV and NiV use ephrin-B2 receptor as points of entry for infection for CedPV infection (22, 34). Human ephrin B2 and B3 genes were cloned into pQCXIH (Clontech) and the resulting plasmids packaged into retrovirus particles in the GP2-293 packaging cell line (Clontech) and pseudotyped with vesicular stomatitis virus G glycoprotein (VSV-G) following the manufacturer's instructions. HeLa-USU cell line (22) was infected with the VSV-G pseudotyped retrovirus particles in the presence of 1 μ g/ml polybrene (Sigma). 8 hours post infection, the medium was changed and the cells were allowed to recover for 24 hours, which allows time for completion of the retroviral insert into the cellular genome and for expression of the hygromycin resistance gene.

[0119] 24 hours post-infection, cells transformed by the retrovirus were selected for by the addition of 200 μ g/ml

hygromycin in the media. Stocks of cells that were resistant to hygromycin were prepared and frozen. HeLa-USU cells and ephrin-expressing HeLa-USU cells were seeded in 6-well tissue culture plates at a density of 250,000 cells/well overnight. The viruses (HeV and CedPV) were diluted to give an MOI of 0.01 and inoculated into the wells. The cell monolayers were examined daily for syncytial CPE.

[0120] For CedPV, similar observations were made with respect to the ephrin-B2 receptor. As shown in FIG. 7, CedPV failed to infect HeLa-USU, but was able to infect and cause syncytial CPE when the human ephrin-B2 gene was expressed. In contrast, when ephrin-B3 molecule was introduced, there was no evidence of infection.

Example 6

[0121] Ferrets, guinea pigs, and mice exhibit differing responses to HeV and NiV infections, with ferrets and guinea pigs, but not mice, developing severe disease characterized by systemic vasculitis (20, 35, 36, 37, 38). CedPV (2 $\times$ 10⁶ TCID₅₀/ml), which was passaged twice in bat PaKi cells, was administered to 2 male ferrets (1 ml oronasally), 4 female guinea pigs (1 ml intraperitoneally) and 5 female Balb-C mice (50 μ l oronasally). Guinea pigs and mice were implanted with temperature sensing microchips (LifeChip Bio-thermo®, Destron Fearing) and weighed daily. Ferret rectal temperature and weight was recorded at sampling times. Animals were observed daily for clinical signs of illness and were euthanized at 21 days post-inoculation. Sera were collected on days 10, 15 and 21 to test for neutralizing antibody against Ced PV.

[0122] Based on the asymptomatic seroconversion to CedPV noted in the ferrets, 7 additional female ferrets were exposed by the oronasal route to a lower dose of 3 $\times$ 10³ TCID₅₀. Two animals were euthanized on each of days 6, 8 and 10 post-inoculation and one on day 20. Nasal washes, oral swabs, and rectal swabs were collected on days 2, 4, 6, 8 and 10 and urine was sampled on the day of euthanasia. Each collected specimen was assessed for the CedPV genome. A wide range of tissue samples were collected at post mortem examination and assessed by routine histology, immunohistochemistry (using rabbit antibodies raised against recombinant CedPV and NiV N proteins, respectively), qPCR (see above) and virus isolation using reagents and procedures previously established (16).

[0123] In contrast to the response from exposure to NiV and HeV, the ferrets and guinea pigs exposed to CedPV remained clinically well, although neutralizing antibody was detected in serum between 10 to 21 days pi (Table 2). Balb-C mice exposed to CedPV also remained clinically well but did not develop neutralizing antibody in serum by day 21 pi. In ferrets electively euthanized at earlier time-points, there was reactive hyperplasia of tonsillar lymphoid tissue, retropharyngeal and bronchial lymph nodes, accompanied by edema and erythrophagocytosis. CedPV antigen was detected in bronchial lymph node of one animal euthanized on day 6 pi, consistent with viral replication in that tissue. Cross-reactive immunostaining against anti-NiV N protein antibodies was also noted (FIG. 8). No other significant histological lesions were identified.

TABLE 2

Antibody responses in CedPV-infected ferrets and guinea pigs			
Animal #	Days post inoculation	Neutralizing antibody titers	
		CedPV	HeV
Ferret 1	0	-ve	-ve
	10	1:320	-ve
	15	1:640	-ve
	21	1:1280	-ve
Ferret 2	0	-ve	-ve
	10	1:320	-ve
	15	1:640	-ve
	21	1:1280	-ve
Guinea pig 1	0	-ve	-ve
	10	-ve	-ve
	21	1:80	-ve
Guinea pig 2	0	-ve	-ve
	10	-ve	-ve
	21	-ve	-ve
Guinea pig 3	0	-ve	-ve
	10	-ve	-ve
	21	-ve	-ve
Guinea pig 4	0	-ve	-ve
	10	-ve	-ve
	21	1:160	-ve

[0124] Viral RNA was detected in selected lymphoid tissues of 3 of 4 ferrets sampled day 6 to 8 pi, including pharynx, spleen, and retropharyngeal and bronchial lymph nodes, as well as the submandibular lymph node of the ferret euthanized on day 20 pi. This pattern of lymphoid involvement suggests that there may be transient replication in the upper and lower respiratory tracts although CedPV genome was not recovered from nasal washes, oral swabs, pharynx or lung tissue of affected animals.

Example 7

[0125] Sera from 100 flying foxes collected during 2003-2005 from Queensland, Australia were screened for neutralizing antibodies to CedPV. Virus neutralization test was conducted as described above (antibody tests). All serum samples were tested at a dilution of 1:20. Due to the antigenic cross-reactivity observed between HeV and CedPV described above, virus neutralization tests were conducted to obtain more accurate infection data for each virus. Overall, 23% of the sera were CedPV-positive and 37% HeV-positive. Coinfection was reflected in 8% of the sera tested.

Example 8

[0126] The CedPV-G and F glycoproteins also represent an important system to explore the mapping of the henipavirus G and F functional domains. The CedPV-F is only 42% and 43% identical with HeV-F and NiV-F respectively; and CedPV-G is 29% and 30% identical with HeV-G and NiV-G. CedPV functional ephrin receptor usage was characterized along with heterotypic F and G coexpression and fusion assays using combinations of CedPV, HeV and NiV. Codon optimized clones were prepared in a pCDNA vector and tagged for detection with the S-peptide tag. Both constructs have been expressed, detected, and found to be functional in our reporter gene cell-cell fusion assay. A pilot assay (FIG. 9) indicates this feasibility of this approach. Ephrin-B2 and -B3 negative HeLa-USU cells are negative CedPV cell-cell fusion, as has the ephrin-B3 expressing cell line Hela-B3.

[0127] Fusion is observed with 293T target cells and ephrin-B2 expressing HeLa-B2 cell line. Importantly, CedPV-F has heterotypic function with both HeV-G and NiV-G, but further; CedPV-G has heterotypic function only with HeV-F and not NiV-F (FIG. 9) and also correlates with ephrin use.

Example 9

[0128] Significant detail is available for the binding between HeV and NiV-G and either ephrin-B2 or -B3. Mutations in G can render it non-functional in fusion promotion activity and virus infectivity, while retaining ephrin receptor binding ability, at locations in the stalk or globular head. In a co-ip assay with the 3 sG proteins (HeV, NiV and CedPV) along with a series of ephrin receptors it was observed that CedPV-sG is able to bind multiple ephrin subtypes including: B1, B2, B3-weak, A1, A2, A4-weak, and A5 (FIG. 10). This remarkably wide receptor binding profile is in sharp contrast to NiV and HeV-G which bind only ephrin-B2 and -B3.

Example 10

[0129] A pilot cell-cell fusion experiment using a HeLa-USU target cell will the various ephrin receptor constructs transfected and expressed is shown in FIG. 11. HeLa-USU target cell populations were prepared by transfecting in the indicated ephrin receptor constructs and then used in cell-cell fusion assay with effector cells expressing either CedPV, HeV or NiV F and G glycoproteins, and a standard fusion-reporter gene assay was carried out. CedPV G and F mediated fusion was highly permissive when either ephrin A1 or A2; or ephrin B1 or B2 was utilized; whereas we know that HeV and NiV make use of only ephrin B2 and B3.

[0130] Further, the background endogenous levels of ephrin A1 (based on gene array data) in the HeLa-USU cells is the cause of the fusion signal in untransfected cells. The results of this experiment indicate the ephrin receptor binding data with CedPV G glycoprotein (FIG. 10) correlates well with CedPV receptor binding and functional cell-cell fusion carried out in vitro. A summary of the ephrin receptor binding and fusion data obtained so far is shown in Table 3 below.

Ephrin	Binding	Fusing
A1	+	+
A2	+	+
A3	-	-
A4	+/-	-
A5	+	-
B1	+	+
B2	+	+
B3	+/-	-

[0131] The following references are referred to herein by number and are incorporated by reference in their entirety.

[0132] 1. Murray K, Selleck P, Hooper P, Hyatt A, Gould A, et al. (1995) A morbillivirus that caused fatal disease in horses and humans. Science 268: 94-97.

[0133] 2. Chua K B, Bellini W J, Rota P A, Harcourt B H, Tamin A, et al. (2000) Nipah virus: a recently emergent deadly paramyxovirus. Science 288: 1432-1435.

[0134] 3. Lamb R A, Parks G D (2007) Paramyxoviridae: The viruses and their replication. In: Knipe D M, Griffin D E, Lamb R A, Straus S E, Howley P M et al., editors. Fields Virology. Philadelphia: Lippincott Williams & Wilkins. pp. 1449-1496.

- [0135] 4. Eaton B T, Broder C C, Middleton D, Wang L F (2006) Hendra and Nipah viruses: different and dangerous. *Nat Rev Microbiol* 4: 23-35.
- [0136] 5. Pallister J, Middleton D, Broder C C, Wang L-F (2011) Henipavirus vaccine development. *Journal of Bioterrorism and Biodefense*: S1:005.
- [0137] 6. Eaton B T, Mackenzie J S, Wang L-F (2007) Henipaviruses. In: Knipe D M, Griffin D E, Lamb R A, Straus S E, Howley P M et al., editors. *Fields Virology*. Philadelphia: Lippincott Williams & Wilkins. pp. 1587-1600.
- [0138] 7. Yob J M, Field H, Rashdi A M, Morrissy C, van der Heide B, et al. (2001) Nipah virus infection in bats (order Chiroptera) in peninsular Malaysia. *Emerg Infect Dis* 7: 439-441.
- [0139] 8. Li Y, Wang J, Hickey A C, Zhang Y, Li Y, et al. (2008) Antibodies to Nipah or Nipah-like viruses in bats, China. *Emerg Infect Dis* 14: 1974-1976.
- [0140] 9. Hayman D T, Suu-Ire R, Breed A C, McEachern J A, Wang L, et al. (2008) Evidence of henipavirus infection in West African fruit bats. *PLoS One* 3: e2739.
- [0141] 10. Halpin K, Hyatt A D, Fogarty R, Middleton D, Bingham J, et al. (2011) Pteropid Bats are Confirmed as the Reservoir Hosts of Henipaviruses: A Comprehensive Experimental Study of Virus Transmission. *Am J Trop Med Hyg* 85: 946-951.
- [0142] 11. Leroy E M, Kumulungui B, Pourrut X, Bouquet P, Hassanin A, et al. (2005) Fruit bats as reservoirs of Ebola virus. *Nature* 438: 575-576.
- [0143] 12. Towner J S, Pourrut X, Albarino C G, Nkogue C N, Bird B H, et al. (2007) Marburg virus infection detected in a common African bat. *PLoS ONE* 2: e764.
- [0144] 13. Li W, Shi Z, Yu M, Ren W, Smith C, et al. (2005) Bats are natural reservoirs of SARS-like coronaviruses. *Science* 310: 676-679.
- [0145] 14. Chua K B, Crameri G, Hyatt A, Yu M, Tompang M R, et al. (2007) A previously unknown reovirus of bat origin is associated with an acute respiratory disease in humans. *Proc Natl Acad Sci USA* 104: 11424-11429.
- [0146] 15. Weingartl H M, Berhane Y, Caswell J L, Loosmore S, Audonnet J C, et al. (2006) Recombinant Nipah virus vaccines protect pigs against challenge. *J Virol* 80: 7929-7938.
- [0147] 16. Mungall B A, Middleton D, Crameri G, Bingham J, Halpin K, et al. (2006) Feline model of acute Nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine. *J Virol* 80: 12293-12302.
- [0148] 17. McEachern J A, Bingham J, Crameri G, Green D J, Hancock T J, et al. (2008) A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats. *Vaccine* 26: 3842-3852.
- [0149] 18. Pallister J, Middleton D, Wang L F, Klein R, Haining J, et al. (2011) A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge. *Vaccine* 29: 5623-5630.
- [0150] 19. Bossart K N, Geisbert T W, Feldmann H, Zhu Z, Feldmann F, et al. (2011) A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge. *Sci Transl Med* 3: 105ra103.
- [0151] 20. Bossart K N, Zhu Z, Middleton D, Klippel J, Crameri G, et al. (2009) A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute Nipah virus infection. *PLoS Pathog* 5: e1000642.
- [0152] 21. Bossart K N, McEachern J A, Hickey A C, Choudhry V, Dimitrov D S, et al. (2007) Neutralization assays for differential henipavirus serology using Bio-Plex Protein Array Systems. *J Virol Methods* 142: 29-40.
- [0153] 22. Bonaparte M I, Dimitrov A S, Bossart K N, Crameri G, Mungall B A, et al. (2005) Ephrin-B2 ligand is a functional receptor for Hendra virus and Nipah virus. *Proc Natl Acad Sci USA* 102: 10652-10657.
- [0154] 23. Negrete O A, Levroney E L, Aguilar H C, Bertolotti-Ciarlet A, Nazarian R, et al. (2005) EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. *Nature* 436: 401-405.
- [0155] 24. Negrete O A, Wolf M C, Aguilar H C, Enterlein S, Wang W, et al. (2006) Two key residues in ephrinB3 are critical for its use as an alternative receptor for Nipah virus. *PLoS Pathog* 2: e7.
- [0156] 25. Guillaume V, Contamin H, Loth P, Georges-Courbot M C, Lefeuvre A, et al. (2004) Nipah virus: vaccination and passive protection studies in a hamster model. *J Virol* 78: 834-840.
- [0157] 26. Drexler J F, Corman V M, Gloza-Rausch F, Seebens A, Annan A, et al. (2009) Henipavirus RNA in African bats. *PLoS ONE* 4: e6367.
- [0158] 27. Crameri G, Todd S, Grimley S, McEachern J A, Marsh G A, et al. (2009) Establishment, immortalisation and characterisation of pteropid bat cell lines. *PLoS ONE* 4: e8266.
- [0159] 28. Chua K B, Wang L F, Lam S K, Crameri G, Yu M, et al. (2001) Tioman virus, a novel paramyxovirus isolated from fruit bats in Malaysia. *Virology* 283: 215-229.
- [0160] 29. Chua K B, Lek Koh C, Hooi P S, Wee K F, Khong J H, et al. (2002) Isolation of Nipah virus from Malaysian Island flying-foxes. *Microbes Infect* 4: 145-151.
- [0161] 30. Chua K B (2003) A novel approach for collecting samples from fruit bats for isolation of infectious agents. *Microbes Infect* 5: 487-490.
- [0162] 31. Tong S, Chern S W, Li Y, Pallansch M A, Anderson U (2008) Sensitive and broadly reactive reverse transcription-PCR assays to detect novel paramyxoviruses. *J Clin Microbiol* 46: 2652-2658.
- [0163] 32. Baker K S, Todd S, Marsh G, Fernandez-Loras A, Suu-Ire R, et al. (2012) Co-circulation of diverse paramyxoviruses in an urban African fruit bat population. *J Gen Virol* 93: 850-856.
- [0164] 33. Thomas S M, Lamb R A, Paterson R G (1988) Two mRNAs that differ by two nontemplated nucleotides encode the amino coterminal proteins P and V of the paramyxovirus SVS. *Cell* 54: 891-902.
- [0165] 34. Bossart K N, Tachedjian M, McEachern J A, Crameri G, Zhu Z, et al. (2008) Functional studies of host-specific ephrin-B ligands as Henipavirus receptors. *Virology* 372: 357-371.
- [0166] 35. Pallister J, Middleton D, Crameri G, Yamada M, Klein R, et al. (2009) Chloroquine administration does not prevent Nipah virus infection and disease in ferrets. *J Virol* 83: 11979-11982.
- [0167] 36. Williamson M M, Hooper P T, Selleck P W, Westbury H A, Slocumbe R F (2000) Experimental hendra virus infection in pregnant guinea-pigs and fruit Bats (*Pteropus poliocephalus*). *J Comp Pathol* 122: 201-207.
- [0168] 37. Westbury H A, Hooper P T, Selleck P W, Murray P K (1995) Equine morbillivirus pneumonia: susceptibility of laboratory animals to the virus. *Aust Vet J* 72: 278-279.

- [0169] 38. Wong K T, Grosjean I, Brisson C, Blanquier B, Fevre-Montange M, et al. (2003) A golden hamster model for human acute Nipah virus infection. *Am J Pathol* 163: 2127-2137.
- [0170] 39. Negredo A (2011) Discovery of an ebolavirus-like filovirus in Europe. *PLoS Pathogens* 7: e1002304.
- [0171] 40. Lamb R A, Collins P L, Kolakofsky D, Melero J A, Nagai Y, et al. (2005) Family Paramyxoviridae. In: Fauquet C M, Mayo J, Maniloff J, Desselberger U, Ball L A, editors. *Virus Taxonomy: 8 th Report of the International Committee on Taxonomy of Viruses*. San Diego: Elsevier Academic Press. pp. 655-668.
- [0172] 41. Chambers R, Takimoto T (2009) Antagonism of innate immunity by paramyxovirus accessory proteins. *Viruses* 1: 574-593.
- [0173] 42. Matsuoka Y, Curran J, Pelet T, Kolakofsky D, Ray R, et al. (1991) The P gene of human parainfluenza virus type 1 encodes P and C proteins but not a cysteine-rich V protein. *J Virol* 65: 3406-3410.
- [0174] 43. Margulies M, Egholm M, Altman W E, Attiya S, Bader J S, et al. (2005) Genome sequencing in microfabricated high-density picolitre reactors. *Nature* 437: 376-380.
- [0175] 44. Palacios G, Quan P L, Jabado O J, Conlan S, Hirschberg D L, et al. (2007) Pannmicrobial oligonucleotide array for diagnosis of infectious diseases. *Emerg Infect Dis* 13: 73-81.
- [0176] 45. Li Z, Yu M, Zhang H, Wang H Y, Wang L F (2005) Improved rapid amplification of cDNA ends (RACE) for mapping both the 5' and 3' terminal sequences of paramyxovirus genomes. *J Virol Methods* 130: 154-156.
- [0177] 46. Tamura K, Dudley J, Nei M, Kumar S (2007) MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. *Mol Biol Evol* 24: 1596-1599.
- [0178] 47. Wang L F, Yu M, White J R, Eaton B T (1996) BTag: a novel six-residue epitope tag for surveillance and purification of recombinant proteins. *Gene* 169: 53-58.
- [0179] 48. Wang L F, Gould A R, Selleck P W (1997) Expression of equine morbillivirus (EMV) matrix and fusion proteins and their evaluation as diagnostic reagents. *Arch Virol* 142: 2269-2279.
- [0180] 49. Prowse S (2000) A new adjuvant. *ANZCCART News* 13: 7.

 SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 8

<210> SEQ ID NO 1

<211> LENGTH: 18162

<212> TYPE: DNA

<213> ORGANISM: Cedar virus

<400> SEQUENCE: 1

```

accagacaaa ggaagtctag tctccggtatt aaatcatatt cgtatgatta atcttaggat      60
cccgtgtatct agaactctgga tctggattcgt gtttaattga attgcgatcg tttataaatt      120
agaaaggaga tttactactc aaaatgtctg acattttcaa tgagactcaa tcatttagaa      180
actatcagtc caacttaggc agagatggca gggccagtgc agcaacgact actttgacaa      240
ctaaagttag gatctttgtt ccagcgaata ataatccaaa cctcagatgg cgtttaacac      300
tattcttgat ggatgtcgtg aggtcacctg cctccgcaga gtctatgaaa gtgggtgctg      360
ggatatcctt ggtatctatg tatgctgaaa aaccgggggc tcttggtgaga gcattattga      420
atgaccacaga tgttgaagcg ataatcatag atgtttatgg ctttgatgaa ggtattccta      480
taatggaacg aagaggtgat aaagctacag atgacatgga ttccctaaga aagattgtta      540
aagctgcaca tgatttcagc agaggaagga gtttatttgt tgatcaaagg gtccaggata      600
ttgttatgtc agatatgggg tcattttgtga atgctattac ttocatagag acgcagatat      660
ggattttgat cgcaaaggct gtaactgccc cagatacagc agaagagagc gaaggaagaa      720
gatgggcaaa atatgttcag caaaagaggg ttaatccttt gttcttgatt tctccacaat      780
ggatcaatga catgagatcc ctgattgcgg caagtcttcc gcttcgtaaa ttcattggtg      840
aactactgat ggaagctaag aaaggacggg ggacaaaagg aagaataatg gagattgtat      900
ccgatatcgg aaattacgtt gaagagacag gaatggcagg gttcttcgct acaataaagt      960
tcgggtcttg gaccaaattc cctgctttgg cacttaatga gctccagagt gacttgaaca     1020
caatgaaaag tctcatgata ctgtacagaa gcataggacc aaaggccccc tttatggtgt     1080
tgttggaaga ttcaattcag accaaatttg ctccaggaag ctatccactt ctttggagtt     1140

```


-continued

ttgcgatggg	tgtaggcaca	actattgaca	gagctatggg	tgctttgaac	attaacagaa	1200
gttatcttga	acctgtctat	tttaggctag	ggcaacaatc	agctaaacat	caagcaggaa	1260
atgttgacaa	agaaatggca	gaaaagttag	gattgacaga	agaccagatc	gtgcacctat	1320
cagctaatgt	gaaggatgca	agtcaaggta	gagatgacaa	tcaaatcaac	atccgagaag	1380
ggaagtccac	aaatgttgtt	gatgacatcc	aggatcatgc	ccagagttcc	tctgaggatt	1440
acaatcctag	taaaaagagt	ttctcaatat	tgacgagcat	cacatccacc	gtagatagtg	1500
ctgacagtag	gtctgcaatg	aatgagtcaa	tgacaacaac	atccttgctg	aaattgagac	1560
agaggctggc	agagaagaaa	ggagactcca	agaacagtca	agacacacct	ccaaaaccac	1620
ccagagcaaa	agatcaaccc	actgatgagg	tctccttcat	ggattccaat	atatgatcag	1680
aatgatggtt	aaaatcaacc	aactaagggc	gcgtagagta	ccttcagata	gaacactaca	1740
ttaatcgggt	gaaacaatag	atttatgggt	ttggtgctta	atTTTTtattt	aatcttactt	1800
gcaaaacagg	cagctgctac	actcgtaacc	actcctcaca	gtaagggcaa	cacgggtcat	1860
agaacttatg	cctatagatt	acctctatct	gtatatctag	ctatgattaa	aatgtatact	1920
tctgctgacc	ggTTTTctag	caacagtcca	cattattact	tatatgggtat	TTTTtaatca	1980
acctTTtata	atcaaatata	ttacaaaaaa	cttaggatcc	aagtgggtcca	aactTTTTttt	2040
gatcaagagt	catattggct	actttaggag	gacactttaa	acacaaattg	ttacaagagg	2100
atattcatca	gatggacaaa	ctacaattga	ttgaagatgg	cctctctact	atcaatttta	2160
tacaggaaaa	taaggaaaaa	ttacagcatt	cttacggaag	atcctccatc	agagagccac	2220
ccacaagtgt	caggggtgaa	gagtgggaga	aatttattcg	aaagatcgct	tctggacctg	2280
aacaagttca	agggggaggga	tctgagactg	agatcacagg	cgataatgga	gatagaggga	2340
atTTtaccaa	tctgatcag	ggaggcggag	tcacaggaca	attcgaagaa	aggtatcaaa	2400
aatgggggtc	acaagattca	gaattacaac	tggaccaaat	ggtgttacac	gatttcttct	2460
atgacgagag	aaggggagaat	cccgacaatg	gaaaaatga	ccgcagctct	aaaaaacggg	2520
ataatatcag	agaaggaaca	cgacaggata	agtacaataa	tcagtctact	gatgaattac	2580
tgtcctgcct	acaaccatct	tctaagaacg	atgtcatcaa	gaatgaaagt	acatcagtgt	2640
caaatTTtga	tgttacagga	aataaactga	atcctgacgc	aaaacccttt	gaaccacact	2700
cccagtcgaa	agagcaccca	accaccacac	agcacaacaa	aatgaccat	cagaccgatg	2760
atgattataa	gaatagaaga	tccagtgaag	acaatgtgat	ctctgatcat	gccaccacaa	2820
tggaagacaa	caacaatttt	atccccggca	ccaaaagaaa	gaatgcattg	agcgaaccca	2880
tatacgtcca	ggtattgccc	tcaaacacag	agggTTTTctc	gggaaaagat	tatccactcc	2940
tcaaggacaa	ctctgtcaag	aagcgtgcag	agccagtcac	cctagaaact	gccaaccacc	3000
ctgcaggctc	tgccgaccaa	gacacaaatc	agattgaaga	aaacatgcag	ttcaaccttc	3060
caaaactgct	cacagaagat	acagacgatg	aaccagagga	taacaatgat	tccatgcctc	3120
ttgaggaaga	cattagagag	atcggttcca	tgctaaaaga	tggaacccaa	gatatcaaga	3180
caaggatgaa	tgagatagat	gacgcaatca	agaagataaa	taagaaatca	aaaaatagaa	3240
gtctggatct	agaatcagac	ggtaaagatc	agggggagaag	agatccatca	gtagacctcg	3300
ggattaaaaa	aagaaaggaa	gggctaagg	ccgcaatgca	aaagacaaaa	gagcaattgt	3360
ctataaaagt	ggagagagag	attggattga	acgacaggat	atgtcaaaat	tcgaagatga	3420

-continued

gtacagaaaa gaaattgata tatgctggga tggaaatgga gtatggacaa acgagtactg	3480
ggtcaggagg tccacaagga tcaaaggatg ggacttctga tgatgtccag gtagacgaag	3540
actacgatga aggggaagac tatgaggcta tgccgtcaga taggttttat acaacattat	3600
cagggtgaaca aaaggataga tttgatctag atgctaacca aatgtctcag tatgacctcg	3660
aggcccaggt ggatgaatta accagaatga atctcatact ctattctaga ttagaaacta	3720
ctaataagtt gcttattgac atattagatc tagctaaaga aatgccaaag ttagttagaa	3780
aagtggataa tcttgagaga cagatgggta acttgaatat gttaacctct acccttgagg	3840
gtcacctatc ttctgtaatg attatgatac ccggtaaagg taagagcgaa aaggaaatcc	3900
ctaaaaatcc ggacctgaga ccaatactgg ggagaagcaa cacgtcgta actgatgta	3960
tcgacctaga ccattacct gataaaggct ccaaaggat caaaccaagt ggatctggag	4020
acagacagta catcggtctc ctagagagca aattttctat aaatgatgag tacaattttg	4080
ctccataccc tatcagggac gaactcctat tgccaggttt aagagatgac aaaaccaatg	4140
cttcacgtt catccagat gacacggaca ggtctccaat ggtgctcaa ataataattc	4200
gacagaacat ccatgatgaa gaagtgaagg atgagctact gtccatacta gaacaacata	4260
acactgtgga ggaattgaat gaaatatgga atactgtgaa tgattacctc gatggcaaca	4320
tctgattaac agatattgag attgatccta ttctaacaa gtaatctctg ataatgatag	4380
tatggaataa gaatactaac cacactattg tactcttgta gaatcttaac gagtgtctaa	4440
tgtcagattt tagcaacaca tactaataac ttgtaatcca tttctcctta ttccatttaa	4500
tctcacatta gaaaaaactt aggatcccg atttgcaaag tcaaacggg atctactatc	4560
agggtgtgga gctaacaata gcggagtctg cataacaaat agcggtcaaa gaagtttgaa	4620
aaccatcata gaatatggat ccgctcagatt tgaggaggat tataatggag gatgataaga	4680
gtctggtcaa caatgatgat agtacagaaa ctgattttct cgagaaaact tggagagaag	4740
ggagtaagat tgacaagatc acaccaggg ttgatgaaaa cgggaatatg gtccccaagt	4800
acgttgtctt caaccggggg aaaaatgaga ggaaaacatc cggatatcaa tatatgattt	4860
gttatggttt cattgaggat ggacctatca atggctcacc aagagtcaaa ggtaatatca	4920
gaaccaccgc ttcttttctt ttgggtgttg gaaaaactta ctctctcca gaagagatct	4980
tacaagagct gacaacactc aagatcactg tcagaaggac agccggatca aatgagaagt	5040
tggtgtatgg aataacaggg cctttaaatc acctttacc gtggtataaa gttttgacag	5100
gtggctccat ttttagtgcg gtgaaggct gttagaatgt ggatcaaata ctattagaca	5160
gaccccaaat acttagagta ttctttctaa gtataactaa attaacagat aaaggtgtgt	5220
atatgatacc caaagtgtt ctcgacttca gatcggataa ttcgatggcc ttcaatctgc	5280
ttgtgtatct caagatagac actgacatca ccaaagcagg catcagaggg attgtcaaca	5340
aagaagggga gaggataacg tcattcatgt tacacatcgg taactttaca agaagaggag	5400
gaaaacatta ctcagtggag tattgcaaaa ggaaaattga caaatgaag ctcacattcg	5460
ccttaggcac tataggcggc ctaagcttac atatcaggat cgatggaagg ataagtaaaa	5520
ggctccaagc acaagtgtgc tttcagagaa acatttgcta ctactaatg gacacaaacc	5580
catggttgaa taaattaacg tggacaataa gttgtgaaat acacaaagtc accgctgtca	5640
ttcagccatc tgtgccaaag gacttcattg tgtatgagga catcttaata gataatacag	5700

-continued

gcaagatcctt	aaaataaagt	aggagagtca	gtcattaccc	agtatatga	ataactaatga	5760
caacttttatt	aatccaatc	tatctccagt	tactagaatt	tctaaaacaa	ttctactgct	5820
cagcaacgca	tctcaaacat	tgtgatcttc	aattatgac	gacgcattgt	aatctatata	5880
gcttttagtt	catgaaatac	taaaaagggc	ttaatcttgt	aagttctcag	caaatactcc	5940
aatgcaaaag	agcgcctcaa	catctcaagc	agcaccacaaa	taaaccacaa	tcaatgtgca	6000
acaagagcaa	tcgtctaaag	tgtgaaaacc	aaaatcacag	atcagaaagg	gcacatatatt	6060
cagtcctgta	aaaataccaa	gtgggattaa	taaaagagga	tcaatcctta	tcattttaag	6120
aaaaacttag	gatcccagag	atcctaaaga	gccaatcct	ttatatattg	atcttgaagg	6180
gctagaagtc	aggctgaaac	acagaggtgg	aggaacacag	gaactaaaat	tgatgaaatc	6240
aaccttagct	caacatctaa	tcaatcaagc	ttaagtcac	ctaatactgt	atacaaccag	6300
cagcgtagag	agtggatttg	atttcggcac	ccttgccaag	tgaaggctat	tactgcctgt	6360
cctttcaatc	agaaaattac	atttaccat	aaagtaatct	caacatgtct	aacaagagga	6420
caacagtatt	gatcataata	agctatacgt	tattttattt	gaataatgca	gcaattgtag	6480
ggtttgattt	tgataaattg	aataaaatag	gtgtgggtgca	aggagagtc	ctaaattata	6540
aaattaaag	agatccaatg	acaaaagacc	ttgtcttgaa	atttatccct	aacatagtga	6600
atatcactga	atgtgtgaga	gagcccttga	gtaggtacaa	tgagaccgtg	aggagattgc	6660
ttttacctat	acacaacatg	cttgggttat	acttgaataa	cacaaatgct	aaaatgactg	6720
ggttgatgat	cgcgggtgtg	atcatgggtg	ggatagcaat	aggatatagc	acagcagctc	6780
agatcacagc	aggttttgct	ctttatgagg	caaaaaagaa	cacagaaaat	attcagaaat	6840
taacagacag	catcatgaaa	acacaggact	cgattgataa	acttactgac	agtgtgggga	6900
caagcatact	tatattgaat	aagctacaga	catacatcaa	caatcaactg	gtaccaaatac	6960
tagagcttct	atcctgccga	caaaacaaaa	ttgagtttga	tctaattgtta	accaagtatt	7020
tggtggatct	tatgactgtt	attggctcta	atatcaataa	tcctgttaat	aaagatatga	7080
ctattcaatc	tttgtcactt	ctttttgatg	gcaattatga	tataatgatg	tcagaacttg	7140
gttatacacc	tcaggatttc	ttagatttga	tagagagtaa	gagtataaca	gggcaaataa	7200
tttatgttga	tatggaaaac	ttgtacgttg	tgatcaggac	atatctacct	accctaattg	7260
aagtacctga	tgcccaaata	tatgagttca	acaaaataac	tatgagtagc	aatggaggag	7320
aatacttgtc	aaccatacct	aatttcatat	taataagagg	taattatatg	tctaatatag	7380
atgttgcaac	atgttatatg	accaaagcaa	gcgtaatttg	taatcaagat	tattcactcc	7440
cgatgagcca	aaacttaaga	agctgttatc	aaggtgagac	agaatactgt	cctgttgagg	7500
cagtcatcgc	gtcacactct	ccaagatttg	ctcttacaaa	tggagttatt	ttcgccaatt	7560
gtataaatac	aatttgtagg	tgtcaagaca	atggtaagac	tatcactcaa	aacataaacc	7620
aattcgtaag	catgatcgac	aacagtactt	gtaatgatgt	catggtagat	aagtttacta	7680
tcaaggtagg	aaaatatatg	gggagaaaa	atatcaataa	tattaatatc	cagataggac	7740
cgcagatcat	aattgataag	gttgacttgt	ctaatagaat	aaacaagatg	aatcaatctt	7800
taaaagatag	tattttctac	ctgagagaag	ccaagagaat	tttagactca	gtaaatatca	7860
gtcttatatc	tccaagcggt	caattgttct	taataataat	atcagtcctc	tcatttatta	7920
tattattgat	tatcatagta	tacttgtagt	gtaaatcaaa	acattcatat	aaatataaca	7980

-continued

aatttataga	tgatcctgat	tattacaatg	attacaaaag	agaacgtatt	aatggcaaag	8040
ccagtaagag	taacaatata	tattatgtag	gtgattaaca	atcgataatc	taaaggatta	8100
cctcactatc	actaccaagg	taacttccat	gtaagatcgg	accttccccg	aagacattaa	8160
ataaaactta	ggatcccaga	gtatccctct	aagtgatcct	tctagattgg	ttactgatat	8220
atatacatat	ttatcctctt	tccgtcgttg	tttattgatc	attaataatg	ctttctcagc	8280
tccaaaaaaa	ttacttagac	aactcaaacc	aacaagggtga	taaaatgaac	aaccagata	8340
agaaattaag	tgtaacttc	aaccctttag	aattagataa	aggtaaaaa	gatctcaata	8400
agtcctatta	tgtaaaaaac	aagaattata	acgtttcaaa	tctattaaat	gaaagtctgc	8460
acgatatcaa	gttttgat	tattgtatat	tctcactgct	aattatcatt	acaataatca	8520
atataatcac	aatatcaatt	gttataactc	gtctgaaagt	acatgaagag	aataatggca	8580
tggaatctcc	taatttcaaa	tctattcaag	atagtctctc	atctcttact	aacatgatca	8640
atacagagat	aactcctaga	ataggggatt	tagttacagc	cacttctggt	actctctctt	8700
catctatcaa	ttatgtcggg	actaagacaa	atcaactggg	caatgaatta	aaagattata	8760
taaccaaag	ttgtggcttt	aagggtccctg	aattaaagt	acatgaatgc	aacataagtt	8820
gtgctgatcc	aaaaattagc	aaatctgcaa	tgtacagcac	caatgcctat	gccgagcttg	8880
ctggtccacc	taagatat	tgtaaaagt	tatccaaaga	ccccgacttt	agactgaagc	8940
agatagatta	tgtaatacca	gtgcagcaag	atcggtctat	ttgtatgaac	aaccctttat	9000
tggaatcttc	tgatgggttt	tttacctaca	tacattatga	aggaataaat	agctgtaaaa	9060
aatcagattc	atttaaagt	ctgctgtcac	atggtgaaat	agttgacagg	ggtgattatc	9120
gaccatcatt	atatctatta	tcaagtcatt	accatcctta	ttcaatgcag	gtaataaact	9180
gtgtacctgt	gacttgtaac	cagtcacct	ttgtattctg	tcatatctcc	aacaacacta	9240
aaacattgga	caattcagat	tactcgtcag	acgagtacta	cataacatat	ttcaatggca	9300
tagatcgtcc	caaaaccaag	aagattccca	ttaacaatat	gacagcagac	aatcgttata	9360
tccattttac	attctcaggt	gggggaggtg	tatgtttagg	tgaagaattt	attattcctg	9420
ttaccacagt	catcaatact	gatgtattca	cgcattgatta	ttgtgagagt	ttcaactggt	9480
cagtccaaac	cggtaaaagt	ctaaaggaga	tatgctctga	gtcattaaga	tctccaacga	9540
actcatcgcg	atacaattta	aacggaatca	tgattataag	tcaaaacaac	atgacagatt	9600
ttaagattca	gttgaatggt	ataacttata	acaaactgtc	attcggaagt	cctggaagac	9660
tgagcaagac	actgggccag	gtcctttatt	accaatcttc	aatgagttgg	gatacttatc	9720
taaaggcagg	atttgtcgag	aaatggaaac	cctttacccc	gaattggatg	aacaatactg	9780
tgatatccag	acctaaccaa	ggtaattgtc	caaggatatca	taaatgcccc	gagatatgtt	9840
atggaggggac	atacaatgat	attgtctctt	tagatctagg	aaaagacatg	tatgttagcg	9900
ttattctaga	ttcagatcag	cttcagagag	atccagagat	tacagtattt	aactctacta	9960
ctatacttta	taaggagaga	gtatccaaag	atgaactaaa	cacaagaagt	actacaacga	10020
gctgttttct	tttctagat	gaaccttggt	gtatatcagt	attagaaaca	aacagattta	10080
acggcaaatac	tattaggccc	gagatttatt	catacaaaat	tcctaagtat	tgtaattttg	10140
atgagcttat	tcctcact	tcaatcaaat	ttaataataac	taatatcaaa	ttgttgcaact	10200
cagctattat	taaaactgga	tcatcagaca	ataaagatgt	atacaagat	atatcgaaga	10260

-continued

gggtattaaa	gaaaacttag	gatcccagat	ccttcaataa	ggcagagcct	tgattgtatc	10320
agcgtcattt	acaattgaat	ctcaattaac	aacactgatt	aataacttaa	gcagaatact	10380
cctattacag	tgtttaattg	acttaatttt	aattgaggat	tttataatcc	tataattgga	10440
gcagatctaa	actctcaccg	attcagttct	aatcctttat	taactaaaga	acaaattcta	10500
aataattgga	tgacgtcaca	ggagacaagc	tggaacaat	ttagttagaa	ggaagaaacc	10560
ttttaccaga	tatggaaagt	gactttgata	tatctgtag	cgacgtactg	taccagaat	10620
gtcatttggg	cagtctcata	gtcggcggta	agctcattac	ttctcttgag	tatgcgaatt	10680
tgactcataa	ccaacctcat	gaagatcaga	cattgctgac	taatataaat	gtcaataaaa	10740
agaagaagat	aaaaagtctc	ctaatatccc	aacaatcttt	atttggaat	gagggttaata	10800
aggagatttt	cgatcttaaa	aattattacc	atgtccccta	tccagaatgt	aacagagatt	10860
tattcttaat	ctctgatgac	aaaatagcat	tcaaactcag	taaaatcatg	gataattcta	10920
ataaactggt	tgatggttta	gagaggaaac	tgagtcgctt	aatttcgaat	gtagataatc	10980
aactattaaa	tgcaacctct	cttcataata	attctgagat	ggatcggaag	ggaaaagaac	11040
atccttgctt	cccagaaaag	agcacaattg	atgatgtaag	acagcagaga	cagacacgag	11100
attttccaaa	gaattcaact	agagagggaa	gatctccaaa	acaccctgat	gccgggtcta	11160
cacctgaaaa	cagtgccaaa	aacgatattg	atagagacaa	cacagacaat	atgccaacag	11220
gccatagttc	gacatctatg	aaaaaaccta	aaatatctgg	agaagaatat	cttagtatgt	11280
ggctagactc	agaggatttg	ggttctaaac	gaatttctgc	acaattaggg	aaggatgtat	11340
catgtaaagg	ccatctgcac	acgacagaag	acaaaccgat	aatagttcct	gacactcgat	11400
atatccaaaa	tcatgaatct	aataacgata	ttttccccaa	aaaagagaaa	aaattctgca	11460
aacttcacc	gtcatcggat	aatttaacca	aatcatggt	gaattcaaaa	tggtacaatc	11520
ctttcctttt	ttggtttact	gtcaagactg	aacttagagc	ctgccagaag	gagaactaca	11580
aaaggaaaaa	cagaaaaattg	ggaattatca	catcgattaa	aggttcatgc	tataagttga	11640
tactcaacca	gaatctagta	gcaatattcg	aggaagacag	cagtggatac	tcagatcata	11700
aaaaaagaaa	aaacgatgc	tactatctaa	ctcccgaat	ggtccttatg	ttctccgatg	11760
taactgaagg	aagattgatg	attgatgttg	caatgagatt	tgacaaaaag	tacaaaactc	11820
tagagaaaaa	ggctttgaaa	ttatggttcc	ttatagacga	gttatctcct	tctatgggaa	11880
atagagtgta	taatattata	tccatgcttg	agcctttgac	tctcgcgata	ttacaggtta	11940
aggatgagtc	aagggtgttg	agaggtgcat	tcatgcatca	ttgtttaggt	gacctcttcg	12000
aagaacttcg	agagtccaag	aactaccgag	aagatgagat	caagagattt	gccaacgacc	12060
taataaatgt	catgacctgt	cgggacattc	atttagtagc	agaattcttc	tcattcttta	12120
ggactttcgg	acatccaata	ttgaacgctc	aaactgcagc	caggaaagtt	agagagtaca	12180
tgtagcaga	taaaatcctt	gagtagcaac	ctatcatgaa	aggatcatgc	attttctgtg	12240
ctataatcat	aatggatttt	agagatagac	atggaggagt	ttggcctcct	cttgatcttc	12300
caaaacattg	ttcaagaac	ataatatctc	tcaaaaatac	aggatgaagg	gtaacttatg	12360
aagtagcaat	aaacaattgg	agatcatttg	tcgggttaaa	gttcaaatgt	tttatgggtc	12420
tcaatttaga	caatgatctc	agcatgtaca	tgaagataa	agcattatca	cctttaaggg	12480
atctttggga	ttcaatctat	tcacgtgaag	taatgtccta	ccaaccacct	agaaacaaaa	12540

-continued

aatcaagaag	attggttgag	gttttcgttg	atgatcagga	ctttgatccc	gttgatatga	12600
taaattatgt	tctgaccgga	gaatatctca	gagatgatga	tttcaatgct	tcttatagtt	12660
taaaagagaa	agagaccaa	caagttggca	ggtgtttgc	taagatgact	tataaaatga	12720
gggctgtca	agttattgct	gagaatttaa	ttgcacatgg	gattgggaga	tatttccatg	12780
aaaacgggat	ggttaaggat	gagcatgagc	tcagcaaatc	actgtttcaa	ttgtctatat	12840
caggaatacc	aagagggaac	aaaaacaaca	aatcgacgaa	cgacacaatc	cacgaaagca	12900
agatcgagaa	taaccattcc	tttaaaaaca	tccagaatcg	atcatttcga	aagacggata	12960
accatacaa	tagatttaac	attgataacc	caactttctt	atcccaaac	tgtaacccca	13020
agtataaccg	taagaattca	gagacaatag	gtatattctc	tcgtgcagaa	acaaaaagca	13080
tgattagaga	acagaaaagt	cacagagaag	tcaaaataaa	taagctagat	atcggcagtg	13140
ataatgaaga	gcaaggaaaa	gagatagatg	cgcgaagta	caaaatcacg	gacaacccaa	13200
atccacacat	aaatcctcaa	gatcaaccgg	gaatctgtca	agaagacaaa	ggcaaagaag	13260
gagcaaagtc	agatctcaca	gaaggcatga	gttttctgga	gatgcacaca	ctctttaacc	13320
cgagtaagag	cgatatcaga	acaaatctcg	aattggaaaa	gagttcactt	tcaaaccctg	13380
gatttatatc	acaaaaagag	aaaagaggca	aaacttataa	tgaatcccat	tactgggaa	13440
agttctctaa	agaggatgaa	gaaagatacg	atgtcatcag	tgcatctctg	acaacagatt	13500
tacgaaaatt	ctgcttaaat	tggagacatg	aatcaatcgg	catttttgca	agaaggatgg	13560
acgaaatcta	tggtttgctt	ggtttcttta	attggatgca	cagaagacta	gagcgatctg	13620
tgttatatgt	tgcgaccctt	cattgcccgc	cgtctatcaa	tgaacatata	gatctaaacg	13680
attcacccca	aagagacata	tttatatact	atccgaaagg	gggtatagaa	ggatacagcc	13740
aaaaactgtg	gacaatagcg	actatccctt	ttctattcct	cagtgtctcat	gagacaaaca	13800
cccgatagc	ggcagttgta	caaggtgaca	atcaatcaat	tgcaattaca	cataagggtcc	13860
accctcattt	gccttacaaa	atgaagaaag	aactctctgc	aatgcaggca	aaaaaatatt	13920
tttcaagggt	acggcacaa	atgaaggcat	tagggcatga	attgaaggcg	accgagacta	13980
tcattagtac	tcatttcttc	atttattcca	agaaaatcca	ctatgacggg	gctgttttat	14040
cacaatctct	gaaatcaatg	gcaagggtg	tattttggtc	agaaacccct	gttgatgaaa	14100
ctagagcagc	atgcagtaat	atcagcaca	caattgcaaa	ggctattgag	aatggttata	14160
gcaggagatc	tggctatctg	ataaatgttc	ttaaaacccat	ccaacaaatt	aatatatcat	14220
tgagttttaa	tataaatgaa	tgcagatgag	atgacataat	cagaccgttt	agagataatc	14280
caaaactggat	caaacatgcc	gcattaatcc	ccgccagctt	gggaggactc	aactatatga	14340
acatgtctcg	attgtatgtg	aggaatatag	gggatccagt	cacagcatcg	atagcagatg	14400
ttaagagaat	gattctcggt	ggtgtactac	ccattggaat	actccacaat	atcatgttgc	14460
aagaacccgg	tgatgccact	tatttggtg	ggtgtagtga	tccatactcc	atcaacctaa	14520
agcagactca	aagtatcaca	aaagttataa	agaacataac	ggcaagagtg	atactaagga	14580
attcgggtcaa	tccactgctc	aaaggtctat	ttcatgaagg	tgcttatgag	gaggacactg	14640
aattagcaac	attcattttg	gacaggagag	tcactctacc	acgagtcggg	cacgagatct	14700
taaacaaact	catcacagga	gcaagagaag	agatctcggg	cttactggat	accacaaaag	14760
gattgataag	aattggcata	gcaaaggag	gattaactca	gagaacatta	tctcgaattt	14820

-continued

ccaattatga	ttatgaacaa	tttttgaacc	taatgaatat	gttgaagaac	aaagaacaaa	14880
acagtgtcat	ttccctgtca	gcttgctctg	ttgactttgc	tatagcttta	agaagcagga	14940
tgtggaggaa	attggcaaaa	ggaagattaa	tatatggttt	agaagtccct	gatccaatag	15000
aagcaatgat	tggctttctc	attcttggga	gtgaaaattg	tctactctgt	gattcaggaa	15060
gcaaaaacta	tacctggttt	ttcatacca	aggatgtaca	gttggataag	attgataaag	15120
atcacgcac	aataagggt	ccctatgtcg	gatcaactac	cgaagaaaga	tcagagataa	15180
agttaggatc	cgtgaaaaat	ccaagcaaat	ccctgaaatc	tgctataaga	ctcgcaactg	15240
tgtacacttg	ggcatttggc	acaagtgatg	ctgaatgggtg	ggaggcttgg	tacttgtcta	15300
atcaacgagc	aaatatacc	ttagatgttc	tcaaaacgat	aacacctata	tctacttcaa	15360
cgaatattgc	tcatagatta	cgagaccgat	caacacaggt	taaatacgcc	agtacatctc	15420
ttaacagagt	atcgcgccat	gtaacaatta	gtaacgataa	catgaatttt	gaatttgacg	15480
gggttaaaat	ggataccaac	ttgattttatc	aacaagtcac	gctgttaggg	ctttcatgct	15540
tggagagttt	attccgaaat	aggaaaatga	caaatagtta	caatatcgtg	taccattttac	15600
acgttcaaga	acattgttgt	gtaaaggctc	tgaatgattt	accttataca	ccgtcaacac	15660
atccagtgcc	aaattataca	gaagtttagag	ataatagggt	aatttacgat	cctcaacctta	15720
tattagaatt	tgatgagcta	agattagcaa	ttcagcaaac	aaagaaagta	gatttggaat	15780
tttcattgtg	ggatacaaaa	gaacttcacg	agaatttagc	tcaaagttta	gcgattacag	15840
taacggatat	tatgacaaaa	tctgataaag	atcatattaa	agaccaaaga	agtatagatg	15900
ttgatgataa	tattaagaca	ctaataactg	agtttttatt	agtagacct	gaaatgtttg	15960
ccgtaaaatt	aggattgcat	atatcaataa	aatggtcatt	tgatattcac	tttaaaagac	16020
caagaggacg	ctatagcatg	atagaatact	tgactgatct	tttggataat	acttcttctc	16080
atgtttatcg	aatccttact	aatgtattat	ctcatcccag	agttatgaga	aaattcacta	16140
atgccgggct	actagaccg	aaatacggtc	cctaccttac	aagtcaagat	ttcaaaaaga	16200
tggcggtaga	tttcataata	acagcgtata	ccacattttt	gaccaattgg	tgtaataata	16260
acaagttttc	aattctaata	cctgaacaag	accctgatat	acttgaatta	agaaaagaca	16320
tcactcatgc	aaggcattta	tgtatgatct	cggatcttta	ctgctactct	ttcaagcaac	16380
cttgataaaa	ggagcttaca	ccacaagaga	agatctgcgt	catggaggac	ttcatagcca	16440
attgtgttgc	taatgatcaa	acaagtgcgg	gctggaacat	aacgccctta	agagtttaca	16500
atctccctgc	atcgaccaca	tacatcagga	gagggataat	aaaacaatta	agaatccgtc	16560
aaagcaatga	gcctattgat	ctggaagata	ttaggattgg	tcagaacccc	gattttgtga	16620
ataaacctat	tgagttttgt	agcagtgaat	tcggtatcac	aatttataac	cttgaagaaa	16680
ttcttcaatc	aaatgtgcat	ctcagtgtaa	atatgaacat	tgactcctca	acaagtaaca	16740
atactgaaaa	tcattttattt	agaagggtag	gcttgaactc	tacttcatct	tataaagcac	16800
tatctttaac	acctgttatt	aaaagatatc	atcaacagaa	cactaatagg	ctgtttatag	16860
gagaaggatc	agggtctatg	atgtatcttt	accagaaaac	cttgggggag	acaatatgct	16920
tctttaattc	gggagtccag	tacaatgagg	atctgggtca	aagggaacaa	tcattatacc	16980
cgagtgaata	cagtatctgt	gaacaaggag	taaaaaaga	aaaccctctc	accgggcatg	17040
ttataaccact	attcaatgga	agaccagaaa	ccacatgggt	aggcaatgat	gattctttca	17100

-continued

```

agtatatatt ggaacatact ataaatagag acatcgggct tgttcaactcc gatatggaaa 17160
caggaatagg gaaggataat tatactatct taaatgaaca tgcacatctt atagcactga 17220
gccttacagt aatgattgat gatggaatct tgggtgtctaa ggtagcttat gcccttgggt 17280
tttgcattct ttcattattg aatatgtacc ggacattttt ttcattagtt ctatgtgcgt 17340
ttccaccgta tagcaatttt gaatcaactg aattttacct gatttgcttg caaaaaagta 17400
taccgggacc tatcacacca gctagagcca tccaacaaac gacgaagcaa tctagagaag 17460
aggataatag tataactaat aatattctca aaatcaaaaa tcttggtcag aaagaattta 17520
tcaaaacagt aaagaaaaaa tacgaaatcc atccttcggt taactgtcct atcaacttca 17580
caaaggatga taaatattta atgagtgttg gggttcaagc caatggctct gatatgatac 17640
gtaaagagac gggctatgac ataggtagca atgtagagaa tctccgagat gtcttaatca 17700
agttgtttgc agatgcagtc accttctatg atgatgtcac aaataaaaaa aactttttta 17760
atccttatcc agtctacaca agaactcagt ataaaattct gatggataaa atatgcaaga 17820
aagtcacctt atacacctta atcatatcat gtaaaggatc caatcaatat tgctgggaaa 17880
ttaaatccca aataagaaag cattgtctca tacttgattt gaaaagtaag gtttttacia 17940
aacttatccc aaagggatta agagaaaggg gtgactcaaa agggatgaag agcatatggt 18000
tcactaaact aaccagtcaa gaggtgaaaa gatggtggaa gatgatatct tacatcgtga 18060
taataagcaa tccataacca catccaactt gtcagttaaa cacttaaatc acaataaact 18120
tgtcatcaga ttaaagaaaa cttataattc ccttttttag gt 18162

```

```

<210> SEQ ID NO 2
<211> LENGTH: 510
<212> TYPE: PRT
<213> ORGANISM: Cedar virus

```

```

<400> SEQUENCE: 2

```

```

Met Ser Asp Ile Phe Asn Glu Thr Gln Ser Phe Arg Asn Tyr Gln Ser
1           5           10           15
Asn Leu Gly Arg Asp Gly Arg Ala Ser Ala Ala Thr Thr Leu Thr
20          25          30
Thr Lys Val Arg Ile Phe Val Pro Ala Asn Asn Asn Pro Asn Leu Arg
35          40          45
Trp Arg Leu Thr Leu Phe Leu Met Asp Val Val Arg Ser Pro Ala Ser
50          55          60
Ala Glu Ser Met Lys Val Gly Ala Gly Ile Ser Leu Val Ser Met Tyr
65          70          75          80
Ala Glu Lys Pro Gly Ala Leu Val Arg Ala Leu Leu Asn Asp Pro Asp
85          90          95
Val Glu Ala Ile Ile Ile Asp Val Tyr Gly Phe Asp Glu Gly Ile Pro
100         105         110
Ile Met Glu Arg Arg Gly Asp Lys Ala Thr Asp Asp Met Asp Ser Leu
115        120        125
Arg Lys Ile Val Lys Ala Ala His Asp Phe Ser Arg Gly Arg Ser Leu
130        135        140
Phe Val Asp Gln Arg Val Gln Asp Ile Val Met Ser Asp Met Gly Ser
145        150        155        160
Phe Val Asn Ala Ile Thr Ser Ile Glu Thr Gln Ile Trp Ile Leu Ile
165        170        175

```


-continued

Ala Lys Ala Val Thr Ala Pro Asp Thr Ala Glu Glu Ser Glu Gly Arg
 180 185 190
 Arg Trp Ala Lys Tyr Val Gln Gln Lys Arg Val Asn Pro Leu Phe Leu
 195 200 205
 Ile Ser Pro Gln Trp Ile Asn Asp Met Arg Ser Leu Ile Ala Ala Ser
 210 215 220
 Leu Ser Leu Arg Lys Phe Met Val Glu Leu Leu Met Glu Ala Lys Lys
 225 230 235 240
 Gly Arg Gly Thr Lys Gly Arg Ile Met Glu Ile Val Ser Asp Ile Gly
 245 250 255
 Asn Tyr Val Glu Glu Thr Gly Met Ala Gly Phe Phe Ala Thr Ile Lys
 260 265 270
 Phe Gly Leu Glu Thr Lys Phe Pro Ala Leu Ala Leu Asn Glu Leu Gln
 275 280 285
 Ser Asp Leu Asn Thr Met Lys Ser Leu Met Ile Leu Tyr Arg Ser Ile
 290 295 300
 Gly Pro Lys Ala Pro Phe Met Val Leu Leu Glu Asp Ser Ile Gln Thr
 305 310 315 320
 Lys Phe Ala Pro Gly Ser Tyr Pro Leu Leu Trp Ser Phe Ala Met Gly
 325 330 335
 Val Gly Thr Thr Ile Asp Arg Ala Met Gly Ala Leu Asn Ile Asn Arg
 340 345 350
 Ser Tyr Leu Glu Pro Val Tyr Phe Arg Leu Gly Gln Gln Ser Ala Lys
 355 360 365
 His Gln Ala Gly Asn Val Asp Lys Glu Met Ala Glu Lys Leu Gly Leu
 370 375 380
 Thr Glu Asp Gln Ile Val His Leu Ser Ala Asn Val Lys Asp Ala Ser
 385 390 395 400
 Gln Gly Arg Asp Asp Asn Gln Ile Asn Ile Arg Glu Gly Lys Phe Thr
 405 410 415
 Asn Val Val Asp Asp Ile Gln Asp His Ala Gln Ser Ser Ser Glu Asp
 420 425 430
 Tyr Asn Pro Ser Lys Lys Ser Phe Ser Ile Leu Thr Ser Ile Thr Ser
 435 440 445
 Thr Val Asp Ser Ala Asp Ser Arg Ser Ala Met Asn Glu Ser Met Thr
 450 455 460
 Thr Thr Ser Leu Leu Lys Leu Arg Gln Arg Leu Ala Glu Lys Lys Gly
 465 470 475 480
 Asp Ser Lys Asn Ser Gln Asp Thr Pro Pro Lys Pro Pro Arg Ala Lys
 485 490 495
 Asp Gln Pro Thr Asp Glu Val Ser Phe Met Asp Ser Asn Ile
 500 505 510

<210> SEQ ID NO 3

<211> LENGTH: 737

<212> TYPE: PRT

<213> ORGANISM: Cedar virus

<400> SEQUENCE: 3

Met Asp Lys Leu Gln Leu Ile Glu Asp Gly Leu Ser Thr Ile Asn Phe
 1 5 10 15

Ile Gln Glu Asn Lys Glu Lys Leu Gln His Ser Tyr Gly Arg Ser Ser

-continued

20							25					30				
Ile	Arg	Glu	Pro	Pro	Thr	Ser	Val	Arg	Val	Glu	Glu	Trp	Glu	Lys	Phe	
	35						40					45				
Ile	Arg	Lys	Ile	Ala	Ser	Gly	Pro	Glu	Gln	Val	Gln	Gly	Gly	Gly	Ser	
	50					55					60					
Glu	Thr	Glu	Ile	Thr	Gly	Asp	Asn	Gly	Asp	Arg	Gly	Asn	Phe	Thr	Asn	
65					70					75					80	
Pro	Asp	Gln	Gly	Gly	Gly	Val	Thr	Gly	Gln	Phe	Glu	Glu	Arg	Tyr	Gln	
			85						90					95		
Lys	Trp	Gly	Ser	Gln	Asp	Ser	Glu	Leu	Gln	Leu	Asp	Pro	Met	Val	Val	
		100						105					110			
His	Asp	Phe	Phe	Tyr	Asp	Glu	Arg	Arg	Glu	Asn	Pro	Asp	Asn	Gly	Lys	
	115						120					125				
Tyr	Asp	Arg	Ser	Ser	Lys	Lys	Arg	Asp	Asn	Ile	Arg	Glu	Gly	Thr	Arg	
	130					135					140					
Gln	Asp	Lys	Tyr	Asn	Asn	Gln	Ser	Thr	Asp	Glu	Leu	Leu	Ser	Cys	Leu	
145					150					155					160	
Gln	Pro	Ser	Ser	Lys	Asn	Asp	Val	Ile	Lys	Asn	Glu	Ser	Thr	Ser	Val	
				165					170					175		
Ser	Asn	Leu	His	Val	Thr	Gly	Asn	Lys	Leu	Asn	Pro	Asp	Ala	Lys	Pro	
		180						185					190			
Phe	Glu	Pro	Thr	Ser	Gln	Ser	Lys	Glu	His	Pro	Thr	Thr	Thr	Gln	His	
	195						200						205			
Asn	Lys	Asn	Asp	His	Gln	Thr	Asp	Asp	Asp	Tyr	Lys	Asn	Arg	Arg	Ser	
	210					215					220					
Ser	Glu	Asn	Asn	Val	Ile	Ser	Asp	His	Ala	Thr	Thr	Met	Glu	Asp	Asn	
225					230					235					240	
Asn	Asn	Phe	Ile	Pro	Ala	Thr	Lys	Arg	Lys	Asn	Ala	Leu	Ser	Glu	Pro	
				245					250					255		
Ile	Tyr	Val	Gln	Val	Leu	Pro	Ser	Asn	Thr	Glu	Gly	Phe	Ser	Gly	Lys	
		260						265					270			
Asp	Tyr	Pro	Leu	Leu	Lys	Asp	Asn	Ser	Val	Lys	Lys	Arg	Ala	Glu	Pro	
	275						280					285				
Val	Ile	Leu	Glu	Thr	Ala	Asn	His	Pro	Ala	Gly	Ser	Ala	Asp	Gln	Asp	
	290					295					300					
Thr	Asn	Gln	Ile	Glu	Glu	Asn	Met	Gln	Phe	Asn	Leu	Pro	Lys	Leu	Leu	
305					310					315					320	
Thr	Glu	Asp	Thr	Asp	Asp	Glu	Pro	Glu	Asp	Asn	Asn	Asp	Ser	Met	Pro	
			325						330					335		
Leu	Glu	Glu	Asp	Ile	Arg	Glu	Ile	Gly	Ser	Met	Leu	Lys	Asp	Gly	Thr	
		340						345					350			
Lys	Asp	Ile	Lys	Thr	Arg	Met	Asn	Glu	Ile	Asp	Asp	Ala	Ile	Lys	Lys	
	355						360					365				
Ile	Asn	Lys	Lys	Ser	Lys	Asn	Arg	Ser	Leu	Asp	Leu	Glu	Ser	Asp	Gly	
	370					375					380					
Lys	Asp	Gln	Gly	Arg	Arg	Asp	Pro	Ser	Val	Asp	Leu	Gly	Ile	Lys	Lys	
385					390					395					400	
Arg	Lys	Glu	Gly	Leu	Lys	Ala	Ala	Met	Gln	Lys	Thr	Lys	Glu	Gln	Leu	
				405						410				415		
Ser	Ile	Lys	Val	Glu	Arg	Glu	Ile	Gly	Leu	Asn	Asp	Arg	Ile	Cys	Gln	
		420						425					430			

-continued

```

Asn Ser Lys Met Ser Thr Glu Lys Lys Leu Ile Tyr Ala Gly Met Glu
  435                      440                      445

Met Glu Tyr Gly Gln Thr Ser Thr Gly Ser Gly Gly Pro Gln Gly Ser
  450                      455                      460

Lys Asp Gly Thr Ser Asp Asp Val Gln Val Asp Glu Asp Tyr Asp Glu
  465                      470                      475                      480

Gly Glu Asp Tyr Glu Ala Met Pro Ser Asp Arg Phe Tyr Thr Thr Leu
                      485                      490                      495

Ser Gly Glu Gln Lys Asp Arg Phe Asp Leu Asp Ala Asn Gln Met Ser
                      500                      505                      510

Gln Tyr Asp Leu Glu Ala Gln Val Asp Glu Leu Thr Arg Met Asn Leu
  515                      520                      525

Ile Leu Tyr Ser Arg Leu Glu Thr Thr Asn Lys Leu Leu Ile Asp Ile
  530                      535                      540

Leu Asp Leu Ala Lys Glu Met Pro Lys Leu Val Arg Lys Val Asp Asn
  545                      550                      555                      560

Leu Glu Arg Gln Met Gly Asn Leu Asn Met Leu Thr Ser Thr Leu Glu
                      565                      570                      575

Gly His Leu Ser Ser Val Met Ile Met Ile Pro Gly Lys Asp Lys Ser
                      580                      585                      590

Glu Lys Glu Ile Pro Lys Asn Pro Asp Leu Arg Pro Ile Leu Gly Arg
  595                      600                      605

Ser Asn Thr Ser Leu Thr Asp Val Ile Asp Leu Asp His Tyr Pro Asp
  610                      615                      620

Lys Gly Ser Lys Gly Ile Lys Pro Ser Gly Ser Gly Asp Arg Gln Tyr
  625                      630                      635                      640

Ile Gly Ser Leu Glu Ser Lys Phe Ser Ile Asn Asp Glu Tyr Asn Phe
                      645                      650                      655

Ala Pro Tyr Pro Ile Arg Asp Glu Leu Leu Leu Pro Gly Leu Arg Asp
  660                      665                      670

Asp Lys Thr Asn Ala Ser Ser Phe Ile Pro Asp Asp Thr Asp Arg Ser
  675                      680                      685

Pro Met Val Leu Lys Ile Ile Ile Arg Gln Asn Ile His Asp Glu Glu
  690                      695                      700

Val Lys Asp Glu Leu Leu Ser Ile Leu Glu Gln His Asn Thr Val Glu
  705                      710                      715                      720

Glu Leu Asn Glu Ile Trp Asn Thr Val Asn Asp Tyr Leu Asp Gly Asn
  725                      730                      735

Ile

```

```

<210> SEQ ID NO 4
<211> LENGTH: 177
<212> TYPE: PRT
<213> ORGANISM: Cedar virus

```

```

<400> SEQUENCE: 4

```

```

Met Ala Ser Leu Leu Ser Ile Leu Tyr Arg Lys Ile Arg Lys Asn Tyr
  1                      5                      10                      15

Ser Ile Leu Thr Glu Asp Pro Pro Ser Glu Ser His Pro Gln Val Ser
  20                      25                      30

Gly Leu Lys Ser Gly Arg Asn Leu Phe Glu Arg Ser Leu Leu Asp Leu
  35                      40                      45

```

-continued

```

Asn Lys Phe Lys Gly Glu Asp Leu Arg Leu Arg Ser Gln Ala Ile Met
 50          55          60

Glu Ile Glu Ala Ile Leu Pro Ile Leu Ile Arg Glu Ala Glu Ser Gln
65          70          75          80

Asp Asn Ser Lys Lys Gly Ile Lys Asn Gly Gly His Lys Ile Gln Asn
          85          90          95

Tyr Asn Trp Thr Gln Trp Leu Tyr Thr Ile Ser Ser Met Thr Arg Glu
          100          105          110

Gly Arg Ile Pro Thr Met Glu Asn Met Thr Ala Ala Leu Lys Asn Gly
          115          120          125

Ile Ile Ser Glu Lys Glu His Asp Arg Ile Ser Thr Ile Ile Ser Leu
          130          135          140

Leu Met Asn Tyr Cys Pro Ala Tyr Asn His Leu Leu Arg Thr Met Ser
145          150          155          160

Ser Arg Met Lys Val His Gln Cys Gln Ile Cys Met Leu Gln Glu Ile
          165          170          175

```

Asn

```

<210> SEQ ID NO 5
<211> LENGTH: 360
<212> TYPE: PRT
<213> ORGANISM: Cedar virus

```

<400> SEQUENCE: 5

```

Met Asp Pro Ser Asp Leu Arg Arg Ile Ile Met Glu Asp Asp Lys Ser
 1          5          10          15

Leu Val Asn Asn Asp Asp Ser Thr Glu Thr Asp Phe Leu Glu Lys Thr
          20          25          30

Trp Arg Glu Gly Ser Lys Ile Asp Lys Ile Thr Pro Glu Val Asp Glu
          35          40          45

Asn Gly Asn Met Val Pro Lys Tyr Val Val Phe Asn Pro Gly Lys Asn
          50          55          60

Glu Arg Lys Thr Ser Gly Tyr Gln Tyr Met Ile Cys Tyr Gly Phe Ile
65          70          75          80

Glu Asp Gly Pro Ile Asn Gly Ser Pro Arg Val Lys Gly Asn Ile Arg
          85          90          95

Thr Thr Ala Ser Phe Pro Leu Gly Val Gly Lys Thr Tyr Ser Ser Pro
          100          105          110

Glu Glu Ile Leu Gln Glu Leu Thr Thr Leu Lys Ile Thr Val Arg Arg
          115          120          125

Thr Ala Gly Ser Asn Glu Lys Leu Val Tyr Gly Ile Thr Gly Pro Leu
          130          135          140

Asn His Leu Tyr Pro Trp Tyr Lys Val Leu Thr Gly Gly Ser Ile Phe
145          150          155          160

Ser Ala Val Lys Val Cys Arg Asn Val Asp Gln Ile Leu Leu Asp Arg
          165          170          175

Pro Gln Ile Leu Arg Val Phe Phe Leu Ser Ile Thr Lys Leu Thr Asp
          180          185          190

Lys Gly Val Tyr Met Ile Pro Lys Ser Val Leu Asp Phe Arg Ser Asp
          195          200          205

Asn Ser Met Ala Phe Asn Leu Leu Val Tyr Leu Lys Ile Asp Thr Asp
          210          215          220

```

-continued

```

Ile Thr Lys Ala Gly Ile Arg Gly Ile Val Asn Lys Glu Gly Glu Arg
225                230                235                240

Ile Thr Ser Phe Met Leu His Ile Gly Asn Phe Thr Arg Arg Gly Gly
                245                250                255

Lys His Tyr Ser Val Glu Tyr Cys Lys Arg Lys Ile Asp Lys Met Lys
                260                265                270

Leu Thr Phe Ala Leu Gly Thr Ile Gly Gly Leu Ser Leu His Ile Arg
                275                280                285

Ile Asp Gly Arg Ile Ser Lys Arg Leu Gln Ala Gln Val Gly Phe Gln
290                295                300

Arg Asn Ile Cys Tyr Ser Leu Met Asp Thr Asn Pro Trp Leu Asn Lys
305                310                315                320

Leu Thr Trp Asn Asn Ser Cys Glu Ile His Lys Val Thr Ala Val Ile
                325                330                335

Gln Pro Ser Val Pro Lys Asp Phe Met Leu Tyr Glu Asp Ile Leu Ile
                340                345                350

Asp Asn Thr Gly Lys Ile Leu Lys
355                360

```

```

<210> SEQ ID NO 6
<211> LENGTH: 557
<212> TYPE: PRT
<213> ORGANISM: Cedar virus

```

```

<400> SEQUENCE: 6

```

```

Met Ser Asn Lys Arg Thr Thr Val Leu Ile Ile Ile Ser Tyr Thr Leu
1                5                10                15

Phe Tyr Leu Asn Asn Ala Ala Ile Val Gly Phe Asp Phe Asp Lys Leu
20                25                30

Asn Lys Ile Gly Val Val Gln Gly Arg Val Leu Asn Tyr Lys Ile Lys
35                40                45

Gly Asp Pro Met Thr Lys Asp Leu Val Leu Lys Phe Ile Pro Asn Ile
50                55                60

Val Asn Ile Thr Glu Cys Val Arg Glu Pro Leu Ser Arg Tyr Asn Glu
65                70                75                80

Thr Val Arg Arg Leu Leu Leu Pro Ile His Asn Met Leu Gly Leu Tyr
85                90                95

Leu Asn Asn Thr Asn Ala Lys Met Thr Gly Leu Met Ile Ala Gly Val
100               105               110

Ile Met Gly Gly Ile Ala Ile Gly Ile Ala Thr Ala Ala Gln Ile Thr
115               120               125

Ala Gly Phe Ala Leu Tyr Glu Ala Lys Lys Asn Thr Glu Asn Ile Gln
130               135               140

Lys Leu Thr Asp Ser Ile Met Lys Thr Gln Asp Ser Ile Asp Lys Leu
145               150               155               160

Thr Asp Ser Val Gly Thr Ser Ile Leu Ile Leu Asn Lys Leu Gln Thr
165               170               175

Tyr Ile Asn Asn Gln Leu Val Pro Asn Leu Glu Leu Leu Ser Cys Arg
180               185               190

Gln Asn Lys Ile Glu Phe Asp Leu Met Leu Thr Lys Tyr Leu Val Asp
195               200               205

Leu Met Thr Val Ile Gly Pro Asn Ile Asn Asn Pro Val Asn Lys Asp

```

-continued

210	215	220
Met Thr Ile Gln Ser Leu Ser Leu Leu Phe Asp Gly Asn Tyr Asp Ile		
225	230	235 240
Met Met Ser Glu Leu Gly Tyr Thr Pro Gln Asp Phe Leu Asp Leu Ile		
	245	250 255
Glu Ser Lys Ser Ile Thr Gly Gln Ile Ile Tyr Val Asp Met Glu Asn		
	260	265 270
Leu Tyr Val Val Ile Arg Thr Tyr Leu Pro Thr Leu Ile Glu Val Pro		
	275	280 285
Asp Ala Gln Ile Tyr Glu Phe Asn Lys Ile Thr Met Ser Ser Asn Gly		
	290	295 300
Gly Glu Tyr Leu Ser Thr Ile Pro Asn Phe Ile Leu Ile Arg Gly Asn		
305	310	315 320
Tyr Met Ser Asn Ile Asp Val Ala Thr Cys Tyr Met Thr Lys Ala Ser		
	325	330 335
Val Ile Cys Asn Gln Asp Tyr Ser Leu Pro Met Ser Gln Asn Leu Arg		
	340	345 350
Ser Cys Tyr Gln Gly Glu Thr Glu Tyr Cys Pro Val Glu Ala Val Ile		
	355	360 365
Ala Ser His Ser Pro Arg Phe Ala Leu Thr Asn Gly Val Ile Phe Ala		
	370	375 380
Asn Cys Ile Asn Thr Ile Cys Arg Cys Gln Asp Asn Gly Lys Thr Ile		
385	390	395 400
Thr Gln Asn Ile Asn Gln Phe Val Ser Met Ile Asp Asn Ser Thr Cys		
	405	410 415
Asn Asp Val Met Val Asp Lys Phe Thr Ile Lys Val Gly Lys Tyr Met		
	420	425 430
Gly Arg Lys Asp Ile Asn Asn Ile Asn Ile Gln Ile Gly Pro Gln Ile		
	435	440 445
Ile Ile Asp Lys Val Asp Leu Ser Asn Glu Ile Asn Lys Met Asn Gln		
	450	455 460
Ser Leu Lys Asp Ser Ile Phe Tyr Leu Arg Glu Ala Lys Arg Ile Leu		
465	470	475 480
Asp Ser Val Asn Ile Ser Leu Ile Ser Pro Ser Val Gln Leu Phe Leu		
	485	490 495
Ile Ile Ile Ser Val Leu Ser Phe Ile Ile Leu Leu Ile Ile Ile Val		
	500	505 510
Tyr Leu Tyr Cys Lys Ser Lys His Ser Tyr Lys Tyr Asn Lys Phe Ile		
	515	520 525
Asp Asp Pro Asp Tyr Tyr Asn Asp Tyr Lys Arg Glu Arg Ile Asn Gly		
	530	535 540
Lys Ala Ser Lys Ser Asn Asn Ile Tyr Tyr Val Gly Asp		
545	550	555

<210> SEQ ID NO 7

<211> LENGTH: 622

<212> TYPE: PRT

<213> ORGANISM: Cedar virus

<400> SEQUENCE: 7

Met Leu Ser Gln Leu Gln Lys Asn Tyr Leu Asp Asn Ser Asn Gln Gln
1 5 10 15

-continued

Gly	Asp	Lys	Met	Asn	Asn	Pro	Asp	Lys	Lys	Leu	Ser	Val	Asn	Phe	Asn	
			20					25					30			
Pro	Leu	Glu	Leu	Asp	Lys	Gly	Gln	Lys	Asp	Leu	Asn	Lys	Ser	Tyr	Tyr	
		35				40						45				
Val	Lys	Asn	Lys	Asn	Tyr	Asn	Val	Ser	Asn	Leu	Leu	Asn	Glu	Ser	Leu	
		50				55					60					
His	Asp	Ile	Lys	Phe	Cys	Ile	Tyr	Cys	Ile	Phe	Ser	Leu	Leu	Ile	Ile	
		65			70					75					80	
Ile	Thr	Ile	Ile	Asn	Ile	Ile	Thr	Ile	Ser	Ile	Val	Ile	Thr	Arg	Leu	
				85					90					95		
Lys	Val	His	Glu	Glu	Asn	Asn	Gly	Met	Glu	Ser	Pro	Asn	Leu	Gln	Ser	
			100					105					110			
Ile	Gln	Asp	Ser	Leu	Ser	Ser	Leu	Thr	Asn	Met	Ile	Asn	Thr	Glu	Ile	
		115					120					125				
Thr	Pro	Arg	Ile	Gly	Ile	Leu	Val	Thr	Ala	Thr	Ser	Val	Thr	Leu	Ser	
		130				135						140				
Ser	Ser	Ile	Asn	Tyr	Val	Gly	Thr	Lys	Thr	Asn	Gln	Leu	Val	Asn	Glu	
		145			150					155					160	
Leu	Lys	Asp	Tyr	Ile	Thr	Lys	Ser	Cys	Gly	Phe	Lys	Val	Pro	Glu	Leu	
			165						170					175		
Lys	Leu	His	Glu	Cys	Asn	Ile	Ser	Cys	Ala	Asp	Pro	Lys	Ile	Ser	Lys	
			180					185					190			
Ser	Ala	Met	Tyr	Ser	Thr	Asn	Ala	Tyr	Ala	Glu	Leu	Ala	Gly	Pro	Pro	
		195				200						205				
Lys	Ile	Phe	Cys	Lys	Ser	Val	Ser	Lys	Asp	Pro	Asp	Phe	Arg	Leu	Lys	
		210				215					220					
Gln	Ile	Asp	Tyr	Val	Ile	Pro	Val	Gln	Gln	Asp	Arg	Ser	Ile	Cys	Met	
		225			230					235					240	
Asn	Asn	Pro	Leu	Leu	Asp	Ile	Ser	Asp	Gly	Phe	Phe	Thr	Tyr	Ile	His	
			245						250					255		
Tyr	Glu	Gly	Ile	Asn	Ser	Cys	Lys	Lys	Ser	Asp	Ser	Phe	Lys	Val	Leu	
			260					265					270			
Leu	Ser	His	Gly	Glu	Ile	Val	Asp	Arg	Gly	Asp	Tyr	Arg	Pro	Ser	Leu	
		275				280						285				
Tyr	Leu	Leu	Ser	Ser	His	Tyr	His	Pro	Tyr	Ser	Met	Gln	Val	Ile	Asn	
		290				295					300					
Cys	Val	Pro	Val	Thr	Cys	Asn	Gln	Ser	Ser	Phe	Val	Phe	Cys	His	Ile	
		305			310					315				320		
Ser	Asn	Asn	Thr	Lys	Thr	Leu	Asp	Asn	Ser	Asp	Tyr	Ser	Ser	Asp	Glu	
			325						330					335		
Tyr	Tyr	Ile	Thr	Tyr	Phe	Asn	Gly	Ile	Asp	Arg	Pro	Lys	Thr	Lys	Lys	
			340					345					350			
Ile	Pro	Ile	Asn	Asn	Met	Thr	Ala	Asp	Asn	Arg	Tyr	Ile	His	Phe	Thr	
		355					360					365				
Phe	Ser	Gly	Gly	Gly	Gly	Val	Cys	Leu	Gly	Glu	Glu	Phe	Ile	Ile	Pro	
		370				375					380					
Val	Thr	Thr	Val	Ile	Asn	Thr	Asp	Val	Phe	Thr	His	Asp	Tyr	Cys	Glu	
		385			390					395					400	
Ser	Phe	Asn	Cys	Ser	Val	Gln	Thr	Gly	Lys	Ser	Leu	Lys	Glu	Ile	Cys	
			405						410					415		
Ser	Glu	Ser	Leu	Arg	Ser	Pro	Thr	Asn	Ser	Ser	Arg	Tyr	Asn	Leu	Asn	

-continued

420					425					430					
Gly	Ile	Met	Ile	Ile	Ser	Gln	Asn	Asn	Met	Thr	Asp	Phe	Lys	Ile	Gln
		435					440					445			
Leu	Asn	Gly	Ile	Thr	Tyr	Asn	Lys	Leu	Ser	Phe	Gly	Ser	Pro	Gly	Arg
		450					455					460			
Leu	Ser	Lys	Thr	Leu	Gly	Gln	Val	Leu	Tyr	Tyr	Gln	Ser	Ser	Met	Ser
		465					470					475			480
Trp	Asp	Thr	Tyr	Leu	Lys	Ala	Gly	Phe	Val	Glu	Lys	Trp	Lys	Pro	Phe
				485					490					495	
Thr	Pro	Asn	Trp	Met	Asn	Asn	Thr	Val	Ile	Ser	Arg	Pro	Asn	Gln	Gly
			500					505					510		
Asn	Cys	Pro	Arg	Tyr	His	Lys	Cys	Pro	Glu	Ile	Cys	Tyr	Gly	Gly	Thr
		515					520					525			
Tyr	Asn	Asp	Ile	Ala	Pro	Leu	Asp	Leu	Gly	Lys	Asp	Met	Tyr	Val	Ser
		530					535					540			
Val	Ile	Leu	Asp	Ser	Asp	Gln	Leu	Ala	Glu	Asn	Pro	Glu	Ile	Thr	Val
		545					550					555			560
Phe	Asn	Ser	Thr	Thr	Ile	Leu	Tyr	Lys	Glu	Arg	Val	Ser	Lys	Asp	Glu
				565					570					575	
Leu	Asn	Thr	Arg	Ser	Thr	Thr	Thr	Ser	Cys	Phe	Leu	Phe	Leu	Asp	Glu
			580					585					590		
Pro	Trp	Cys	Ile	Ser	Val	Leu	Glu	Thr	Asn	Arg	Phe	Asn	Gly	Lys	Ser
		595					600					605			
Ile	Arg	Pro	Glu	Ile	Tyr	Ser	Tyr	Lys	Ile	Pro	Lys	Tyr	Cys		
		610					615					620			

<210> SEQ ID NO 8
 <211> LENGTH: 2501
 <212> TYPE: PRT
 <213> ORGANISM: Cedar virus

<400> SEQUENCE: 8

Met	Glu	Ser	Asp	Phe	Asp	Ile	Ser	Val	Ser	Asp	Val	Leu	Tyr	Pro	Glu
1				5					10					15	
Cys	His	Leu	Asp	Ser	Pro	Ile	Val	Gly	Gly	Lys	Leu	Ile	Thr	Ser	Leu
		20						25					30		
Glu	Tyr	Ala	Asn	Leu	Thr	His	Asn	Gln	Pro	His	Glu	Asp	Gln	Thr	Leu
		35					40					45			
Leu	Thr	Asn	Ile	Asn	Val	Asn	Lys	Lys	Lys	Lys	Ile	Lys	Ser	Pro	Leu
		50				55					60				
Ile	Ser	Gln	Gln	Ser	Leu	Phe	Gly	Asn	Glu	Val	Asn	Lys	Glu	Ile	Phe
		65			70				75					80	
Asp	Leu	Lys	Asn	Tyr	Tyr	His	Val	Pro	Tyr	Pro	Glu	Cys	Asn	Arg	Asp
			85					90					95		
Leu	Phe	Leu	Ile	Ser	Asp	Asp	Lys	Ile	Ala	Phe	Lys	Leu	Ser	Lys	Ile
			100					105					110		
Met	Asp	Asn	Ser	Asn	Lys	Leu	Phe	Asp	Gly	Leu	Glu	Arg	Lys	Leu	Ser
		115					120					125			
Arg	Leu	Ile	Ser	Asn	Val	Asp	Asn	Gln	Leu	Leu	Asn	Ala	Thr	Ser	Leu
		130				135					140				
His	Asn	Asn	Ser	Glu	Met	Asp	Arg	Lys	Gly	Lys	Glu	His	Pro	Cys	Phe
		145			150				155					160	

-continued

Pro	Glu	Lys	Ser	Thr	Ile	Asp	Asp	Val	Arg	Gln	Gln	Arg	Gln	Thr	Arg	
				165					170					175		
Asp	Phe	Pro	Lys	Asn	Ser	Thr	Arg	Glu	Gly	Arg	Ser	Pro	Lys	His	Pro	
			180					185					190			
Asp	Ala	Gly	Pro	Thr	Pro	Glu	Asn	Ser	Ala	Lys	Asn	Asp	Leu	His	Arg	
		195					200					205				
Asp	Asn	Thr	Asp	Asn	Met	Pro	Thr	Gly	His	Ser	Ser	Thr	Ser	Met	Lys	
	210					215					220					
Lys	Pro	Lys	Ile	Ser	Gly	Glu	Glu	Tyr	Leu	Ser	Met	Trp	Leu	Asp	Ser	
	225				230					235					240	
Glu	Asp	Leu	Gly	Ser	Lys	Arg	Ile	Ser	Ala	Gln	Leu	Gly	Lys	Asp	Val	
				245					250						255	
Ser	Cys	Lys	Gly	His	Leu	His	Thr	Thr	Glu	Asp	Lys	Pro	Ile	Ile	Val	
			260					265					270			
Pro	Asp	Thr	Arg	Tyr	Ile	Gln	Asn	His	Glu	Ser	Asn	Asn	Asp	Ile	Phe	
		275					280					285				
Pro	Lys	Lys	Glu	Lys	Lys	Phe	Cys	Lys	Leu	Pro	Pro	Ser	Ser	Asp	Asn	
		290				295					300					
Leu	Thr	Lys	Ile	Met	Val	Asn	Ser	Lys	Trp	Tyr	Asn	Pro	Phe	Leu	Phe	
	305				310					315					320	
Trp	Phe	Thr	Val	Lys	Thr	Glu	Leu	Arg	Ala	Cys	Gln	Lys	Glu	Asn	Tyr	
				325					330					335		
Lys	Arg	Lys	Asn	Arg	Lys	Leu	Gly	Ile	Ile	Thr	Ser	Ile	Lys	Gly	Ser	
			340					345					350			
Cys	Tyr	Lys	Leu	Ile	Leu	Asn	Gln	Asn	Leu	Val	Ala	Ile	Phe	Glu	Glu	
		355				360						365				
Asp	Ser	Ser	Gly	Tyr	Ser	Asp	His	Lys	Lys	Arg	Lys	Lys	Arg	Cys	Tyr	
	370					375					380					
Tyr	Leu	Thr	Pro	Glu	Met	Val	Leu	Met	Phe	Ser	Asp	Val	Thr	Glu	Gly	
	385				390					395					400	
Arg	Leu	Met	Ile	Asp	Val	Ala	Met	Arg	Phe	Asp	Lys	Lys	Tyr	Lys	Thr	
				405					410					415		
Leu	Glu	Lys	Lys	Ala	Leu	Lys	Leu	Trp	Phe	Leu	Ile	Asp	Glu	Leu	Phe	
			420					425					430			
Pro	Ser	Met	Gly	Asn	Arg	Val	Tyr	Asn	Ile	Ile	Ser	Met	Leu	Glu	Pro	
		435					440					445				
Leu	Thr	Leu	Ala	Ile	Leu	Gln	Val	Lys	Asp	Glu	Ser	Arg	Leu	Leu	Arg	
	450					455					460					
Gly	Ala	Phe	Met	His	His	Cys	Leu	Gly	Asp	Leu	Phe	Glu	Glu	Leu	Arg	
	465				470					475					480	
Glu	Ser	Lys	Asn	Tyr	Pro	Glu	Asp	Glu	Ile	Lys	Arg	Phe	Ala	Asn	Asp	
			485						490					495		
Leu	Ile	Asn	Val	Met	Thr	Cys	Arg	Asp	Ile	His	Leu	Val	Ala	Glu	Phe	
		500						505					510			
Phe	Ser	Phe	Phe	Arg	Thr	Phe	Gly	His	Pro	Ile	Leu	Asn	Ala	Gln	Thr	
		515					520					525				
Ala	Ala	Arg	Lys	Val	Arg	Glu	Tyr	Met	Leu	Ala	Asp	Lys	Ile	Leu	Glu	
		530				535					540					
Tyr	Glu	Pro	Ile	Met	Lys	Gly	His	Ala	Ile	Phe	Cys	Ala	Ile	Ile	Ile	
	545				550					555					560	
Asn	Gly	Phe	Arg	Asp	Arg	His	Gly	Gly	Val	Trp	Pro	Pro	Leu	Asp	Leu	

-continued

565								570					575				
Pro	Lys	His	Cys	Ser	Lys	Asn	Ile	Ile	Ser	Leu	Lys	Asn	Thr	Gly	Glu		
			580				585						590				
Gly	Val	Thr	Tyr	Glu	Val	Ala	Ile	Asn	Asn	Trp	Arg	Ser	Phe	Val	Gly		
			595				600						605				
Leu	Lys	Phe	Lys	Cys	Phe	Met	Gly	Leu	Asn	Leu	Asp	Asn	Asp	Leu	Ser		
			610				615						620				
Met	Tyr	Met	Lys	Asp	Lys	Ala	Leu	Ser	Pro	Leu	Arg	Asp	Leu	Trp	Asp		
			625				630						640				
Ser	Ile	Tyr	Ser	Arg	Glu	Val	Met	Ser	Tyr	Gln	Pro	Pro	Arg	Asn	Lys		
				645						650			655				
Lys	Ser	Arg	Arg	Leu	Val	Glu	Val	Phe	Val	Asp	Asp	Gln	Asp	Phe	Asp		
				660						665			670				
Pro	Val	Asp	Met	Ile	Asn	Tyr	Val	Leu	Thr	Gly	Glu	Tyr	Leu	Arg	Asp		
				675						680			685				
Asp	Asp	Phe	Asn	Ala	Ser	Tyr	Ser	Leu	Lys	Glu	Lys	Glu	Thr	Lys	Gln		
			690				695						700				
Val	Gly	Arg	Leu	Phe	Ala	Lys	Met	Thr	Tyr	Lys	Met	Arg	Ala	Cys	Gln		
			705				710						720				
Val	Ile	Ala	Glu	Asn	Leu	Ile	Ala	His	Gly	Ile	Gly	Arg	Tyr	Phe	His		
				725						730			735				
Glu	Asn	Gly	Met	Val	Lys	Asp	Glu	His	Glu	Leu	Ser	Lys	Ser	Leu	Phe		
				740						745			750				
Gln	Leu	Ser	Ile	Ser	Gly	Ile	Pro	Arg	Gly	Asn	Lys	Asn	Asn	Lys	Ser		
			755				760						765				
Thr	Asn	Asp	Thr	Ile	His	Glu	Ser	Lys	Ile	Glu	Asn	Asn	His	Ser	Phe		
			770				775						780				
Lys	Asn	Ile	Gln	Asn	Arg	Ser	Phe	Arg	Lys	Thr	Asp	Asn	Pro	Tyr	Asn		
			785				790						800				
Arg	Phe	Asn	Ile	Asp	Asn	Pro	Thr	Phe	Leu	Ser	Pro	Asn	Cys	Asn	Pro		
				805						810			815				
Lys	Tyr	Asn	Arg	Lys	Asn	Ser	Glu	Thr	Ile	Gly	Ile	Phe	Ser	Arg	Ala		
				820						825			830				
Glu	Thr	Lys	Ser	Met	Ile	Arg	Glu	Gln	Lys	Ser	His	Arg	Glu	Val	Lys		
				835						840			845				
Ile	Asn	Lys	Leu	Asp	Ile	Gly	Ser	Asp	Asn	Glu	Glu	Gln	Gly	Lys	Glu		
			850				855						860				
Ile	Asp	Ala	Ala	Lys	Tyr	Lys	Ile	Thr	Asp	Asn	Pro	Asn	Pro	His	Ile		
				870						875			880				
Asn	Pro	Gln	Asp	Gln	Pro	Gly	Ile	Cys	Gln	Glu	Asp	Lys	Gly	Lys	Glu		
				885						890			895				
Gly	Ala	Lys	Ser	Asp	Leu	Thr	Glu	Gly	Met	Ser	Phe	Leu	Glu	Met	His		
				900						905			910				
Thr	Leu	Phe	Asn	Pro	Ser	Lys	Ser	Asp	Ile	Arg	Thr	Asn	Leu	Glu	Leu		
				915						920			925				
Glu	Lys	Ser	Ser	Leu	Ser	Asn	Pro	Gly	Phe	Ile	Ser	Gln	Lys	Glu	Lys		
			930				935						940				
Arg	Gly	Lys	Thr	Tyr	Asn	Glu	Ser	His	Ser	Leu	Gly	Lys	Phe	Ser	Lys		
			945				950						960				
Glu	Asp	Glu	Glu	Arg	Tyr	Asp	Val	Ile	Ser	Ala	Phe	Leu	Thr	Thr	Asp		
				965						970			975				

-continued

Leu	Arg	Lys	Phe	Cys	Leu	Asn	Trp	Arg	His	Glu	Ser	Ile	Gly	Ile	Phe
			980						985					990	
Ala	Arg	Arg	Met	Asp	Glu	Ile	Tyr	Gly	Leu	Pro	Gly	Phe	Phe	Asn	Trp
			995				1000						1005		
Met	His	Arg	Arg	Leu	Glu	Arg	Ser	Val	Leu	Tyr	Val	Ala	Asp	Pro	
	1010					1015						1020			
His	Cys	Pro	Pro	Ser	Ile	Asn	Glu	His	Ile	Asp	Leu	Asn	Asp	Ser	
	1025					1030						1035			
Pro	Glu	Arg	Asp	Ile	Phe	Ile	His	His	Pro	Lys	Gly	Gly	Ile	Glu	
	1040					1045						1050			
Gly	Tyr	Ser	Gln	Lys	Leu	Trp	Thr	Ile	Ala	Thr	Ile	Pro	Phe	Leu	
	1055					1060						1065			
Phe	Leu	Ser	Ala	His	Glu	Thr	Asn	Thr	Arg	Ile	Ala	Ala	Val	Val	
	1070					1075						1080			
Gln	Gly	Asp	Asn	Gln	Ser	Ile	Ala	Ile	Thr	His	Lys	Val	His	Pro	
	1085					1090						1095			
His	Leu	Pro	Tyr	Lys	Met	Lys	Lys	Glu	Leu	Ser	Ala	Met	Gln	Ala	
	1100					1105						1110			
Lys	Lys	Tyr	Phe	Ser	Arg	Leu	Arg	His	Asn	Met	Lys	Ala	Leu	Gly	
	1115					1120						1125			
His	Glu	Leu	Lys	Ala	Thr	Glu	Thr	Ile	Ile	Ser	Thr	His	Phe	Phe	
	1130					1135						1140			
Ile	Tyr	Ser	Lys	Lys	Ile	His	Tyr	Asp	Gly	Ala	Val	Leu	Ser	Gln	
	1145					1150						1155			
Ser	Leu	Lys	Ser	Met	Ala	Arg	Cys	Val	Phe	Trp	Ser	Glu	Thr	Leu	
	1160					1165						1170			
Val	Asp	Glu	Thr	Arg	Ala	Ala	Cys	Ser	Asn	Ile	Ser	Thr	Thr	Ile	
	1175					1180						1185			
Ala	Lys	Ala	Ile	Glu	Asn	Gly	Tyr	Ser	Arg	Arg	Ser	Gly	Tyr	Leu	
	1190					1195						1200			
Ile	Asn	Val	Leu	Lys	Thr	Ile	Gln	Gln	Ile	Asn	Ile	Ser	Leu	Ser	
	1205					1210						1215			
Phe	Asn	Ile	Asn	Glu	Cys	Met	Thr	Asp	Asp	Ile	Ile	Arg	Pro	Phe	
	1220					1225						1230			
Arg	Asp	Asn	Pro	Asn	Trp	Ile	Lys	His	Ala	Ala	Leu	Ile	Pro	Ala	
	1235					1240						1245			
Ser	Leu	Gly	Gly	Leu	Asn	Tyr	Met	Asn	Met	Ser	Arg	Leu	Tyr	Val	
	1250					1255						1260			
Arg	Asn	Ile	Gly	Asp	Pro	Val	Thr	Ala	Ser	Ile	Ala	Asp	Val	Lys	
	1265					1270						1275			
Arg	Met	Ile	Leu	Gly	Gly	Val	Leu	Pro	Ile	Gly	Ile	Leu	His	Asn	
	1280					1285						1290			
Ile	Met	Leu	Gln	Glu	Pro	Gly	Asp	Ala	Thr	Tyr	Leu	Asp	Trp	Cys	
	1295					1300						1305			
Ser	Asp	Pro	Tyr	Ser	Ile	Asn	Leu	Lys	Gln	Thr	Gln	Ser	Ile	Thr	
	1310					1315						1320			
Lys	Val	Ile	Lys	Asn	Ile	Thr	Ala	Arg	Val	Ile	Leu	Arg	Asn	Ser	
	1325					1330						1335			
Val	Asn	Pro	Leu	Leu	Lys	Gly	Leu	Phe	His	Glu	Gly	Ala	Tyr	Glu	
	1340					1345						1350			

-continued

Glu Asp 1355	Thr	Glu	Leu	Ala	Thr 1360	Phe	Ile	Leu	Asp	Arg 1365	Arg	Val	Ile
Leu Pro 1370	Arg	Val	Gly	His	Glu 1375	Ile	Leu	Asn	Asn	Ser 1380	Ile	Thr	Gly
Ala Arg 1385	Glu	Glu	Ile	Ser	Gly 1390	Leu	Leu	Asp	Thr	Thr 1395	Lys	Gly	Leu
Ile Arg 1400	Ile	Gly	Ile	Ala	Lys 1405	Gly	Gly	Leu	Thr	Gln 1410	Arg	Thr	Leu
Ser Arg 1415	Ile	Ser	Asn	Tyr	Asp 1420	Tyr	Glu	Gln	Phe	Leu 1425	Asn	Leu	Met
Asn Met 1430	Leu	Lys	Asn	Lys	Glu 1435	Gln	Asn	Ser	Val	Ile 1440	Ser	Leu	Ser
Ala Cys 1445	Ser	Val	Asp	Phe	Ala 1450	Ile	Ala	Leu	Arg	Ser 1455	Arg	Met	Trp
Arg Lys 1460	Leu	Ala	Lys	Gly	Arg 1465	Leu	Ile	Tyr	Gly	Leu 1470	Glu	Val	Pro
Asp Pro 1475	Ile	Glu	Ala	Met	Ile 1480	Gly	Phe	Leu	Ile	Leu 1485	Gly	Ser	Glu
Asn Cys 1490	Leu	Leu	Cys	Asp	Ser 1495	Gly	Ser	Lys	Asn	Tyr 1500	Thr	Trp	Phe
Phe Ile 1505	Pro	Lys	Asp	Val	Gln 1510	Leu	Asp	Lys	Ile	Asp 1515	Lys	Asp	His
Ala Ser 1520	Ile	Arg	Val	Pro	Tyr 1525	Val	Gly	Ser	Thr	Thr 1530	Glu	Glu	Arg
Ser Glu 1535	Ile	Lys	Leu	Gly	Ser 1540	Val	Lys	Asn	Pro	Ser 1545	Lys	Ser	Leu
Lys Ser 1550	Ala	Ile	Arg	Leu	Ala 1555	Thr	Val	Tyr	Thr	Trp 1560	Ala	Phe	Gly
Thr Ser 1565	Asp	Ala	Glu	Trp	Trp 1570	Glu	Ala	Trp	Tyr	Leu 1575	Ser	Asn	Gln
Arg Ala 1580	Asn	Ile	Pro	Leu	Asp 1585	Val	Leu	Lys	Thr	Ile 1590	Thr	Pro	Ile
Ser Thr 1595	Ser	Thr	Asn	Ile	Ala 1600	His	Arg	Leu	Arg	Asp 1605	Arg	Ser	Thr
Gln Val 1610	Lys	Tyr	Ala	Ser	Thr 1615	Ser	Leu	Asn	Arg	Val 1620	Ser	Arg	His
Val Thr 1625	Ile	Ser	Asn	Asp	Asn 1630	Met	Asn	Phe	Glu	Phe 1635	Asp	Gly	Val
Lys Met 1640	Asp	Thr	Asn	Leu	Ile 1645	Tyr	Gln	Gln	Val	Met 1650	Leu	Leu	Gly
Leu Ser 1655	Cys	Leu	Glu	Ser	Leu 1660	Phe	Arg	Asn	Arg	Lys 1665	Met	Thr	Asn
Ser Tyr 1670	Asn	Ile	Val	Tyr	His 1675	Leu	His	Val	Gln	Glu 1680	His	Cys	Cys
Val Lys 1685	Ala	Leu	Asn	Asp	Leu 1690	Pro	Tyr	Thr	Pro	Ser 1695	Thr	His	Pro
Val Pro 1700	Asn	Tyr	Thr	Glu	Val 1705	Arg	Asp	Asn	Arg	Leu 1710	Ile	Tyr	Asp
Pro Gln 1715	Pro	Ile	Leu	Glu	Phe 1720	Asp	Glu	Leu	Arg	Leu 1725	Ala	Ile	Gln
Gln Thr	Lys	Lys	Val	Asp	Leu	Glu	Phe	Ser	Leu	Trp	Asp	Thr	Lys

-continued

1730	1735	1740
Glu Leu His Glu Asn Leu Ala Gln Ser Leu Ala Ile Thr Val Thr		
1745	1750	1755
Asp Ile Met Thr Lys Ser Asp Lys Asp His Ile Lys Asp Gln Arg		
1760	1765	1770
Ser Ile Asp Val Asp Asp Asn Ile Lys Thr Leu Ile Thr Glu Phe		
1775	1780	1785
Leu Leu Val Asp Pro Glu Met Phe Ala Val Asn Leu Gly Leu His		
1790	1795	1800
Ile Ser Ile Lys Trp Ser Phe Asp Ile His Phe Lys Arg Pro Arg		
1805	1810	1815
Gly Arg Tyr Ser Met Ile Glu Tyr Leu Thr Asp Leu Leu Asp Asn		
1820	1825	1830
Thr Ser Ser His Val Tyr Arg Ile Leu Thr Asn Val Leu Ser His		
1835	1840	1845
Pro Arg Val Met Arg Lys Phe Thr Asn Ala Gly Leu Leu Val Pro		
1850	1855	1860
Lys Tyr Gly Pro Tyr Leu Thr Ser Gln Asp Phe Lys Lys Met Ala		
1865	1870	1875
Val Asp Phe Ile Ile Thr Ala Tyr Thr Thr Phe Leu Thr Asn Trp		
1880	1885	1890
Cys Asn Asn Asn Lys Phe Ser Ile Leu Ile Pro Glu Gln Asp Pro		
1895	1900	1905
Asp Ile Leu Glu Leu Arg Lys Asp Ile Thr His Ala Arg His Leu		
1910	1915	1920
Cys Met Ile Ser Asp Leu Tyr Cys Tyr Ser Phe Lys Gln Pro Trp		
1925	1930	1935
Ile Lys Glu Leu Thr Pro Gln Glu Lys Ile Cys Val Met Glu Asp		
1940	1945	1950
Phe Ile Ala Asn Cys Val Ala Asn Asp Gln Thr Ser Ala Gly Trp		
1955	1960	1965
Asn Ile Thr Pro Leu Arg Val Tyr Asn Leu Pro Ala Ser Thr Thr		
1970	1975	1980
Tyr Ile Arg Arg Gly Ile Ile Lys Gln Leu Arg Ile Arg Gln Ser		
1985	1990	1995
Asn Glu Pro Ile Asp Leu Glu Asp Ile Arg Ile Gly Gln Asn Pro		
2000	2005	2010
Asp Phe Val Asn Lys Pro Ile Glu Phe Cys Ser Ser Glu Phe Gly		
2015	2020	2025
Ile Thr Ile Tyr Asn Leu Glu Glu Ile Leu Gln Ser Asn Val His		
2030	2035	2040
Leu Ser Val Asn Met Asn Ile Asp Ser Ser Thr Ser Asn Asn Thr		
2045	2050	2055
Glu Asn His Leu Phe Arg Arg Val Gly Leu Asn Ser Thr Ser Ser		
2060	2065	2070
Tyr Lys Ala Leu Ser Leu Thr Pro Val Ile Lys Arg Tyr His Gln		
2075	2080	2085
Gln Asn Thr Asn Arg Leu Phe Ile Gly Glu Gly Ser Gly Ser Met		
2090	2095	2100
Met Tyr Leu Tyr Gln Lys Thr Leu Gly Glu Thr Ile Cys Phe Phe		
2105	2110	2115

-continued

Asn Ser Gly Val Gln Tyr Asn Glu Asp Leu Gly Gln Arg Glu Gln	2120	2125	2130
Ser Leu Tyr Pro Ser Glu Tyr Ser Ile Cys Glu Gln Gly Val Lys	2135	2140	2145
Lys Glu Asn Pro Leu Thr Gly His Val Ile Pro Leu Phe Asn Gly	2150	2155	2160
Arg Pro Glu Thr Thr Trp Val Gly Asn Asp Asp Ser Phe Lys Tyr	2165	2170	2175
Ile Leu Glu His Thr Ile Asn Arg Asp Ile Gly Leu Val His Ser	2180	2185	2190
Asp Met Glu Thr Gly Ile Gly Lys Asp Asn Tyr Thr Ile Leu Asn	2195	2200	2205
Glu His Ala His Leu Ile Ala Leu Ser Leu Thr Val Met Ile Asp	2210	2215	2220
Asp Gly Ile Leu Val Ser Lys Val Ala Tyr Ala Pro Gly Phe Cys	2225	2230	2235
Ile Ser Ser Leu Leu Asn Met Tyr Arg Thr Phe Phe Ser Leu Val	2240	2245	2250
Leu Cys Ala Phe Pro Pro Tyr Ser Asn Phe Glu Ser Thr Glu Phe	2255	2260	2265
Tyr Leu Ile Cys Leu Gln Lys Ser Ile Pro Gly Pro Ile Thr Pro	2270	2275	2280
Ala Arg Ala Ile Gln Gln Thr Thr Lys Gln Ser Arg Glu Glu Asp	2285	2290	2295
Asn Ser Ile Thr Asn Asn Ile Leu Lys Ile Lys Asn Leu Val Gln	2300	2305	2310
Lys Glu Phe Ile Lys Thr Val Lys Lys Lys Tyr Glu Ile His Pro	2315	2320	2325
Ser Phe Asn Cys Pro Ile Asn Phe Thr Lys Asp Asp Lys Tyr Leu	2330	2335	2340
Met Ser Val Gly Phe Gln Ala Asn Gly Pro Asp Met Ile Arg Lys	2345	2350	2355
Glu Thr Gly Tyr Asp Ile Gly Ser Asn Val Glu Asn Leu Arg Asp	2360	2365	2370
Val Leu Ile Lys Leu Phe Ala Asp Ala Val Thr Phe Tyr Asp Asp	2375	2380	2385
Val Thr Asn Lys Lys Asn Phe Leu Asn Pro Tyr Pro Val Tyr Thr	2390	2395	2400
Arg Thr Gln Tyr Lys Ile Leu Met Asp Lys Ile Cys Lys Lys Val	2405	2410	2415
Thr Leu Tyr Thr Leu Ile Ile Ser Cys Lys Gly Ser Asn Gln Tyr	2420	2425	2430
Cys Trp Glu Ile Lys Ser Gln Ile Arg Lys His Cys Leu Ile Leu	2435	2440	2445
Asp Leu Lys Ser Lys Val Phe Thr Lys Leu Ile Pro Lys Gly Leu	2450	2455	2460
Arg Glu Arg Gly Asp Ser Lys Gly Met Lys Ser Ile Trp Phe Thr	2465	2470	2475
Lys Leu Thr Ser Gln Glu Val Lys Arg Trp Trp Lys Met Ile Ser	2480	2485	2490

-continued

Tyr Ile Val Ile Ile Ser Asn Pro
2495 2500

1-11. (canceled)

12. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of

- a) a polypeptide with an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:2,
- b) a polypeptide comprising the amino acid sequence of SEQ ID NO:2,
- c) a polypeptide consisting of the amino acid sequence of SEQ ID NO:2,
- d) a polypeptide with an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:3,
- e) a polypeptide comprising the amino acid sequence of SEQ ID NO:3,
- f) a polypeptide consisting of the amino acid sequence of SEQ ID NO:3,
- g) a polypeptide with an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:4,
- h) a polypeptide comprising the amino acid sequence of SEQ ID NO:4,
- i) a polypeptide consisting of the amino acid sequence of SEQ ID NO:4,
- j) a polypeptide with an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:5,
- k) a polypeptide comprising the amino acid sequence of SEQ ID NO:5,
- l) a polypeptide consisting of the amino acid sequence of SEQ ID NO:5,
- m) a polypeptide with an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:6,
- n) a polypeptide comprising the amino acid sequence of SEQ ID NO:6,
- o) a polypeptide consisting of the amino acid sequence of SEQ ID NO:6,
- p) a polypeptide with an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:7,
- q) a polypeptide comprising the amino acid sequence of SEQ ID NO:7,
- r) a polypeptide consisting of the amino acid sequence of SEQ ID NO:7,
- s) a polypeptide with an amino acid sequence at least 85% identical to the amino acid sequence of SEQ ID NO:8,
- t) a polypeptide comprising the amino acid sequence of SEQ ID NO:8, and
- u) a polypeptide consisting of the amino acid sequence of SEQ ID NO:8.

13. An isolated polynucleotide encoding the polypeptide of claim **12**, or the complement thereof.

14. The polynucleotide of claim **13**, wherein the polynucleotide is RNA.

15. The polynucleotide of claim **14**, wherein the molecule is DNA.

16. A vector comprising the nucleic acid molecule of claim **15**.

17. A host cell comprising the vector of claim **16**.

18. The host cell of claim **17**, wherein the host cell is a prokaryotic cell.

19. The host cell of claim **17**, wherein the host cell is a eukaryotic cell.

20. The host cell of claim **19**, wherein the host cell is a mammalian cell.

21. A method for producing a polypeptide, the method comprising culturing the host cell of claim **17** in conditions that promote protein production and isolating the polypeptide from the culture.

22. An antibody or fragment thereof that specifically binds to the polypeptide of claim **12**.

23. The antibody of claim **22**, wherein the antibody is a monoclonal antibody or fragment thereof, a polyclonal antibody or a fragment thereof, a humanized antibody or a fragment thereof, a recombinantly produced antibody or a fragment thereof or a chimeric antibody or a fragment thereof.

24. A vaccine comprising the antibody or fragment of claim **22**.

25. A method of treating or preventing an infection of Hendra virus, Nipah virus, Cedar virus, or other paramyxoviruses in a subject, the method comprising administering the vaccine of claim **24** to a subject in need of treatment or prevention thereof.

26. A method of detecting the presence of a first polynucleotide in a sample, wherein the first polynucleotide comprises a nucleotide sequence of at least 100 contiguous nucleotides of SEQ ID NO:1, the method comprising contacting the sample with a binding molecule that selectively binds to at least a portion of the first polynucleotide, or the complement thereof, and detecting the binding of the binding molecule to the first polynucleotide.

27. The method of claim **26** wherein the first polynucleotide comprises a nucleotide sequence that is at least 200, 300, 400, 500, 600, 700, 800, 900, 1000, 2000, 3000, 4000, 5000, 6000, 7000, 8000, 9000, 10000, 11000, 12000, 13000, 14000, 15000, 16000, 17000 or 18000 contiguous nucleotides of SEQ ID NO:1.

28. The method of claim **26** wherein the binding molecule is a second polynucleotide comprising at least 20, 30, 40, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900 or 1000 nucleotides in length.

29. The method of claim **26** wherein the first polynucleotide is amplified using PCR or RT-PCR prior to detection.

30. A recombinant virus comprising the polynucleotide of claim **12**.

31. The recombinant virus of claim **30** wherein the virus is an attenuated virus.

* * * * *